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Introduction 
 
 
 
 
 
  
Introduction 
Gastric cancer is the second leading cause of death from cancer worldwide, with an 
estimated 700,000 deaths annually, and 876,000 new cases every year (1). The 
overwhelming majority (around 95%) are adenocarcinoma of the stomach, the 
remainder comprising non-Hodgkin’s lymphomas and stromal tumors. The Laurén 
classification system classifies gastric adenocarcinoma under two major 
histopathological variants: a more common intestinal type, and a diffuse type, showing 
histological characteristics of well- and poorly differentiated adenocarcinoma, 
respectively. The intestinal type predominates in high-risk regions, which shows a 
correlation with Helicobacter pylori (H. pylori) prevalence, is more likely to be sporadic 
and related to environmental risk factors (2). This gastric cancer type shows large 
geographic differences in incidence, with relatively low rates in most Western 
Countries, including the United States and the United Kingdom, and with relatively high 
rates in Japan, Korea, and China, and part of South America, where the prevalence of 
H. pylori is relatively high. The diffuse gastric cancer type is more uniformly distributed 
geographically, typically develops from H. pylori free individuals, and seems to have a 
primary genetic aetiology. While intestinal type adenocarcinoma progresses through a 
relatively well defined series oh histological steps, including atrophic gastritis, intestinal 
metaplasia and displasia, the diffuse type cancer consists of individually infiltrating 
neoplastic cells with no glandular structure, and is not associated with definite 
precancerous lesions (2). Mortality rates for gastric cancer have been decreasing since 
two decades due to declined incidence and improvement of survival (3), especially for 
the intestinal histologic type. As for the anatomical sub-site, there are two main types 
of stomach cancer. Distal gastric cancer involves the lower portion of the stomach, and 
is the predominant type, while the other type is cancer of the gastric cardia, sometimes 
grouped with oesophageal junction cancers. 
 
Concerning the environmental risk factors for gastric cancer, there are strong 
evidences that non-starchy vegetables, allium vegetables and fruit protect from gastric 
cancer, while salt, salty foods actually increase the risk. There are also suggestive 
evidence for an increased risk associated with the use of processed and red meat, 
smoked and grilled food, and cigarette smoking, while for the alcohol the evidences are 
inconclusive, suggesting a major role especially for the anatomic sub-site of cardia 
gastric cancer (4,5). Lastly, the lack of food refrigeration, which allows bacteria 
overgrowth and nitrosamine production played a key role especially in the past (6). As 
for the hereditary forms of gastric cancer, it is known that a positive family history for 
gastric cancer confers an increased risk (7). In family studies, first degree relatives of 
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patients with gastric cancer have two-to-three fold increased risk, which could not be 
explained by familial clustering of H. pylori infection (8). Although most carcinoma of 
the stomach, both intestinal and diffuse, occurs sporadically without a demonstrated 
inherited predisposition, a small proportion of gastric cancer arises in clearly inherited 
predisposition syndromes including hereditary non-polyposis colon cancer syndrome 
caused by germline mutations in mismatch repair genes (e.g., MLH1, MSH2, MSH6, 
PMS1 and PMS2); hereditary diffuse gastric carcinoma resulting from germline 
mutations in the CHD1 gene (known also as E-cadherin gene); Li Fraumeni syndrome 
caused by mutations in p53 gene, and familial adenomatous polyposis due to 
mutations in the APC gene (9).  
 
Most of the research conducted so far, however, concerns the effect of environmental 
and genetic factors on sporadic gastric cancer. In 1994, the IARC classified the 
infection with H. pylori as a class I human carcinogen (10). This germ causes an initial 
damage by initiating chronic inflammation of gastric mucosa, which is mediated by an 
array of pro-and anti-inflammatory cytokines. During the following decades H. pylori 
infection can remain silent or evolve into more-severe diseases, such as atrophic 
gastritis, peptic ulcer, intestinal metaplasia, dysplasia and cancer. However, even 
though past or present H. pylori infection has been found in up to 70% of patients with 
sporadic adenocarcinoma of the stomach, only 2% of infected individuals actually 
develop stomach cancer (11), so that H. pylori appears to be neither a necessary nor 
even a sufficient cause. This has been explained by the complex interplay between 
other component causative factors for gastric cancer, such as tobacco smoking, low 
fruit and vegetable intake, high meat and salt intake and alcohol consumption (7). 
Additionally, more recently the long suspected influence of genetic susceptibility to H. 
pylori damages of gastric mucosa has come to forefront. Since El-Omar et al (12) 
firstly investigated in 2000 the relationship between the pro-inflammatory IL-1 gene 
cluster polymorphisms and non-cardia gastric cancer, several studies have been 
published. According to a recent meta-analysis (13), Caucasian individuals carrying the 
T variant allele of IL-1B-511 have an increased risk of developing gastric cancer 
compared with the homozygous wild types. Another large meta-analysis (14) also 
showed that Caucasians carrying the *2 polymorphic allele of the receptor antagonist 
of IL-1β, coded by the IL-1 RN gene, have a significantly increased risk of gastric 
cancer, especially in combination with H. pylori infection.  
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Beside the IL-1 gene cluster, which mainly affects the capacity of the host in handling 
the H. pylori attack and mediating the resulting inflammation, other candidate genes 
have been investigated in association with the risk of sporadic gastric cancer (9,15). 
Among the most extensively gene studied are those affecting with the individual ability 
to detoxify tobacco and alcohol carcinogens that might be relevant for gastric 
carcinogenesis (16). Most of the published studies, however, considered only few 
phase I and/or II metabolic gene variants at time, and even less their interaction and 
combination with tobacco and alcohol exposures (17), so that results concerning the 
effect of metabolic gene polymorphisms on gastric cancer risk remain inconclusive. 
Other genes relevant for tumorigenesis were also investigated in relation with gastric 
cancer. Among them, the methylenetetrahydrofolate reductase (MTHFR) gene, which is 
involved in the DNA synthesis and in gene expression control through DNA 
methylation, and genes involved in the cell cycle control such as p53 and p73 tumor 
suppressor genes. While evidences suggest a key role for MTHFR in gastric 
carcinogenesis (18), results on the potential effect of p53 and p73 genes are 
inconclusive, with no one study considering the combination of the two most common 
gene variants in relation with gastric cancer. 
 
Generally speaking, the majority of the genetic association studies conducted so far in 
relationship with sporadic gastric cancer, however, are underpowered to detect a 
robust association, or to explore gene-gene and gene-environment interactions. As 
such, some authors attempted to quantitatively summarize the results of the literature 
on certain gene polymorphisms and gastric cancer by using the meta-analytical 
approach. Currently meta-analysis is the most cited study design in health sciences 
(19), and it is widely accepted as one of the highest levels of evidence in medicine to 
evaluate existing data. Initially adopted to summarize the results from clinical trials, 
meta-analyses were then widely applied to observational studies, including genetic 
epidemiology studies. The reliability of meta-analysis results, however, depends mainly 
on a rigorous methodology, on the quality of primary studies included and the 
availability for individual data collected from primary studie. In this context, the Meta-
analysis of Observational Studies in Epidemiology group proposed a checklist for 
authors of a meta-analysis containing specifications on how to structure the 
background, search strategy, methods, results, discussion and conclusion (20).  More 
recently, another eminent research group published the PRISMA statement for 
reporting systematic reviews and meta-analyses, builded on the QUORUM statement 
(21), that further clarified how to elaborate and report such studies (22). 
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The objective of the work described in this thesis was dual: 
- to investigate the association of candidate genes and gastric cancer risk by 
selecting genes that, given their function, should have a high probability to be 
involved in gastric cancer; 
- to assess the cumulative evidence on the most extensively studied gene 
polymorphisms in association with gastric cancer risk through meta-analyses 
and pooled analysis.  
 
The first aim was conducted at the Institute of Hygiene in collaboration with the 
Department of Surgery located in the Policlinico ‘A. Gemelli’ teaching hospital, which 
enrols since 2002 consecutive cases of primary gastric adenocarcinoma patients with 
histological confirmation that undergo curative gastrectomy. The study is approved by 
the local review board and written informed consent is obtained from each subject, and 
the procedures adopted are in accordance with the Helsinki Declaration. Control 
subjects are selected from gastric cancer-free patients admitted to the same hospital 
during the same time period with a broad range of diagnoses. 
 
The candidate genes for the case-control study were selected according to their 
relevance in different oncogenic process, namely detoxification of carcinogens, 
synthesis of DNA and cell cycle control. This work is described in the chapter 2 of this 
thesis. Chapter 2.1 reports the results of the effect of polymorphisms in genes involved 
in the bioactivation (phase I enzymes) and detoxification (phase II enzymes) of 
promutagens and carcinogens on gastric cancer risk. Chapter 2.2 describes the 
potential role on gastric cancer aetiology of two functional polymorphisms in the 
MTHFR gene, which is involved in the metabolism of folate and providing methyl donor 
for DNA methylation and deoxynucleoside synthesis. Chapter 2.3 studies the 
association between polymorphisms in p53 and p73 tumour suppressor genes and 
gastric cancer. In all the studies the relevant gene-gene and gene-environment 
interactions were explored. 
The second part of this thesis reports the results of three meta-analyses and a pooled 
analysis summarizing the effect of polymorphisms in a phase I enzyme (Chapter 3.1), 
phase II enzymes (Chapters 3.2 and 3.3), and in MTHFR gene (Chapter 3.4), on the 
risk of gastric cancer. Chapter 4 reviews the main results of the studies described in 
this thesis and discusses them in the context of the current knowledge and potential 
methodological limitations. Finally, some suggestions for future research are provided. 
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2.1 
 
Polymorphisms in metabolic genes, 
 their combination and interaction  
with tobacco smoke and alcohol  
consumption and risk of gastric cancer:  
a case-control study in an Italian population 
 
 
 
ABSTRACT 
 
The distribution and the potential gene-gene and gene-environment interaction of 
selected metabolic genetic polymorphisms was investigated in relation to gastric cancer 
risk in an Italian population. One hundred and seven cases and 254 hospital controls, 
matched by age and gender, were genotyped for CYP1A1, CYP2E1, mEH, GSTM1, 
GSTT1, NAT2 and SULT1A1 polymorphisms. Haplotype analysis was performed for 
EPHX1 exons 3 and 4, as well as CYP2E1 RsaI (*5 alleles) and CYP2E1 DraI (*5A or *6 
alleles). The effect modification by alcohol and cigarette smoking was tested with the 
heterogeneity test, while the attributable proportion (AP) was used to measure the 
biological interaction from the gene-gene interaction analysis. Gastric cancer risk was 
found to be associated with the inheritance of GSTT1 null genotype (OR= 2.10, 95% 
CI: 1.27-3.44) and the SULT1A1 His/His genotype (OR= 2.46, 95% CI: 1.03-5.90). No 
differences were observed for the haplotype distributions among cases and controls. An 
increased risk was detected among individuals carrying the *6 variant allele of CYP2E1 
if ever-drinkers (OR= 3.70; 95% CI: 1.45-9.37) with respect to never-drinkers (OR= 
0.18; 95% CI: 0.22-1.46) (p for heterogeneity = 0.001). Similarly, the effect of 
SULT1A1 variant genotype resulted restricted to ever-smokers, with an OR of 2.58 
(95% CI: 1.27-5.25) for the carriers of His allele among smokers, and an OR of 0.86 
(95% CI: 0.45-1.64) among never-smokers (p for heterogeneity = 0.03). Gene-gene 
interaction analyses demonstrated that individuals with combined GSTT1 null and NAT2 
slow acetylators had an additional increased risk of gastric cancer, with an OR of 3.00 
(95% CI: 1.52-5.93) and an AP of 52%. GSTT1, SULT1A1 and NAT2 polymorphisms 
appear to modulate individual’s susceptibility to gastric cancer in this Italian 
population, particularly when more than one unfavourable genotype is present, or 
when combined with cigarette smoke. All the results need to be confirmed by larger 
prospective studies. 
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INTRODUCTION 
 
Gastric cancer is the second most common cause of mortality from cancer, with 
647,000 deaths reported worldwide in 2002 (1). In many populations, particularly in 
high-income countries, in the last decades its incidence has gradually decreased, 
however it still represents the fifth most common type of cancer in Europe and the 
fourth internationally (1). The development of gastric cancer appears to be the result 
of a complex interaction between lifestyle and genetic factors. Among the lifestyle and 
related risk factors, Helicobacter pylori infection, tobacco smoking, a high intake of salt 
and lack of food refrigeration all seem to play a major role (2). Additionally, gastric 
cancer shows a familial clustering (3). With regards to genetic factors, several Single 
Nucleotide Polymorphisms (SNPs) might potentially alter the individual susceptibility to 
gastric cancer, among them genes coding for metabolic enzymes (4). 
A major part of carcinogenic substances require metabolic activation by enzymes to be 
genotoxic, and inherited variations in carcinogens metabolizing genes may alter 
enzyme activity and subsequently carcinogens activation or deactivation. Phase I 
enzymes, including Cytochrome P450 (CYP) and microsomal Epoxide Hydrolase (mEH), 
activate several compounds to form genotoxic electrophilic intermediates. Activated 
metabolites are then, in part, detoxified by phase II enzymes, such as glutathione S-
transferase (GST), N-acetyltransferase (NAT) and Sulfotransferase (SULT) (5). We 
recently showed, for the first time, that SULT1A1 Arg213His polymorphism might affect 
the risk of gastric cancer (6), while contradictory results concerning several SNPs in 
metabolic genes have been reported (7-15). 
Based on the knowledge that metabolic genes are presumed to modulate an 
individual’s susceptibility to cancer by interacting with carcinogens, and since the 
inheritance of several unfavourable genotypes is supposed to additionally increase the 
risk of gastric cancer (8,9,11), this hospital-based case-control study aims to 
investigate the effect on gastric cancer of selected SNPs of CYP1A1, CYP2E1, mEH, 
GSTM1, GSTT1, NAT2, SULT1A1, and their differential effect according to tobacco 
smoking and alcohol habits. We also investigated to what extent the inheritance of 
more than one unfavourable genotype affects the risk of gastric cancer. 
 
 
METHODS 
 
Study population  
The study subjects were selected according to a case-control study design as 
previously described (16). Briefly, cases were consecutive primary gastric 
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adenocarcinoma patients, with histological confirmation, who underwent a curative 
gastrectomy in the "A. Gemelli" teaching hospital, located within the Università 
Cattolica del Sacro Cuore in Rome. We defined gastric cancer cases as including 
International Classification of Disease Ninth revision codes 151.0-151.9. Controls were 
selected from cancer-free patients, with a broad range of diagnoses including around 
15% of blood donors, admitted to the same hospital during the identical time period 
and were frequency matched to cases for age (±5 years) and gender. All subjects were 
Caucasians born in Italy. According to the Lauren histotype classification (17), the 
majority (57.8%) of the gastric cancer cases were intestinal. The tumours were located 
in the antrum (39.3%), in the corpus (14.8%), in the antrum/corpus (28.0%), in the 
cardia (10.3%), stumps (5.6%) and in the fundum (2.0%). Based on the cytological 
and architectural atypisms, as well as the histo-pathological reports (18), patients’ 
tumours were classified accordingly: 68.3% scarcely differentiated, 29.2% moderately 
differentiated, 2.5% well-differentiated, while 53.8% were staged I-II and 46.2% 
staged III-IV. With a response rate of 95% and 90% respectively for cases and 
controls, 102 gastric cancer and 254 controls were recruited. A venous blood sample 
was drawn from each participant, collected into an EDTA-coated tubes from which DNA 
was isolated from peripheral blood lymphocytes. The study was approved by the local 
review board and written informed consent was obtained from each subject. The 
procedures followed were in accordance with the Helsinki Declaration. 
 
Data collection  
Cases and controls were interviewed by trained medical doctors using a standard 
questionnaire to elicit information on demographic variables, tobacco smoking 
(including cigarette, cigar and pipe) and drinking history, dietary habits and family 
history of cancer. Questions pertaining to lifestyle focused on the time period ending 
one year prior to diagnosis. Smoking status was categorized as never and ever-
smokers (including both current and former smokers) and alcohol consumption as 
drinkers/non-drinkers. Fruit and vegetables intake was classified as high if the 
participant consumed at least two portions of fruit and two portions of vegetables per 
day. Meals salt addition was referred to the use of adding salt to the entrées during the 
main meals. Family history (including non-melanoma skin cancer) of cancer referred to 
parents, siblings and offspring. Data concerning previous Helicobacter pylori infection 
was not available for either cases or controls. The response rate for completing the 
interview was 99.1% for cases (106/107) and 99.6% (253/254) for controls, with the 
exception of data relating to a family history of cancer [(unknown in 7.4% (8/107) of 
cases and 3.5% (9/254) of controls)]. 
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Genotyping 
GSTM1 and GSTT1 null alleles were identified using a multiplex-Polymerase Chain 
Reaction (PCR)-based method as described by Arand et al. (19). The polymorphic site 
at nucleotide 638 in exon 7 (Arg213His) of the SULT1A1 gene was genotyped by PCR- 
Restriction Fragment Length Polymorphisms (RFLP) analysis as described by Coughtrie 
et al.(20). Identification of the mEH exon 3 (Tyr113His) and exon 4 (His139Arg) 
polymorphisms was performed using a RFLP-based method (21). CYP1A1 3’-flanking 
region MspI polymorphism (CYP1A1*2A allele), CYP2E1 RsaI polymorphism (CYP2E1*5 
alleles) and CYP2E1 DraI (*5A or *6 alleles) were also determined by PCR-RFLP 
analyses (21). Three known slow acetylator alleles, NAT2*5A, *6A and *7A were 
identified as previously described by Peluso et al (22). Fast acetylator genotypes are 
the homo-heterozyogous wild-type alleles (*4A), slow acetylator genotypes are those 
with 2 slow acetylator alleles (23). Quality control for each genotyping was performed 
in each experiment, and 10% of the total samples were randomly selected and 
reanalyzed with 100% concordance. The analyst was blinded to the case or control 
status of the samples.  
 
Statistical analysis 
The relationship between gastric cancer and putative risk factors were measured using 
the adjusted odds ratios (ORs) and their 95% CI derived from logistic regression 
analysis using STATA software (version 8.2). We considered possible risk factors for 
gastric cancer as potential confounders if the addition of that variable to the model 
changed the OR by 10% or greater. Confounding checks were performed in both of the 
univariate and final multivariate models. If a factor was identified as a confounder of 
any estimated main effect, it was kept in all models. Based on these criteria, we 
controlled for age, gender, alcohol consumption and family history of cancer, when 
appropriate. In the multivariable model, we adjusted for the continuous variables of 
age and alcohol (g/day).  
The genotypes of GSTM1 and GSTT1 were dichotomized according to the presence 
versus absence of the null allele, and NAT2 was dichotomized according to the inferred 
phenotype (slow versus fast). We analyzed exon 3 and exon 4 mEH genotypes by 
“imputed phenotype” as suggested from Smith and Harrison (24). Lastly, we conducted 
haplotype analysis for EPHX1 exons 3 and 4, as well as CYP2E1*5 and *5A or *6 using 
Cocaphase software  
(http://www.mrc-bsu.cam.ac.uk/personal/frank/software/unphased).  
Hardy-Weinberg Equilibrium (HWE) was tested for separately all of the case and 
control SNPs. In order to assess if the effect of the studied polymorphisms is modified 
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by tobacco smoking and alcohol consumption, we performed a stratified logistic 
regression analysis. An heterogeneity test was then used to test differences among the 
strata. 
Biological interaction between two genes was estimated using departure from additivity 
of effects as the criterion of interaction, as suggested by Rothman (25). To quantify the 
amount of interaction, the attributable proportion (AP) due to interaction was 
calculated as described by Andersson et al (26). The AP due to interaction is the 
proportion of individuals among those exposed to the two interacting factors that is 
attributable to the interaction per se and it is equal to 0 in the absence of a biological 
interaction (25). Finally, in order to test for more than multiplicative effect among two 
genes, the likelihood ratio test was used, with the homozygous wild-type individuals for 
both genes as the reference group. 
 
 
RESULTS 
 
General characteristics of the study population are presented in Table 1. Alcohol 
consumption and family history of cancer were associated with an increased risk of 
gastric cancer, with ORs of 2.10 (95% CI: 1.22-3.60) and an OR of 1.93 (95% CI: 
1.14-3.26), respectively (Table 1). The genotype frequencies of our control group were 
in line with those for Caucasians and were in HWE both for cases and controls (p > 
0.05) (5, 20). As shown in Table 2, we found a significant difference in the distribution 
of GSTT1 null and SULT1A1 His/His genotype amongst cases and controls: 37.1% 
versus 22.4% (OR= 2.10, 95% CI: 1.27-3.44) and 10.3% versus 5.1% (OR= 2.46; 
95% CI: 1.03-5.90), respectively. An increased risk was also detected for NAT2 slow 
acetylators (OR= 1.38, 95% CI: 0.88-2.19), however not statistically significant. 
Haplotype analyses indicated that there was no significant linkage disequilibrium 
between EPHX1 exons 3 and 4, as well as CYP2E1*5 and *5A or *6, amongst the cases 
and the controls. Furthermore, the frequency of the estimated haplotypes was the 
same among the groups (data not shown).  
Data were stratified according to the histologic type and similar effects were shown 
among the two strata (data not shown). From the stratified analysis according to 
smoking status (Table 3), the significant association for SULT1A1 observed in the 
overall analysis seems to be limited to ever smokers, with a p value for heterogeneity 
among the two strata of 0.03 (Table 3). On the other hand, the increased risk for 
GSTT1 null individuals was significant regardless of the smoking status (Table 3). 
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Table 1. Odds Ratios (95% CI) of gastric cancer according to the collected variables and their frequency 
distribution among 107 cases and 254 controls  
 Cases n (%) Controls n (%) OR (95% CI) † 
Age (years± SD) 66.4±12.0 64.0±12.8 - 
Male gender  56 (52.3) 141 (55.5) - 
Alcohol drinkers     
                 Never-drinkers° 32 (29.9) 121 (47.6) 1* 
                 Drinkers 73 (70.1) 133 (52.4) 2.10 (1.22-3.60) 
Smoking status    
                 Never 57 (53.3) 146 (57.5) 1* 
                 Ever 50 (46.7) 108 (42.5) 1.10 (0.64-1.90) 
Pack-years of smoking    
                 0  60 (56.0) 147 (57.8) 1* 
                 1-25 21 (19.6) 63 (24.8) 0.97 (0.50-1.92) 
                 > 25 26 (24.4) 44 (17.4) 1.03 (0.50-2.10) 
Fruit and vegetables intake     
                 High‡ 19 (17.9) 40 (16.6) 1* 
                 Low 87 (82.1) 212 (83.4) 0.92 (0.45-1.84) 
Meals salt addition ^    
No 91 (85.1) 235 (92.9) 1* 
Yes 16 (14.9) 18 (7.1) 1.70 (0.78-3.67) 
Family history of cancer     
      No 61 (61.6) 192 (78.4) 1* 
      Yes 38 (38.4)   53 (21.6) 1.93 (1.14-3.26) 
Family history of gastric cancer     
      No 88 (91.7) 237 (94.4) 1* 
      Yes   8 (8.3)  14 (5.6) 1.88 (0.80-4.44) 
 
* Reference category 
† OR adjusted for age, gender, alcohol consumption and family history of cancer 
° Never-drinkers defined as those who are teetotaller 
‡ High fruit and vegetables consumption is defined as at least 2 portions of fruit and 2 portions of 
vegetables per day 
^ Adding salt to the entrées during the main meals 
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Table 2. Odds Ratios (95% CI) of gastric cancer for SNPs in metabolic genes and their frequency 
distribution among 107 cases and 254 controls 
 
  Cases n (%) Controls n (%)  OR (95% CI) * † 
GSTM1 null 59 (56.2) 134 (52.7) 1.13 (0.71-1.79) 
GSTT1 null 39 (37.1)   57 (22.4) 2.10 (1.27-3.44) 
CYP1A1*2A 23 (20.5)   56 (22.0) 0.88 (0.50-1.54) 
CYP2E1*5   5 (4.7)   20 (7.8) 0.54 (0.20-1.50) 
CYP2E1*5A or *6 14 (14.5)   27 (10.6) 1.33 (0.67-2.65) 
NAT2 Slow ‡ 64 (59.8) 131 (51.8) 1. 38 (0.88-2.19) 
Arg/His 39 (36.5)   85 (33.5) 1.35 (0.82-2.21) SULT1A1 
 His/His 11 (10.3)   13 (5.1) 2.46 (1.03-5.90) 
Tyr/His 41 (38.7)   90 (36.0) 1.24 (0.76-2.04) 
EPHX1 exon 3 
His/His 15 (14.1)   28 (11.2) 1.37 (0.67-2.80) 
His/Arg 32 (30.5)   95 (37.4) 0.77 (0.47-1.27) 
EPHX4 exon 4 
Arg/Arg   6 (5.7)     6 (2.4) 2.28 (0.70-7.20) 
Rapid 15 (15.8)   59 (23.7) 0.60 (0.30-1.15) 
Slow 24 (25.3)   54 (21.2) 1.00 (0.55-1.78) Imputed mEH 
phenotypes ^ 
Very slow   8 (8.4)   21 (8.6) 0.82 (0.33-2.00) 
 
* OR adjusted for age and gender 
† Reference groups are the homozygous wild genotypes for each gene 
‡ Reference group is fast acetylators (homo-heterozygous for the wild-type allele) 
^ Reference group is the normal imputed phenotype 
 
 
As for the effect modification by alcohol habits, drinking subjects carrying the variant 
allele of CYP2E1 (*5A or*6 alleles) had an OR of 3.70 (95% CI: 1.45-9.37) of gastric 
cancer compared to those drinking without the variant allele, with the result of the 
heterogeneity test among the strata showing a significant effect modification by alcohol 
(p value = 0.001, Table 3). To reduce the chance of multiple testing, we limited the 
gene-gene interaction analyses to the three SNPs that exhibited the most prominent 
association with gastric cancer. It was observed that in all of the combinations 
individuals carrying two risk genotypes had an additional risk compared to those with 
only one risk genotype, with an AP greater than 0, however there was no evidence of 
multiplicative interaction (p values > 0.05, Table 4). The observed effect was 
particularly high amongst individuals with both GSTT1 null and NAT2 slow (OR= 3.00, 
95% CI: 1.52-5.93; AP = 52%) (Table 4). Additionally, by stratifying these data 
according to smoking status (data not shown), ever-smoker individuals with combined 
GSTT1 null and NAT2 slow had an OR of 4.23 (95% CI: 1.49-12.01) compared to ever-
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smokers with combined normal variants, while an OR of 2.60 (95% CI: 1.00-6.67) 
appeared using the same comparators amongst never-smokers (p value of 
heterogeneity among the two estimates = 0.49).  
 
 
Table 3. Odds Ratios (95% CI) of gastric cancer for SNPs in metabolic genes according to smoking status 
and alcohol habits 
 
  Never-smokers  
(57 cases, 146 controls) 
Ever-smokers  
(50 cases, 108 controls) 
p for 
heterogeneity 
 
cases/ 
controls OR (95% CI) * † 
cases/ 
controls OR (95% CI)   
GSTM1 null 33/70 1.55 (0.83-2.90) 26/64 0.70 (0.35-1.39) 0.10 
GSTT1 null 21/34 2.09 (1.06-4.11) 18/23 2.17 (1.02-4.59) 0.92 
CYP1A1*2A  14/33 1.09 (0.53-2.27) 8/23 0.66 (0.27-1.61) 0.40 
CYP2E1*5 4/11 0.86 (0.26-2.88) 1/9 0.20 (0.02-2.70) 0.24 
CYP2E1*5A or *6  10/17 1.59 (0.67-3.79) 5/10 0.99 (0.31-3.13) 0.58 
NAT2 Slow ‡ 34/77 1.39 (0.74-2.60) 30/54 1.50 (0.75-2.98) 0.87 
SULT1A1 His carriers 22/62 0.86 (0.45-1.64) 27/36 2.58 (1.27-5.25) 0.03 
EPHX1 exon 3 His carriers 28/62 1.31 (0.70-2.46) 28/56 1.12 (0.57-2.22) 0.69 
EPHX4 exon 4 Arg 
carriers 
21/63 0.84 (0.44-1.60) 16/38 0.89 (0.43-1.85) 0.85 
  Never-drinkers  
(32 cases, 121 controls) 
Ever-drinkers  
(73 cases, 133 controls) 
p for 
heterogeneity 
  
cases/ 
controls 
OR (95% CI) 
cases/ 
controls 
OR (95% CI)   
GSTM1 null 16/64 0.95 (0.43-2.10) 43/70 1.23 (0.69-2.20) 0.55 
GSTT1 null 13/24 3.15 (1.32-7.47) 26/33 1.72 (0.92-3.22) 0.27 
CYP2E1*5 0/10 - 5/10 0.86 (0.28-2.68) - 
CYP2E1*5A or *6  1/19 0.18 (0.22-1.46) 14/8 3.70 (1.45-9.37) 0.001 
SULT1A1 His carriers 16/51 1.42 (0.63-3.17) 33/47 1.56 (0.86-2.82) 0.98 
* OR adjusted for age and gender  
† Reference groups are the homozygous wild genotypes for each gene  
‡ Reference group is fast acetylators (homo-heterozygous for the wild-type allele) 
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Table 4. Age and gender adjusted Odds Ratios (95% CI) of gastric cancer for selected gene-gene 
interaction analyses 
  GSTT1 SULT1A1 
  Present Null Arg/Arg His carriers 
Fast 1*  1. 38 (0.63-3.01) 1* 1.45 (0. 71-2.95) 
cases/controls  30/93 13/29 23/74 20/48 
Slow 1.07 (0.61-1.88) 3.00 (1.52-5.93) 1.40 (0. 75-2.60) 2.00 (1.03-3.89) 
cases/controls 36/103 26/28 35/81 29/50 
 p for interaction† = 0.17 p for interaction = 0.97 
NAT2 
 AP‡= 52% AP= 8% 
Arg/Arg 1* 1.53 (0.86-2.71) - - 
cases/controls 35/122 22/34   
His carriers 2.30 (1.18-4.45) 2.87 (1.36-6.05) - - 
cases/controls 31/75 17/23   
 p for interaction = 0.70   
SULT1A1 
 AP= 1%  
 
* Reference category; † By likelihood ratio test; ‡ Attributable Proportion due to biological interaction (see 
methods) 
 
 
DISCUSSION 
 
This case-control study of 107 surgical cases of gastric adenocarcinoma and 254 
controls born in Italy evaluated the effect on gastric cancer risk of several metabolic 
gene polymorphisms simultaneously. Results showed a significantly increased risk for 
GSTT1 null and for SULT1A1 homozygotes, and an additional risk for NAT2 slow 
acetylator individuals, although not statistically significant. Risks associated with those 
genes became substantive when two unfavourable genotypes were combined, with 
evidence of biological interaction between them. From the gene-environment 
interaction analysis, we showed effect modification of the association between 
SULT1A1 and gastric cancer by tobacco smoking, and CYP2E1 (*5A or*6 alleles) by 
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alcohol drinking. In addition, our results confirm previous findings of gastric cancer risk 
to be increased by alcohol intake and family history for cancer (27,28).  
Several limitations should be taken into account in the interpretation of our results. 
Firstly, based on the prevalence of the analyzed genotypic variants in our population 
(Table 2), our study was powered to detect an OR of 2.0 for common polymorphisms 
(with a significance level of 5%), however not for CYP2E1*5 allele carriers, CYP2E1*5A 
or*6 allele carriers and the homozygotes variants of SULT1A1, EPHX3 and EPHX4. The 
study’s sample size limits the ability to explore the combined effects of the genotypes, 
or gene-environment interactions, which highlights the need to increase the sample 
size in order to confirm our results. However, when appropriately conducted, large and 
small studies should give, theoretically, the same results, with just a more precise 
effect measure estimate from the larger ones (29). Secondly, as in all case-control 
studies information bias may exist, leading to biased ORs related to the gene-
environment interaction results. Thirdly, data on Helicobacter pylori infection were not 
available in our population. 
This is the first study conducted on an homogenous ethnic group who evaluated the 
effect on gastric cancer risk of several metabolic genes SNPs contemporarily, and the 
effect of their combination with tobacco and alcohol. One of the main source of 
confounding in the genetic association studies arises from population stratification, 
since the ethnicity itself may be related to a specific disease and to the allele 
frequencies as well (30,31). Our study showed a significant association between GSTT1 
null genotype and gastric cancer, which is in keeping with the results of a recent meta-
analysis considering only high-quality papers (8). Individuals who have the 
homozyogous deletion in GSTT1 have no enzyme activity, and thus are more 
susceptible to carcinogens such as benzo()pyrene-7,8-diol epoxide and smaller 
reactive hydrocarbons, such as ethylene oxide and diepoxybutane (8). We also 
reported that individuals carriers of the SULT1A1 variant allele, who have limited 
detoxification capability of xeniobiotics through sulfonate conjugation, have an 
additional risk of gastric cancer if smokers.  
 
To our knowledge, we reported for the first time a strong effect modification by alcohol 
of the association between CYP2E1*5A or *6 alleles and gastric cancer, with an 
increased risk among ever-drinkers. Two previous studies (32,33) reported no 
association between CYP2E1*5A or *6 allele and gastric cancer, however no one of 
them stratified data according to alcohol habits. Additionally, one study evaluating the 
identical association among black South-African males showed an increased risk of 
oesophageal cancer among drinkers carrying the CYP2E1*5A or *6 alleles (34). CYP2E1 
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is a naturally ethanol-inducible enzyme that is mainly involved in the metabolic 
activation of N-nitrosamines present in tobacco smoke and some dietary compounds, 
for which a causative role in gastric carcinogenesis has been hypothesised (2), and in 
the metabolism of fatty acids and several halogenated and aromatic compounds (35). 
Additionally, CYP2E1 plays a minor role in alcohol metabolism, through the oxidation of 
ethanol to acetaldehyde and 1-hydroxyacetyl radicals (35). The *5A or *6 alleles of 
CYP2E1 is characterized by some studies in an increased gene expression (36), so that 
individuals carrying the unfavourable variant might be at higher risk of gastric cancer 
because of: i) hyper activation of N-nitrosamines in more reactive species, especially 
among drinkers since enzyme activity is induced by alcohol; ii) hyper production of 
reactive oxygen species and subsequent cell toxicity generated by ethanol metabolism 
among drinkers. We expected to gain similar results for CYP2E1 RsaI polymorphism, 
identically associated with increased enzyme activity, however the few subjects in the 
stratified analysis probably did not show it. Since these results, however, are based on 
very few subjects (only one case drinker bearing *5A or *6 alleles) they need to be 
confirmed by larger studies. 
Among the main results of our study, we found that GSTT1 null genotype individuals 
contemporarily NAT2 slow acetylators have a strongly increased risk of gastric cancer, 
with a more than just the additive effect of the risks associated with each of the two 
inherited SNPs. N-acetylation is considered a major detoxification step for carcinogenic 
aromatic arylamines, while GSTT1 is involved in the detoxification of polycyclic 
aromatic hydrocarbons, so individuals with one or both depleted phase II enzyme 
activities might be particularly susceptible to gastric damage from carcinogens, which 
is supported by the finding of an additional risk for ever-smokers. We used the 
attributable proportion due to interaction as a measure to quantify the biological 
interaction between those combined SNPs and showed a strong interaction between 
them. Assuming that the relationships studied are causal and based on the definition of 
biological interaction among two component causes (25,37), our results suggest that 
52% of gastric cancer cases among GSTT1 null individuals with combined NAT2 slow 
acetylator phenotype are caused through a mechanism in which both risk factors are 
biological dependent in the same disease process. In other words, since biological 
interaction among two causes occurs when the effect of one is dependent from the 
presence of the other, in the absence of either of the two components (GSTT1 null or 
NAT2 slow), than a substantial number of gastric cancer cases would not occur. Given 
that in our population 25% of cases had a combination of those unfavourable 
genotypes, this means that a non negligible proportion of gastric cancer cases would 
have never developed if those enzymatic activities were adequate.  
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In conclusion, this study suggests that in this Italian population, GSTT1, SULT1A1 and 
NAT2 polymorphisms may modulate an individual’s susceptibility to gastric cancer, 
particularly when more than one unfavourable genotype is present and in combination 
with cigarette smoke. Additionally, we showed that individuals carrying the *5A or *6 
alleles of CYP2E1 are at increased risk for gastric cancer in drinkers. Clearly, since our 
study is based on a limited number of cases, it is critical that larger prospective studies 
possibly based on a single ethnic group confirms our results. 
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Methylenetetrahydrofolate reductase  
C677T and A1298C polymorphisms and  
susceptibility to gastric adenocarcinoma  
in an Italian population 
 
 
 
ABSTRACT 
 
Methylenetetrahydrofolate reductase (MTHFR) plays a central role in the metabolism of 
folate, which provides methyl donor for DNA methylation and deoxynucleoside 
synthesis. We performed a case-control study to explore the relationship between two 
common MTHFR polymorphisms (C677T and A1298C), their combination and 
interaction with environmental exposures, on gastric adenocarcinoma susceptibility and 
progression in an Italian population. One hundred and two cases and 254 hospital 
controls, matched by age and gender, were enrolled. Individuals carrying MTHFR 677T 
allele showed an increased risk of gastric cancer (OR=1.62; 95% CI: 0.98-2.67), 
particularly among ever smokers (OR= 2.10; 95% CI: 1.07-5.33) and, among 677 TT 
individuals, those with a low intake of fruit and vegetables (OR= 2.18; 95% CI: 1.05-
4.54). The strongest effect, however, was noted for the MTHFR 677 TT genotype 
among the diffuse gastric cancer histotype (OR=2.92; 95% CI: 1.12-7.60). No 
association was detected for the effect of MTHFR A1298C polymorphism. Survival 
analysis did not show any association between each polymorphism on the overall 
survival, although when the analysis was restricted to the first year of follow up after 
the surgical intervention an improved survival was noted among MTHFR 677 CC 
subjects compared to the T allele carriers (p value for log-rank test = 0.02). In 
conclusion, MTHFR 677 any T genotype appears to modulate individual’s susceptibility 
to gastric cancer, particularly when combined with cigarette smoke and among those 
with a low intake of fruit and vegetables. Our results also suggest that aberrant DNA 
methylation pattern, trough impaired folate metabolism, might play a key role in 
gastric carcinogenesis. A possible survival effect of MTHFR C677T genotype in gastric 
cancer patients deserves further investigations with larger sample sizes. 
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INTRODUCTION 
 
Fruit and vegetables intake has been repeatedly reported as protective for cancer 
occurrence including gastric cancer (1). A recent meta-analysis of prospective studies 
showed an inverse association between fruit and vegetables intake and gastric cancer 
incidence, particularly for follow-up periods at least of 10 years (2). The protective 
effect against cancer might be referable to the combined action of a number of the 
antioxidants micronutrients, such as β-carotene, vitamin C and E, retinol, and the 
folate content (3). Folate is a water-soluble B vitamin that plays the fundamental role 
of providing methyl groups for intracellular methylation reactions and de novo 
deoxynucleoside synthesis (4). Two prominent mechanisms whereby folate deficiency 
may influence cancer risk have been described (5): low folate levels might induce 
misincorporation of uracil into DNA, which could lead to chromosomal breaks and 
mutations; and/or by causing DNA hypomethylation, resulting in altered gene 
expression (6).  
Besides an inadequate folate intake, functional polymorphisms in key enzymes 
involved in folate metabolic pathway are supposed to modify the risk of cancer. Among 
them, the methylenetetrahydrofolate reductase (MTHFR) enzyme irreversibly converts 
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the primary circulating 
form of folate. Two functional polymorphisms of the MTHFR, C677T and A1298C, have 
been identified (7), so that heterozygotes (CT) and homozygotes (TT) for the mutant 
allele of 677 respectively have 65% and 30% of the enzyme activity of individuals with 
wild-type genotype, while CC homozygotes for MTHFR 1298 polymorphism have an 
enzyme activity around 50-60% of those without the variant allele (7, 8). Individuals 
with the TT genotype for MTHFR 677 have significantly lower plasma folate levels than 
those with the wild-type genotype, while for the 1298 variant the evidences are 
inconsistent (9). Some nutrients (eg, vitamin B6 and B12, and methionine) involved in 
the folate metabolic pathway, as well as alcohol (a folate antagonist) and smoking 
(which impairs folate stauts) may interact with folate and the MTHFR polymorphisms in 
relation to cancer risk (10,11).  
A recently published meta-analysis shows no significant protective effect of dietary 
folate intake on gastric cancer, while an increased risk associated with the MTHFR 677 
TT genotype has been detected (5). Few studies, however, explored a possible effect 
modification of MTHFR C677T polymorphism on gastric cancer risk by environmental 
exposures affecting folate status (12,13,14), and no one ever explored this aspect in 
relation to MTHFR A1298C polymorphism. Furthermore, nothing is known about the 
influence of those genetic variants on the survival of gastric cancer patients. In the 
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present study we aimed to investigate the effect of both MTHFR C677T and A1298C 
polymorphisms, their combination and the interaction with lifestyle exposures that 
might affect plasma folate levels, on gastric cancer development and progression in an 
Italian population. 
 
 
METHODS 
 
Study population and genotyping 
The study subjects were selected according to a case-control study design as 
previously described (15). Briefly, cases were consecutive primary gastric 
adenocarcinoma patients, with histological confirmation, who underwent a curative 
gastrectomy in the "A. Gemelli" teaching hospital, located within the Università 
Cattolica del Sacro Cuore in Rome. Controls were selected from cancer-free patients, 
with a broad range of diagnoses, admitted to the same hospital during the identical 
time period and were frequency matched to cases for age (±5 years) and gender. All 
subjects were Caucasians born in Italy. According to the Lauren classification, the 
majority (57.8%) of the gastric cancer cases were intestinal (16). The tumours were 
located in the antrum (39.3%), in the corpus (14.8%), in the antrum/corpus (28.0%), 
in the cardia (10.3%), stumps (5.6%) and in the fundum (2.0%). Based on the 
cytological and architectural atypisms, as well as the histo-pathological reports (17), 
patients’ tumours were classified accordingly: 68.3% scarcely differentiated, 29.2% 
moderately differentiated, 2.5% well-differentiated, while 53.8% were staged I-II and 
46.2% staged III-IV. With a response rate of 95% and 90% respectively for cases and 
controls, 102 gastric cancer and 254 controls were recruited.  
A venous blood sample was drawn from each participant, collected into an EDTA-
coated tubes from which DNA was isolated from peripheral blood lymphocytes. 
Genotyping for MTHFR C677T and A1298C polymorphisms were performed using a 
restriction-fragment length polymorphism based method, as already described by Yi et 
al (18). Quality control for each genotyping was performed in each experiment, and 
10% of the total samples were randomly selected and reanalyzed with 100% 
concordance. The analyst was blinded to the case or control status of the samples. The 
study was approved by the local review board and written informed consent was 
obtained from each subject. The procedures followed were in accordance with the 
Helsinki Declaration. 
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Data collection  
Cases and controls were interviewed by trained medical doctors using a standard 
questionnaire to elicit information on demographic variables, cigarette smoking and 
drinking history, dietary habits and family history of cancer. Questions pertaining to 
lifestyle focused on the time period ending one year prior to diagnosis. Smoking status 
was categorized as never and ever-smokers (including both current and former 
smokers). Pack-years were calculated as years smoked multiplied by the current 
number (or previous number, for those who had quit) of cigarettes smoked per day 
divided by 20. Fruit and vegetables intake was classified as high if the individual 
consumed at least two portions of fruit and vegetables per day. Family history of 
cancer referred to parents, siblings and offspring. Cases were actively followed-up after 
the day of surgical intervention with a median follow-up time of 19.5 months, and 
information on all-cause mortality was collected. The proportion of lost to follow-up 
was 11.7% (12/102).  
 
Statistical analysis  
The relationship between gastric cancer and putative risk factors were measured using 
the adjusted odds ratios (ORs) and their 95% CI derived from logistic regression 
analysis using STATA software (version 8.2). A variable was defined as confounder if 
the addition of that variable to the model changed the OR by 10% or greater. If a 
factor was identified as a confounder of any estimated main effect, it was kept in all 
models. Based on these criteria, we controlled for age, gender, alcohol consumption 
and family history of cancer, when appropriate. In the multivariable model, we 
adjusted for the continuous variables of age and alcohol. Hardy-Weinberg Equilibrium 
(HWE) was tested for separately all of the case and control polymorphisms.  
In order to asses if the effect of the studied polymorphisms is modified by lifestyle 
exposures that might affect folate status, we performed a logistic regression analysis 
stratified for alcohol, smoking status and fruit and vegetables intake (the main source 
of dietary folate). An heterogeneity test was then used to test differences among the 
strata. In this analysis we used as a reference group those homozygous wild-type 
individuals who had not been exposed to environmental factors; smoking status was 
here considered as ever/never cigarette smokers and alcohol consumption as 
users/non-users.  
Finally, the log-rank test was used to evaluate the association between both MTHFR 
polymorphisms and the survival at 1-year, 3-years and the overall survival after gastric 
surgery intervention. The risk of death was also estimated by Cox’s proportional 
hazards model, when applicable. Hazard ratios (HR) were adjusted for age and gender, 
with the wild-type genotypes as the reference group.  
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RESULTS 
 
General characteristics of the study population are presented in Table 1. Alcohol 
consumption and family history of cancer were associated with an increased risk of 
gastric cancer, with ORs of 2.10 (95% CI: 1.21-3.67) and 3.74 (95% CI: 1.13-12.45) 
for moderate and heavy drinkers, respectively, and an OR of 1.80 (95% CI: 1.04-3.06) 
for individuals with a familial history of cancer (see Table 1). The genotype frequencies 
of our control group were in line with those for Caucasians (19) and were in HWE both 
for cases and controls (p > 0.05). As shown in Table 2, we found a significant 
difference in the distribution of MTHFR 677T carriers among cases and controls: 71.6% 
versus 61.4%, respectively, with an OR of 1.62 (95% CI: 0.98-2.67). When results 
were stratified according to tumour histology, the strongest effect was noted among 
the diffuse type, with an OR of 2.92 (95% CI: 1.12-7.60) for MTHFR 677 TT (Table 2). 
From the analysis of the combined effect of the MTHFR C677T and A1298C, no one 
subject was homozygous for the mutant allele at both sites (data not shown). Among 
subjects carrying both MTHFR 677 TT and 1298 AA, the OR was 2.21 (95% CI: 0.84-
5.80), and similarly individuals with both MTHFR 677 CT and 1298 AC genotypes had 
an OR for gastric cancer of 1.95 (95% CI: 0.80-4.81) compared to those with 
combined 677 CC/1298 AA (data not shown). The heterogeneity test, however, showed 
that none of these differences was statistically significant, probably due to the very 
small number of both variant alleles in the analysis. 
From our analysis there was no evidence of effect modification of MTHFR 677 and 1298 
polymorphisms by the lifestyle exposures (Table 3), however ever smokers carrying 
the MTHFR 677 T allele showed a significant increased risk (OR= 2.40; 95% CI: 1.07-
5.33) of gastric cancer, while among never smokers that risk appeared not significant 
(OR= 1.16; 95% CI: 0.60-2.52). Additionally, when MTHFR 677 TT genotype was 
stratified according to the fruit and vegetable intake, an OR of 0.49 (95% CI: 0.04-5.9) 
and 2.18 (95% CI: 1.05-4.54) resulted among high and low consumers, respectively 
(data not shown; p value of heterogeneity among the estimates= 0.09).  
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Table 1. Odds Ratios (95% CI) for gastric cancer according to selected variables and their frequency 
distribution among 102 gastric cancer cases and 254 controls 
 Cases n (%) Controls n (%) OR (95% CI) † 
Age (years± SD) 66.3±12.1 64.0±13.0 - 
Male gender 54 (53.0) 141 (55.5) - 
Alcohol drinkers     
                 0- 6 g/day 40 (39.6) 150 (59.3) 1* 
                 7- 29 g/day 53 (52.5) 96 (37.9) 2.10 (1.21-3.67) 
                 > 30 g/day 8 (7.9) 7 (2.8) 3.74 (1.13-12.45) 
Smoking status    
                 Never 54 (53.0) 146 (57.5) 1* 
                 Ever 48 (47.1) 108 (42.5) 1.09 (0.63-1.90) 
Pack-years of smoking     
                  0 55 (55.0) 146 (57.7) 1* 
                  1-25 21 (21.0) 62 (24.5) 0.97 (0.50-1.92) 
                  > 25 24 (24.0) 44 (17.8) 1.05 (0.53-2.12) 
Fruit and vegetables intake     
                  High‡ 19 (18.8) 40 (15.9) 1* 
                  Low 82 (81.2) 212 (84.1) 0.96  (0.50-1.85) 
Meals salt addition      
                   No 88 (86.3) 235 (92.9) 1* 
                   Yes 14 (13.7) 18 (7.1) 1.52  (0.68-3.41) 
Family history of cancer     
                   No 59 (62.8) 192 (78.4) 1* 
                   Yes 35 (37.2) 53 (21.6) 1.80  (1.04-3.06) 
 
† = OR adjusted by age, gender, alcohol consumption and family history of cancer 
* = Reference category 
‡=  At least two portions of fruit and vegetables per day 
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Table 2. Distribution of the studied polymorphisms in 102 gastric cancer cases and 254 controls  
 
  Cases n (%) Controls n (%) 
All cases 
OR (95% CI) † 
Intestinal 
OR (95% CI) † 
Diffuse 
OR (95% CI) † 
MTHFR 677      
CC 29 (28.4)   98 (38.6) 1* 1* 1* 
CT 51 (50.0) 115 (45.3) 1.53 (0.90-2.62) 1.27 (0.67-2.41) 2.45 (1.09-5.50) 
TT 22 (21.6)   41 (16.1) 1.84 (0.95-3.59) 1.27 (0.55-2.92) 2.92 (1.12-7.60) 
T carriers 73 (71.6) 156 (61.4) 1.62 (0.98-2.67) 1.27 (0.70-2.32) 2.58 (1.19-5.58) 
MTHFR 1298      
AA 50 (49.0) 125 (49.2) 1* 1* 1* 
AC 43 (42.2) 107 (42.1) 0.98 (0.60-1.59)  0.47 (0.33-1.63)  0.72 (0.36-1.45)  
CC  9 (8.8)   22 (8.7) 0.97 (0.42-2.27) - 1.50 (0.52-3.91) 
C carriers 52 (51.0) 129 (50.8) 0.98 (0.62-1.55) 1.06 (0.60-1.88) 0.84 (0.44-1.60) 
† = OR adjusted by age and gender 
* = Reference category 
 
 
The mortality rate in our gastric cancer cases was 1.01/100 person-months (95% CI: 
0.70-1.45). Patients carrying at least one MTHFR 677 T allele did not show a different 
median survival time (p value for log-rank test = 0.49), with an HR of 1.19 (95% CI: 
0.49-2.92) and 1.79 (95% CI: 0.67-4.78) for MTHFR CT and TT genotypes, 
respectively. Namely, 10 out of 51 MTHFR CT individuals and 8 out of 22 MTHFR TT 
died in the follow-up period. Similar results were obtained for MTHFR 1298T carriers, 
with an HR of 1.05 (95% CI: 0.50-2.22; p value for log-rank test= 0.82) compared 
with the homozygous wild-type. When the analysis was restricted to 1 year survival, 
MTHFR 677 CC subjects all resulted alive respect to those carrying at least one 677 T 
allele (p value for log-rank test = 0.02) (Figure). However, when the time period was 
extended to 3-years the effect was not longer detected (p value for log-rank test = 
0.60). Absence of a survival affect was noted for MTHFR 1298C carriers when 
restricting the analysis to the first year and three years after the surgical intervention 
(data not shown). 
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Figure. Association between MTHFR C677T genotypes and 12 months survival after the gastric surgery 
intervention   
 
p value log-rank test = 0.02 
 
 
DISCUSSION 
 
This case-control study of 102 surgical cases of gastric adenocarcinoma and 254 
controls evaluated the effect on gastric cancer risk of two common MTHFR 
polymorphisms. Results showed an increased risk for MTHFR 677T carriers, with a 
growing trend from individuals carrying only one variant allele to those carrying two (p 
value for trend = 0.05). That risk became higher in patients with the diffuse gastric 
cancer histological type. No association was detected for the effect of MTHFR A1298C 
polymorphism on gastric cancer risk, also with no evidence of effect modification by 
the lifestyle exposures. An increased risk was detected among ever-smokers carrying 
at least one MTHFR 677 variant allele and among those MTHFR 677 TT with a low 
intake of fruit and vegetables, despite the results of the heterogeneity test did not 
support a true effect modification in both instances. Our results also confirm previous 
findings of gastric cancer risk to be increased by alcohol intake and familial clustering 
(20,21). Additionally, from the survival analysis a possible effect was noted when 
considering only the first year follow-up, with all died subjects among those carrying at 
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least one 677 T allele. 
Some limitations of the study need to be considered before interpreting the results. 
Firstly, based on the prevalence of the analyzed genotypic variants in our control 
population (see Table 2), our study is powered to detect a minimum OR of 2.0 for the 
effect of MTHFR 677T carriers and MTHFR 1298C carriers (with a significance level of 
0.05), however the power is lower for the homozygote variants of both genotypes. The 
study sample size also limits the ability to explore the effect modification of the 
environmental exposures, or the the combined effects of both genotypes, which 
highlights the need to increase the sample size in order to confirm our results. 
However, when appropriately conducted, large and small studies should give, 
theoretically, the same results, with just a more precise effect measure estimate from 
the larger ones (22). Secondly, as in all case-control studies information bias may 
exist, leading to biased ORs related to the lifestyle exposures.  
Our study supports the evidence of an increased risk for gastric cancer among 
individuals carrying the unfavourable variant of MTHFR 677, thus confirming the results 
of the two recently published meta-analyses (5,23). Individuals who are MTHFR 677T 
carriers have reduced enzyme activity and, particularly among those with inadequate 
folate intake (13), subsequent aberrant genomic DNA methylation. We also observed 
that the risk for MTHFR 677T carriers is higher among those with a diffuse gastric 
cancer histotype, which is the most deadly form of gastric cancer (24), as already 
noted by Lacasana-Navarro et al. (25). Recently, aberrant methylation of proto-
oncogenes has been explored as both a mechanism and marker of carcinoma 
progression (26), with some papers reporting a different methylation pattern between 
the intestinal and diffuse gastric cancer histotype (27,28). Taken together, these 
results suggest that global aberrant DNA methylation pattern might play a key role in 
gastric cancer susceptibility and progression, with the MTHFR enzyme playing a central 
part. 
In the present study we observed that the effect of the MTHFR 677 variant genotype is 
particularly strong among ever-smokers, which is in keeping with the results from Gao 
et al (14). As for the negative effect of smoking on folate status, some authors 
reported that elevated folate turnover in response to rapid tissue proliferation in 
aerodigestive tissues among people exposed to tobacco smoke might partially explain 
this phenomenon, that might be even worsened among individuals carrying the 
unfavourable MTHFR genotype variant (29). We cannot ignore, however that this effect 
might be confused by alcohol intake or dietary habits (30).  
To our knowledge, no one study ever explored whether or not the effect of MTHFR 677 
TT genotype on gastric cancer is modified by folate levels measured by serological 
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tests, however two studies reported a strong association between MTHFR 677 TT and 
gastric cancer in populations with folate deficiency (13,31). Also, a prospective study 
on colorectal cancer risk reported that the protective effect of MTHFR 677 TT genotype 
disappears among those with folate deficiency (32), so we would expect a partial 
reduction of the negative effect on gastric cancer risk by the MTHFR 677 variant among 
those with adequate folate intake. From our study it appears that the effect of the 
MTHFR 677 variant genotypes on gastric cancer might be modified by fruit and 
vegetables intake, the main source of dietary folate, particularly among TT individuals. 
The lack of statistical power, however, limits our result which need to be confirmed by 
increasing the sample size. 
As for the combined inheritance of the two MTHFR variants, although all the reported 
results are not statistically significant for an  = 0.05, there is a slight evidence of an 
increased risk in individuals carrying at least one T allele of MTHFR C677T, which is 
keeping with the results of Miao et al. (31).  
Finally, we were not able to detect any effect of the studied polymorphisms on the 
overall survival after surgical gastrectomy intervention, however when considering the 
first year of follow-up an increased mortality rate was experienced from MTHFR 677T 
carriers when compared with the CC individuals. Despite the result is based on a very 
few number of subjects, it suggests that a different pathway of tumour progression 
might be experienced from gastric cancer patients based on their MTHFR 677 
polymorphism that eventually affects folate blood levels and DNA methylation status. A 
recent study on the assessment of folic acid supplementation on colorectal adenomas 
failed to detect a preventive effect, while an increased risk of colorectal neoplasia was 
revealed among treated individuals (33). To our knowledge, similar trials have never 
been conducted on gastritis or gastric cancer individuals, therefore the exact effect on 
gastric carcinogenesis of folic acid levels, affected by MTHFR status, deserves 
additional investigations in order to integrate all the results into one coherent picture.  
In conclusion, this study supports the role of MTHFR C677T polymorphism, but not 
A1298C, in gastric carcinogenesis, particularly for the diffuse histotype which is usually 
associated with a poorer prognosis. In order to gain a clearer picture of the events 
influencing gastric cancer susceptibility and progression through the folate metabolic 
pathway, it is critical that larger prospective studies with appropriate collection of data 
on lifetsyle exposures and folate intake are implemented. This would lay the foundation 
for evaluating possible benefits from preventive nutritional intervention in at-risk 
individuals for gastric cancer.  
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A case-control study on the effect of  
p53 and p73 polymorphisms on  
gastric cancer risk and progression 
 
 
 
ABSTRACT 
 
p53 protein and its functional homologue p73 share some functions, as modulating 
cell-cycle control and apoptosis. Based on the functional interaction between p53 and 
p73 in carcinogenesis, we investigated the combined effect of p73 G4C14-to-A4T14 
and p53 polymorphisms and their interaction with selected environmental factors, on 
the risk of gastric cancer in hospital-based case-control study conducted in Italy. Their 
effect on cancer progression has also been investigated. One-hundred fifteen cases and 
295 hospital controls were genotyped for p73 G4C14-to-A4T14, and p53 exon4 
(Arg72Pro), intron 3 and 6 polymorphisms. An increased risk of gastric cancer was 
found to be associated with the inheritance of p73 homozygous variant genotype 
among the gastric cancer intestinal histotype [(odds ratio (OR) = 6.75; 95% 
confidence interval (95% CI)=1.88–24.24)]. An effect modification of p73 variant allele 
by gender was observed [(OR= 2.82; 95% CI: 1.24–6.40) among females, versus an 
OR of 0.70 (95% CI: 0.32-1.54) among males; p value for heterogeneity among strata 
estimates = 0.03]. Gene-gene interaction analyses demonstrated that individuals with 
combined p53 exon 4 and intron 6 variant alleles are borderline significantly protected 
from gastric cancer (OR=0.52; 95% CI: 0.26-1.07; p value for interaction=0.005), 
which was confirmed by the haplotype analysis. Lastly, a poorer survival resulted 
among gastric cancer cases with an intestinal histotype carriers of the variant allele of 
p53 intron 6 compared to those carrying both wild-type alleles (p value for log-rank 
test = 0.02). This study shows that p73 G4C14-to-A4T14 polymorphism might be a 
risk factor for gastric cancer, as reported from other studies in different tumour sites 
among Caucasians. Along with the protective effect of p53 exon 4-intron 6 allelic 
variants, already noted for breast and lung cancer, our results require confirmation 
from larger studies. 
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INTRODUCTION 
 
The incidence of gastric cancer is decreasing in recent decades in most western 
countries; nevertheless it remains the second leading cause of death from cancer 
worldwide (1). Gastric carcinogenesis is a multistep process, in which environmental 
and genetic factors interact.  
The response of gastric mucosa to exogenous damaging injuries is partly 
regulated by inhibitory and stimulatory factors, which are products of proto-oncogenes 
and tumor suppressor genes. Improper function of these inhibitory and stimulatory 
factors is associated with a chronic damage of the gastric mucosa (2). Among these 
key proteins are: the p53 tumor suppressor gene (17p13), which encodes a protein 
involved in cell cycle regulation and differentiation, DNA repair, and apoptosis (3), and 
the p73 gene (1p36-33), a p53 homologue for both the amino acid sequence (4) and 
DNA binding domain that encodes a protein inhibiting cell growth by inducing apoptosis 
in a p53-like manner (4,5). It has been reported that the p73 gene maps on a region 
often deleted in a variety of human cancers (6). Both p53 and p73 genes are highly 
polymorphic, with at least 13 single nucleotide polymorphisms (SNPs) described for 
p53 and 19 for p73 (7).  
Currently the p53 exon4 Arg72Pro polymorphism is the only p53 SNP whose 
role has been extensively studied in relation to gastric cancer. A polymorphism in this 
codon has been suggested to modulate p53-dependent apoptosis and modify 
sensitivity to chemotherapeutic agents (8). A recent meta-analysis shows a 
significantly higher frequency of the homozygous variant genotype in gastric cancer 
cases compared with controls in Asians but not Caucasians (2). Two intronic 
polymorphisms of p53 consisting of a 16-bp duplication in intron 3 and a G→A 
transition in intron 6 have been investigated in relation to lung, ovarian, breast and 
colon cancer, with conflicting results (9-12). To our knowledge, no study has 
investigated the association of these two SNPs with gastric cancer. As for the p73 
gene, several reports investigated the relationship between the p73 G4C14-to-A4T14 
polymorphism and cancer (7,13-15). Among these, a study conducted in Asians 
showed no association with gastric cancer (14). The p73 G4C14-to-A4T14 dinucleotide 
polymorphism consists of two SNPs in complete linkage disequilibrium (13) located at 
positions 4 (G→A) and 14 (C→T) in the non-coding region of exon 2. These lie just 
upstream of the initiating AUG of the exon and potentially influence gene expression by 
forming a stem-loop structure (15). The influence of p53 intron 3 and 6 polymorphisms 
on the survival of gastric or other cancer patients has never been investigated. A poor 
disease-free survival for breast, lung, colorectal and head and neck cancer has been 
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reported in patients homozygous for the p53 exon4 Arg72Pro mutant allele compared 
with the wild type genotype (8,16-18). One study reports an improved survival of 
colorectal cancer patients carrying the variant allele of p73 G4C14-to-A4T14 (19). 
The aim of our hospital-based case-control study was to investigate the effects 
of the p73 G4C14-to-A4T14 polymorphism and three p53 polymorphisms in exon 4 and 
introns 3 and 6, on gastric adenocarcinoma risk and progression in an Italian 
population. We also explored the impact of different combinations of these 
polymorphisms and their interaction with environmental factors on the risk of gastric 
cancer. 
 
 
METHODS 
Study population and genotyping 
The study subjects were selected according to a case-control study design as 
previously described (20,21). Briefly, cases were consecutive primary gastric 
adenocarcinoma patients, with histological confirmation, who underwent a curative 
gastrectomy in the "A. Gemelli" teaching hospital during the period from 2002 to 2007. 
Controls were selected from cancer-free patients, with a broad range of diagnoses, 
admitted to the same hospital during the same time period. All subjects were 
Caucasians born in Italy. With a response rate of 95% and 90% respectively for cases 
and controls, 115 gastric cancer and 295 controls were recruited, the majority (58.2%) 
of the gastric cancer cases were intestinal, according to Lauren classification (22). The 
tumours were located in the antrum (40.0%), in the corpus (14.6%), in the 
antrum/corpus (24.6%), in the cardia (3.6%), stumps (5.4%), in the fundum (1.8%), 
in the cardia/corpus (7.3%) and the entire stomach (2.7%). Based on the cytological 
and architectural atypisms, as well as the histo-pathological reports (23), patients’ 
tumours were classified as follows: 69.5% poorly differentiated (G3), 28.1% 
moderately differentiated (G2), 2.4% well-differentiated (G1). 54.2% of tumors were 
staged I-II and 45.8% were staged III-IV.  
A venous blood sample was drawn from each participant and collected into an 
EDTA-coated tube from which DNA was isolated from peripheral blood lymphocytes. 
Genotyping for p53 exon 4 codon 72 (rs1042522), p53 intron 3 (rs17883323), p53 
intron 6 (rs1625895) polymorphisms was performed using a polymerase chain reaction 
(PCR) followed by restriction-fragment length polymorphism, as already described by 
Wu et al (9). Genotyping of p73 exon 2 G4C14-to-A4T14 (rs 2273953/rs 1801173) was 
performed using PCR as described by Niwa et al (4). We conducted haplotype analysis 
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for p53 intron 3, p53 exon 4 codon 72 and p53 intron 6 polymorphisms using EH 
software (24) and cocaphase (25). 
Quality control for each genotyping was performed in each experiment, and 
10% of the total samples were randomly selected and retested with 100% 
concordance. The analyst was blinded to the case or control status of the samples. The 
study was approved by the local review board and written informed consent was 
obtained from each subject. The procedures followed were in accordance with the 
Helsinki Declaration. 
 
Data collection  
Cases and controls were interviewed by trained medical doctors using a structured 
questionnaire to collect information on demographic data, cigarette smoking, drinking 
history, dietary habits, physical activity and family history of cancer. Participants were 
asked to focus on the year prior to diagnosis (for controls the year prior to the 
interview date) when answering questions regarding lifestyle habits. Smoking status 
was categorized as never- and ever-smokers (including both current and former 
smokers). Pack-years were calculated as years smoked multiplied by the current 
number (or previous number, for those who had quit) of cigarettes smoked per day 
divided by 20. Fruit and vegetable intake was classified as high if the individual 
consumed at least two portions of fruit and two portions of vegetables per day. “Meals 
salt addition” referred to the use of adding salt to the main-meal entrées. Physical 
activity was classified as high if the individual has physical training at least 2 
times/week. Family history of cancer referred to parents, siblings and offspring. Data 
concerning previous Helicobacter pylori infection were not available for either cases or 
controls. The response rate for completing the interview was 92% for cases and 97% 
for controls, with the exception of data relating to grilled meat intake (unknown in 12% 
of cases and 16.6% of controls) and the family history of cancer (unknown in 7.8% of 
cases and 3% of controls). Cases were actively followed-up after the day of surgical 
intervention with a median follow-up time of 19 months and information on all-cause 
mortality was collected. The proportion of lost to follow-up was 11.3% (13/115).  
 
Statistical analysis  
The relationship between gastric cancer and putative risk factors was measured using 
the adjusted odds ratios (ORs) and their 95% CI derived from logistic regression 
analysis using STATA software (version 8.2). A variable was defined as confounder if 
the addition of that variable to the model changed the OR by 10% or greater. If a 
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factor was identified as a confounder of any estimated main effect, it was kept in all 
models. Based on these criteria, we controlled for age, alcohol consumption, family 
history of cancer, fruit and vegetable intake and salt use. In the multivariate model, we 
adjusted for the continuous variables of age and alcohol. Hardy-Weinberg Equilibrium 
(HWE) was tested separately for all of the case and control SNPs.  
In order to examine if the effects of the studied polymorphisms are modified 
by age, gender, family history of cancer, and some environmental exposures, we 
performed a logistic regression analysis stratified for age, gender, alcohol, smoking 
status and family history of cancer. An heterogeneity test was then used to test 
differences among the strata. In this analysis we used as a reference group those 
homozygous wild-type individuals who had not been exposed; age was categorized 
binomially (< 45 and ≥ 45 years old), smoking status was considered as ever/never 
cigarette smokers, and alcohol consumption as drinkers/non-drinkers (the latter 
including individuals whose alcohol intake was less than 7 g/day). A gene-gene 
interaction analysis was performed among the four SNPs, and the likelihood ratio test 
was used for more than multiplicative effect among each pair of SNPs, with the 
homozygous wild-type individuals for both genes as the reference group (26).  
Additionally, the log-rank test was used to evaluate the effect of the four SNPs 
on survival at 1-year, 2-years, and the overall survival after gastric surgery 
intervention. Finally, we stratified survival analyses by cancer histotype 
(intestinal/diffuse).  
 
 
RESULTS 
 
General characteristics of the study population are presented in Table 1. Alcohol 
consumption and meals salt addition were associated with an increased risk of gastric 
cancer, with ORs of 1.70 (95% CI: 1.02-2.83) and 6.71 (95% CI: 2.19-20.56) for 
moderate and heavy drinkers, respectively, and an OR of 2.27 (95% CI: 1.05-4.90) for 
individuals usually adding salt to meals (Table 1). Additionally, family history of cancer 
was associated with an increased risk of gastric cancer, with an OR of 2.02 (95% CI: 
1.18-3.46; Table 1). The genotype frequencies of our control group were in line with 
those for Caucasians (9) and respected HWE as detailed in Table 2 (p value > 0.05). As 
shown in Table 2, there were no significant differences in the distribution of the p53 
polymorphisms among cases and controls, even when cases were stratified by tumour 
histology.  
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Table 1. Odds Ratios (95% CI) for gastric cancer according to selected variables and their frequency 
distribution among 115 gastric cancer cases and 295 controls 
 
Cases n (%) Controls n (%) OR (95% CI) † 
Age (years± SD) 66.7±11.7 63.5±13.1 - 
Male gender 63 (54.8) 165 (56.0) - 
Alcohol drinkers    
                 0-6 g/day 49 (42.6) 182 (61.7) 1* 
                 7-29 g/day 53 (46.0) 106 (35.9) 1.70 (1.02-2.83) 
                ≥ 30 g/day 13 (11.4) 7 (2.4) 6.71 (2.19-20.56) 
Smoking status    
                 Never 63 (55.3) 176 (59.7) 1* 
                 Ever 51 (44.7) 119 (40.3) 1.05 (0.63-1.76) 
Pack-years of smoking    
                  0 64 (57.7) 179 (62.0) 1* 
                  1-25 21 (18.9) 66 (22.8) 0.96 (0.50-1.81) 
                  > 25 26 (23.4) 44 (15.2) 1.35 (0.68-2.68) 
Fruit and vegetables intake    
                  High‡ 19 (16.8) 40 (14.0) 1* 
                  Low 94 (83.2) 247 (86.0) 0.91 (0.47-1.76) 
Meals salt addition    
                  No 96 (84.2) 266 (93.0) 1* 
                  Yes 18 (15.8) 20 (7.0) 2.27 (1.05-4.90) 
Physical activity    
                  High #   17 (14.9) 30 (10.2) 1* 
                  Low 97 (85.1) 263 (89.8) 0.67 (0.33-1.36) 
Family history of cancer    
                   No 67 (63.2) 232 (81.4) 1* 
                   Yes 39 (36.8) 53 (18.6) 2.02 (1.18-3.46) 
Family history of gastric cancer    
                   No 100 (91.7) 270 (94.7) 1* 
                   Yes  9 (8.3) 15 (5.3) 0.56 (0.20-1.60) 
 
* Reference category 
† OR adjusted by age, gender, alcohol consumption, family history of cancer, and meals salt addition 
* Reference category 
‡ At least two portions of fruit and vegetables per day 
# At least two times/week 
 
 
On the other hand, our data showed a significant difference in the distribution of the 
p73 AT/AT genotype among cases and controls: 7.0% versus 3.4%, respectively, with 
an OR of 4.77 (95% CI: 1.50-15.19) (Table 2). 
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When results were stratified according to tumour histology, the significant association 
between p73 homozygous variant genotype and gastric cancer was limited to the 
intestinal type, with an OR of 6.75 (95% CI: 1.88-24.24; Table 2). The estimated p53 
pairwise haplotype frequencies among the three polymorphisms and their linkage 
disequilibrium values in cases and controls are shown in Table 3. The pairwise linkage 
disequilibria were highly significant in both control and patient population (p value for 
χ2 test < 0.001). The frequency of exon 4 (Pro)/intron 6 A diplotype was lower in cases 
than in controls (9.8% versus 17.7%), with a decreased gastric cancer risk (OR= 
0.56; 95% CI: 0.37-0.97) if compared with the reference exon 4 (Arg)/intron 6 G 
diplotype. 
There were no significant differences in the remaining diplotype frequencies among 
cases and controls (p value > 0.1; Table 3). When the estimation of haplotype 
frequencies was extended to all three SNPs (Table 4), results show no significant 
difference in the haplotype frequencies among cancer patients and controls (p value > 
0.1). 
From the analysis there was no evidence of effect modification of the four SNPs by 
environmental exposures (data not shown), neither by age nor family history of cancer. 
The only one exception was gender, which was shown to be an effect modifier of the 
association between p73 variant allele carriers and gastric cancer [(OR= 2.82 (95% CI: 
1.24-6.40) among females versus OR= 0.70 (95% CI: 0.32-1.54) in males (p value of 
heterogeneity among the estimates = 0.03)]. From the gene-gene interaction analysis 
there was no evidence of multiplicative interaction among the four polymorphisms (p 
values > 0.05, Table 5), except for individuals carrying the mutant alleles of both p53 
exon 4 and p53 intron 6 that appeared to be protected from gastric cancer with an OR 
of 0.52 (95% CI: 0.26-1.07; p value for interaction = 0.005), showing a less than 
multiplicative combined effect. On the other hand an OR of 3.19 (95% CI: 1.01-10.02) 
was observed for those p53 exon 4 wild-type homozygotes, carrying also one p53 
intron 6 variant allele at least. 
The mortality rate in our gastric cancer cases was 1.01/100 person-months (95% CI:  
0.71-1.44). Individuals carrying at least one variant allele for each of the four SNPs did 
not show a different median survival time (p value of log-rank test > 0.05), even when 
the analysis was restricted to 1 year and 2-years after the surgical intervention (data 
not shown). However, when the analysis was restricted to the intestinal histotype, an 
increased overall mortality rate was observed among individuals carrying the p53 
intron 6 variant allele compared to those with both wild-type alleles (p value for log-
rank test = 0.02).  
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Table 2. Distribution of the studied polymorphisms in 115 gastric cancer cases and 295 controls 
 
Cases 
n (%) 
Controls 
n (%) 
HWE^ 
All cases 
OR (95% CI) † 
Intestinal (n.61) 
OR (95% CI) † 
Diffuse (n.44) 
OR (95% CI) † 
p53 intron 3  
(rs1788332)   
 
   
WW 80 (70.2) 209 (70.8) 1* 1* 1* 
WM 27 (23.7) 76 (25.8) 0.91 (0.51-1.63) 1.07 (0.53-2.13) 0.69 (0.30-1.59) 
MM 7 (6.1) 10 (3.4) 1.65 (0.52-5.22) 1.12 (0.22-5.60) 2.08 (0.55-7.79) 
M carriers 34 (29.8) 86 (29.2) 
0.349 
1.02 (0.60-1.76) 1.10 (0.56-2.13) 0.86 (0.41-1.82) 
p53 exon4 Arg72Pro  
(rs1042522)    
 
   
Arg/Arg 71 (62.3) 169 (57.3) 1* 1* 1* 
Arg/Pro 34 (29.8) 102 (34.6) 0.80 (0.47-1.38) 0.76 (0.39-1.49) 0.80 (0.38-1.67) 
Pro/Pro 9 (7.9) 24 (8.1) 0.74 (0.29-1.83) 0.59 (0.18-1.93) 0.89 (0.27-2.92) 
Pro carriers 43 (37.7) 126 (42.7) 
0.130 
0.79 (0.47-1.30) 0.72 (0.39-1.36) 0.82 (0.41-1.62) 
p53 intron 6  
(rs1625895)   
 
   
GG 82 (71.9) 192 (65.1) 1* 1* 1* 
GA 25 (22.0) 87 (29.5) 0.73 (0.41-1.30) 0.65 (0.32-1.34) 0.80 (0.37-1.72) 
AA 7 (6.1) 16 (5.4) 0.96 (0.32-2.83) 0.55 (0.11-2.74) 1.46 (0.42-5.09) 
A carriers 32 (28.1) 103 (34.9) 
0.148 
0.75 (0.44-1.27) 0.62 (0.31-1.23) 0.91 (0.45-1.82) 
p73 exon 2 G4A    
(rs 1801173/ 
rs 2273953)   
 
   
GC/GC 84 (73.7) 214 (72.5) 1* 1* 1* 
GC/AT 22 (19.3) 71 (24.1) 0.96 (0.53-1.75) 0.84 (0.39-1.81) 1.28 (0.60-2.72) 
AT/AT 8 (7.0) 10 (3.4) 4.77 (1.50-15.19) 6.75 (1.88-24.24) 3.33 (0.59-18.78) 
AT carriers 30 (26.3) 81 (27.5) 
0.183 
1.25 (0.73-2.16) 1.28 (0.66-2.49) 1.41 (0.68-2.90) 
 
^ p value for the 2 -test   
† = OR adjusted by age and gender 
* = Reference category 
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Table 3. Pairwise haplotype frequency in the gastric cancer patients and controls 
 No. alleles Estimated haplotype frequency D’ p value 
   ‡ 1 - 1 1 - 2^ 2 - 1 2 - 2   
Intron 3-exon 4†        
Cases 228 0.709 0.110 0.062 0.117 0.55 <0.001 
Controls 588 0.713 0.122 0.031 0.132 0.74 <0.001 
        
Intron 3-intron 6†        
Cases 228 0.774 0.046 0.055 0.125 0.67 <0.001 
Controls 588 0.763 0.074 0.035 0.128 0.73 <0.001 
        
exon 4-intron 6*        
Cases 228 0.699 0.073 0.129 0.098 0.45 <0.001 
Controls 588 0.719 0.026 0.078 0.177 0.83 <0.001 
 
† 2 -test: cases versus controls; p value >0.1 
* p value< 0.001 
‡ 1= intron 3 (W), exon 4 Arg, intron 6 G 
^ 2= intron 3 (M), exon 4 Pro, intron 6 A 
 
 
Table 4. Estimated p53 haplotype frequencies in the gastric cancer patients and controls 
  
Alleles 
 
 
1 - 1 - 1 
 
1 - 1 - 2 
 
1 - 2 - 1 
 
1 - 2 - 2 
 
2 - 1 - 1 
 
2 - 1 - 2 
 
2 - 2 - 1 
 
2 - 2 - 2 
Intr 3-ex 4-intr 6          
Cases 228 0.655 0.040 0.119 0.027 0.027 0.029 0.027 0.074 
Controls 588 0.693 0.020 0.070 0.053 0.026 0.005 0.008 0.123 
 
2 -test: cases vs controls; p value > 0.1 
1=intron 3 (W), exon 4 Arg, intron 6 G; 2= intron (M), exon 4 Pro, intron 6 A 
 
 
DISCUSSION 
 
This case-control study of 115 gastric cancer cases and 295 hospital based controls 
evaluated the effect of four polymorphisms in the p53 and p73 genes on the gastric 
adenocarcinoma risk in an Italian population. To our knowledge, this is the first study 
showing in a Caucasian population that the p73 exon 2 homozygous variant genotype  
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increases the risk of gastric cancer 4.77-times compared with individuals with the wild 
type genotype, and that the risk is particularly increased for the intestinal histotype. 
Additionally, the gene-environment interaction analysis shows an effect modification by 
gender on the association of p73 and gastric cancer, with an increased risk only among 
females. Results show the absence of a significant association between p53 exon 4 and 
gastric cancer, which is in line with the results of a recently published meta-analysis 
(2), while for the first time a borderline significant protective effect was detected for 
individuals carrying the mutant alleles of p53 exon 4 and intron 6. Lastly, our results 
failed to detect an association between p53 introns 3 and 6 and gastric cancer, as 
previously shown in relation with other tumour sites (27,28), while carriers of the p53 
intron 6 variant allele had a poorer prognosis for intestinal gastric adenocarcinoma 
after surgical intervention.  
Before interpreting our results, some limitations of the study should be taken 
into account. Firstly, on the basis of the prevalence of the analyzed polymorphisms in 
our control population, our study is powered to detect a minimum OR of 1.9 for the 
effect of mutant allele carriers for all studied polymorphisms (with a significance level 
of 5%), and an OR of 4.0 for p73 homozygous variant genotype. The study’s sample 
size limits the possibility to explore the combined effects of the genotypes, or gene-
environment interactions, thus we need to increase the sample size in order to confirm 
our results. However, when appropriately conducted, large and small studies should 
give, theoretically, the same results, with just a more precise effect measure estimate 
in the larger studies (29). Secondly, as in all case-control studies, information bias may 
exist, leading to biased ORs related to data about the lifestyle and environmental 
exposures. Thirdly, data on Helicobacter pylori infection were unavailable in our 
population. 
Our study reports for the first time a strong association between the p73 exon 
2 G4C14-to-A4T14 polymorphism and gastric cancer risk in a Caucasian population. 
When results are stratified according to tumor histology, the effect of the homozygous 
variant seems to be limited to the intestinal subtype. One study conducted in a 
Japanese population (14) reported no association between this SNP and digestive tract 
cancers including gastric cancer, however discrepant results are reported for other 
tumour sites. In a large hospital-based case control study of a Non-Hispanic White 
population, Li et al. (30) showed that the p73 AT variant allele is associated with an 
increased risk of head and neck cancer and lung cancer (13). Identical results were 
reported in a Swedish population of colorectal cancer patients carrying the homozygous 
variant genotype (19). On the other hand, Ryan et al. (31) showed in a small Irish 
population that p73 AT/AT carriers are significantly protected from oesophageal cancer. 
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In contrast, several studies conducted in Asians did not provide evidence for an 
association between the p73 G4C14-to-A4T14 polymorphism and the risk of lung 
(15,32,33), breast (34,35) or oesophageal cancer (14,36), except one study which 
showed a borderline increased risk for cervical cancer (4). We can argue, as previously 
suggested (13), that the p73 exon 2 G4C14-to-A4T14 polymorphism might play a 
different role in cancer risk depending on ethnic group and cancer site. In our study 
gender appears to be an effect modifier of the association between p73 AT variant 
allele and gastric cancer, with females at an increased risk compared to males. Based 
on previous findings showing that women tend to have a lower capacity for DNA repair 
with respect to men (31), it is possible that women carrying the p73 G4C14-to-A4T14 
mutant allele are more sensitive to carcinogens. In order to confirm the potential role 
of the p73 G4C14-to-A4T14 polymorphism on gastric cancer risk, both on the intestinal 
histotype and in females, further studies on its functional effect are needed. 
Nevertheless, our results are in line with the majority of those from Caucasian studies 
on different tumour sites. Since this polymorphic site is located in a non coding region 
it remains to be explained how the variant allele can modulate the protein function. It 
is possible that the p73 G4C14-to-A4T14 polymorphism can be functional because it is 
in linkage disequilibrium with functional alleles at other susceptibility loci (13).  
Our study failed to detect any association between the three studied p53 SNPs 
in exon 4, introns 3 and 6, and gastric cancer. This result is confirmed by the 
haplotype analysis showing no differences in the diplotype distribution among cases 
and controls. Our gene-gene interaction and haplotype analyses show that individuals 
carrying both mutant alleles of p53 exon 4 and intron 6 are protected from gastric 
cancer risk. These results are in line with those reported for lung and breast cancer (9, 
37). In addition a 3.19-fold increased gastric cancer risk was detected among 
individuals carrying the p53 exon 4 wild-type homozygote genotype and at least one 
p53 intron 6 variant allele, thus suggesting a positive synergism between the two SNPs 
only in presence of both variant alleles. Further studies are needed to confirm this 
result in larger populations and to clarify the mechanism through which the combined 
effect of these two strongly linked p53 SNPs influence the protein function allowing for 
a protective effect against cancer.  
The results of the present study show no effect of each of the studied 
polymorphisms on the overall survival rate after surgical gastrectomy intervention. This 
issue has never been addressed by other studies on gastric cancer. When the analysis, 
however, was restricted to the intestinal histotype, an increased mortality rate appears 
for those carrying the variant allele of p53 intron 6 when compared with individuals 
carrying the wild-type genotype. A similar result has been reported for chronic 
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lymphocitic leukaemia patients when considering the time of treatment-free survival as 
the main outcome (38). 
In conclusion, our study provides, for the first time, evidence that the p73 G4C14-to-
A4T14 polymorphism is significantly associated with an increased gastric cancer risk in 
a Caucasian population, and that individuals carrying the mutant allele of both p53 
exon 4 and p53 intron 6 are protected against gastric cancer. Larger prospective 
studies are needed to confirm our results.  
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CYP2E1PstI/RsaI polymorphism and interaction  
with tobacco, alcohol and GSTs in gastric cancer  
susceptibility: a meta-analysis of the literature 
 
 
 
ABSTRACT 
 
Studies investigating the association between Cytochrome P450 2E1 (CYP2E1) 5’-
flanking region (PstI/RsaI) polymorphism and gastric cancer risk report conflicting 
results. The rationale for this meta-analysis was to determine whether c2 variant allele 
of CYP2E1 increases gastric cancer risk, especially by interacting with smoking, alcohol 
and other metabolic gene polymorphisms. Two investigators independently searched 
the Medline and Embase databases. A qualitative scoring of papers was applied to their 
evaluation. Authors of the identified papers were contacted to obtain data on the 
mentioned co-exposures. A measurement of the biological interaction among two 
putative risk factors was estimated by the attributable proportion (AP) due to 
interaction. We identified thirteen case-control studies, which included 2066 gastric 
cancer cases and 2754 controls. Using the random effects model, we found no 
association between PstI/RsaI genotype and gastric cancer risk [OR= 0.97 (95% CI: 
0.79-1.18) for c2 allele carriers and OR= 1.36 (95% CI: 0.82-2.25) for c2 
homozygotes compared with homozygotes wild type]. When only high-quality scored 
studies were considered, a statistically significant increased risk appeared among 
Asians [OR= 1.50 (95% CI: 1.16-1.94) for c2 carriers and OR= 2.62 (95% CI: 1.23-
5.57) for c2 homozygotes]. No interaction was detected between CYP2E1-
smoking/alcohol (AP= 0), while an AP of 60% appeared for individuals both c2 
homozygotes and Glutathione S-Transferase M1 (GSTM1) null compared with both 
homozygotes wild type. This meta-analysis suggests that the CYP2E1 PstI/RsaI 
polymorphism may be a risk factor for gastric cancer in Asians, and that a synergistic 
interaction among GSTM1 and CYP2E1 may account for a proportion of gastric cancer 
cases. 
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INTRODUCTION 
 
Cytochrome P450 2E1 (CYP2E1), a member of the cytochrome P-450 superfamily, is a 
naturally ethanol-inducible enzyme that is mainly involved in the metabolic activation 
of low molecular weight compounds such as N-nitrosamines, and in alcohol metabolism 
(1,2). N-nitrosamines are formed endogenously in the stomach and are present in 
various environmental factors including tobacco smoke and some diet compounds (3). 
Functional CYP2E1 polymorphisms, whose expression in gastric tissues is well-
documented (4), might therefore impact on the susceptibility for gastric cancer, for 
which N-nitrosamines are suspected of having a causative role. Two point mutations in 
the 5’-flanking region (PstI, RsaI), that are in close linkage disequilibrium, are known 
to alter the transcriptional activity of the gene (1). These mutations generate the 
CYP2E1*1 (c1) allele and the less common CYP2E1*2 (c2) allele and have been 
reported to be associated with a greater risk for oral, pharyngeal (5), liver (6) and lung 
cancers (7, 8). Recent meta-analyses reported, however, the absence of an association 
between these polymorphisms and oesophageal cancer (9), hepatocellular carcinoma 
(10) and alcoholic liver disease (11).  
Despite the biological plausibility of CYP2E1 5’-flanking region polymorphism as a 
modulator of gastric cancer susceptibility, previously inconsistent results have 
appeared in the literature (12-23), probably due to the small sample sizes and the lack 
of investigations of gene-environment or gene-gene interactions. To clarify the effect of 
CYP2E1 PstI polymorphism on the risk of gastric cancer, we have carried out a meta-
analysis of the studies published until 31st April, 2006. Since we would expect to find 
an interaction between smoking habits, alcohol consumption and other metabolic gene 
polymorphisms with the CYP2E1 c2 variant allele, with respect to gastric cancer risk, 
we performed stratified meta-analyses after collecting the original data from the 
published papers. 
 
 
METHODS 
  
Data collection 
Papers published before the end of April 2006 were identified through a search of 
Medline and Embase using the following terms: “Cytochrome p450 2E1/IIE1” or 
“CYP2E1/IIE1”, “gastric” and “cancer” or “carcinoma”, without restriction on language. 
A cited reference search of the retrieved articles was carried out and furthermore 
publications were also identified by reviewing the bibliographies of the retrieved 
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articles. Articles reporting on CYP2E1 genotype identified by RsaI or PstI enzymes in 
cases of gastric cancer and controls were identified (12-24). If more than one article 
was published by the same author using the same case series, we selected the study 
where the most individuals were investigated. In addition, for those papers reporting 
only the number of CYP2E1 c2 carriers, the corresponding authors were contacted by 
email and fax in order to obtain the number of individuals with the homozygous variant 
genotype.  
Since our a priori hypothesis was that the variant allele might affect gastric 
cancer risk by interacting with smoking habits, alcohol intake and Glutathione S-
Transferase (GST) M1 and T1 polymorphisms, investigators associated with eligible 
studies were invited to contribute data to our effort. The corresponding authors of the 
published papers who reportedly collected data on the mentioned co-exposures without 
publishing the results in extenso, were contacted by e-mail and fax. We invited them to 
fill in an empty table with the CYP2E1 PstI/RsaI genotype data for cases and controls 
stratified for smoking status/alcohol consumption/GSTM1/GSTT1 polymorphisms. 
After several efforts for data collection, information on the absolute number of 
homozygous c2 individuals in cases and controls, and on CYP2E1 genotypes stratified 
for the mentioned co-exposures, have been received for all the included studies bar 
one and all bar three, respectively. 
 
Quality assessment and statistical analysis 
Each article was blinded with respect to the authors, institutions and journals. The 
articles were read and scored for quality by two independent researchers using a 
published quality score system (24), with exception of the articles written in a non-
English language (21-23). In brief, papers were rated according to several items on the 
scale in relation to two areas: the effort of the study to minimize potential bias and the 
data analysis, with items concerning the first area having twice the weight of those 
evaluating data analysis. A quality score was then calculated for each paper and 
reported as a%age of the met applicable criteria from the quality scale. High-quality 
studies were considered to be those with a value of at least 70% of the total score 
(19/27). The same two researchers extracted the data from each article using a 
structured sheet and entered it into a database. The followings items were considered: 
year and location of the study; ethnicity; characteristics of the case and control 
groups; number of individuals heterozygous and homozygous for the CYP2E1 c2 allele 
in cases and controls; smoking status; alcohol consumption; GSTM1 and GSTT1 
polymorphisms. 
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In carrying out the meta-analyses, random effect models were used, taking 
into account the possibility of heterogeneity between studies, which was tested with 
the I2 test and a standard χ2 test. The ORs of gastric cancer associated with c2 allele 
carriers and homozygous c2 genotype for the CYP2E1 RsaI/PstI polymorphism were 
estimated using the homozygous wild-type (c1/c1) as the reference group. In order to 
detect publication bias, ORs and 95% CI were plotted against standard errors in each 
study and the Egger test was performed (25). To determine the deviation from Hardy-
Weinberg equilibrium among control populations we used a program provided on the 
web site http://ihg.gsf.de/cgi-bin/hw/hwa2.pl. 
Sources of heterogeneity were investigated by subgroup meta-analyses based 
on the ethnicity (Asian and Caucasian populations) and the quality (high and low) of 
the studies (26). Subgroup meta-analyses were performed in an attempt to evaluate if 
heterozygous and homozygous variant genotypes of CYP2E1 RsaI/PstI polymorphism 
modify the risk of gastric cancer by interacting with smoking, alcohol and GSTM1 and 
GSTT1 polymorphisms. For these purposes, we stratified subjects (both c2 carriers and 
c2 homozygous) according to smoking status (ever/never smokers); alcohol 
consumption (users/non-users); GSTM1 and GSTT1 polymorphisms (present/null 
variant). 
In order to evaluate the presence of a biological interaction between each 
couple of the investigated risk factors, additional gene-gene and gene-environment 
interaction meta-analyses were performed by using the homozygous wild-type 
individuals not exposed to the environmental factor, or the homozygous wild-type 
individuals for both genes, as reference groups, as suggested by Botto and Khoury 
(27). To quantify the amount of biological interaction, the attributable proportion (AP) 
due to interaction was calculated using departure from additivity of effects as the 
criterion for interaction, as suggested by Rothman (28). The AP is the proportion of 
individuals among those exposed to the two interacting factors that is attributable to 
the interaction per se and it is equal to 0 in the absence of biological interaction (28). 
When more than additive interaction was evident, we additionally tested for more than 
multiplicative effect between the two risk factors by using a case-only study design 
(under the assumption of independence of the two factors in the control population) 
(29). Statistical analyses were carried out in RevMan program, release 4.2 (30). 
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RESULTS 
 
Twelve case-control studies (12-23), of which two were written in a non-English 
language (21,23), were identified, and by adding our recently submitted study (31) we 
had a total of 2066 gastric cancer cases and 2754 controls (Table). Studies were 
carried out in Japan, China, Taiwan, Korea, Brazil and Italy. Allele and genotype 
frequencies in all control groups did not deviate from values predicted by Hardy-
Weinberg equilibrium. Quality scores for the individual studies ranged from 56% to 
81%, with 6 of the 13 studies being classified as high-quality (12-14,17,22,31), of 
which three were Asian and three were Caucasian. Our meta-analysis gave an overall 
OR of 0.97 (95% CI: 0.79-1.18) for gastric cancer risk among c2 allele carriers of 
CYP2E1 RsaI/PstI polymorphism and an overall OR of 1.36 (95% CI: 0.82-2.25) for c2 
homozygotes (Figure 1).  
 
 
Table. Studies of the CYP2E1- PstI/RsaI polymorphism and gastric cancer risk 
Reference, year Population 
No. 
cases 
No. controls 
c2-carriers 
No. cases/controls 
Kato et al, 1995 (15) Japanese  150 203 gastric ulcers 40/41 
Wang et al, 1998 (21) Taiwanese  83 83 healthy individuals 39/30 
Nishimoto et al, 2000 (17) Japanese  59  133 hospital inpatients 48/48 
Nishimoto et al, 2000 (17)  Brazilian  189  191 hospital inpatients 6/10 
Cai et al, 2001 (12)  Chinese  91 94 healthy individuals 36/24 
Gao et al, 2002 (14) Chinese  98 196 population 41/38 
Tsukino et al, 2002 (20)  Japanese  120 158 healthy individuals 41/44 
Wu et al, 2002 (22) Taiwanese  356 278 hospital inpatients 40/28 
Park et al, 2003 (18) Korean  120 145 cancer free patients 33/35 
Ye et al, 2003 (23) Chinese  56 56 healthy individuals 30/54 
Colombo et al, 2004 (13) Brazilian  100  150 population 11/11 
Suzuki et al, 2004 (19) Japanese  145  177 autopsy subjects 26/37 
Nan et al, 2005 (16) Korean  416 630 hospital inpatients 35/36 
Boccia et al (31) * Italian  83 254 hospital inpatients 5/8 
 
* Number of cases is smaller than published version of the paper, because cases were added after initial 
submission and rejection of the manuscript 
 
When stratifying for ethnicity, an OR of 1.01 (95% CI: 0.81-1.25) and 0.72 (95% CI: 
0.44-1.18) resulted for c2 carriers, while an OR of 1.44 (95% CI: 0.85-2.42) and 0.42 
(95% CI: 0.05-3.85) resulted for c2 homozygotes, among Asians and Caucasians, 
respectively (Figure 1). When studies were stratified for quality, an overall OR of 1.15 
(95% CI: 0.81-1.56) for c2 carriers and an OR of 2.14 (95% CI: 0.96-4.74) for c2 
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homozygotes emerged for the high-quality scored studies. These results produced a 
significant OR of 1.50 (95% CI: 1.16-1.94) for c2 carriers and an OR of 2.62 (95% CI: 
1.23-5.57) for c2 homozygotes when only high-quality studies among Asians were 
considered, while the result was not significant among low-quality scored studies (data 
not shown).  
The results of the stratified meta-analyses according to smoking status, 
alcohol consumption and GSTs genotypes are shown in Figures 2 and 3. The analysis 
stratified by smoking status is based on 7 studies (12-14,16,17,20,21), the one by 
alcohol intake on 6 studies (12-14,16,17,19), the one by GSTM1 is based on 5 studies 
(13,16,19,21,22), and the stratified meta-analysis according to GSTT1 status on 5 
studies (13,16,17,22,23). The overall ORs appeared similar among each subgroup, 
even when further stratified by ethnicity (data not shown). On the other hand, an 
effect modification due to GSTM1 genotype for gastric cancer risk appeared for c2 
homozygotes individuals compared with c1/c1 homozygotes. In fact, an OR of 4.93 
(95% CI: 0.73-33.08) emerged for individuals both c2 homozygotes and GSTM1 null 
when compared with c1 homozyogotes, albeit not significant, while an OR of 1.89 
(95% CI: 1.00-3.58) appeared for the same comparison among GSTM1 wild-type 
individuals (Figure 3). 
The computation of the attributable proportion due to interaction showed an 
absence of biological interaction among each pair of tested risk factors, with an AP=0 
for all of the combinations. The only one exception is represented by the interaction 
between CYP2E1 c2 homozygotes and GSTM1 null, for which an OR of 5.36 (95% CI: 
1.01-28.47) for gastric cancer risk appeared in comparison to individuals with both 
wild-type genotype (data not shown). In this case an AP of 60% of gastric cancer cases 
among the CYP2E1 c2 homozygotes with GSTM1 null genotype appeared to be related 
to the biological interaction among the two unfavourable genotypes, with a more than 
additive effect on gastric cancer risk. Lastly, case-only meta-analysis showed no 
evidence of more than multiplicative effect (OR= 1.04; 95% CI: 0.69-1.80) for the 
association of CYP2E1 c2 homozygotes and GSTM1 null on gastric cancer risk (data not 
shown). 
Evidence of heterogeneity appeared when all the studies were pooled, with a I2 of 
51.3% and a χ2 p value = 0.01 for c2 carriers, and a I2 of 47.7% and a χ2 p value = 
0.03 for c2 homozygotes (Figure 1). When stratified by ethnicity, the heterogeneity still 
remained among Asians, but disappeared when only the three high-quality Asian 
studies were pooled (Figure 1). No evidence of heterogeneity appeared within strata 
after stratification for smoking status and alcohol consumption (Figure 2), probably due  
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Fig. 1. Forest plots depicting the Odds ratios (OR) and 95% confidence intervals (CI) from studies 
examining the association between gastric cancer and CYP2E1 RsaI/PstI 5’-flanking gene polymorphisms 
(c2 variant allele carriers or c2 homozygotes versus c1 homozygotes), and stratified meta-analyses 
according to ethnicity and quality of the studies. The centre of each square represents the OR, the area of 
the square is the inverse of the variance and the horizontal line indicates the 95% CI. The summary OR is 
represented by the diamond, where its centre indicates the OR and its ends correspond to the 95% CI. I2 
and p value for χ2 of heterogeneity are reported for each subgroup analysis. Only one study (19) did not 
provide information on the number of c2 homozygotes. 
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Fig. 2. ORs and 95% CI from the subgroup meta-analyses examining the association between gastric 
cancer and CYP2E1 RsaI/PstI 5’-flanking gene polymorphisms (c2 variant allele carriers or c2 homozygotes 
versus c1 homozygotes), according to smoking status and alcohol consumption (see materials and 
methods). The centre of each square represents the OR, the area of the square is the inverse of the 
variance and the horizontal line indicates the 95% CI. The summary OR is represented by the diamond, 
where its centre indicates the OR and its ends correspond to the 95% CI. I2 and p value for χ2 of 
heterogeneity are reported for each subgroup analysis. See results for details of the studies included. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subgroups  No. cases/No. controls OR (random)  OR (random)
 95% CI  95% CI
Ever-smokers
 
209/271      1.14 [0.51, 2.53]
c2 carriers 
Never-smokers 146/264      0.95 [0.74, 1.23]
Alcohol-drinkers 150/210      1.26 [0.58, 2.75]
Non-drinkers 161/283      1.01 [0.79, 1.29]
Ever-smokers 25/31      1.14 [0.51, 2.53]
c2 homozygotes
Never-smokers
 
19/21      1.47 [0.74, 2.92]
Alcohol-drinkers
 
17/13      1.26 [0.58, 2.75]
Non-drinkers 11/18      1.26 [0.58, 2.75]
 0.01  0.1  1  10  100
 0         0.59 
I2                     p 
% 
 0         0.56 
 0         0.88 
 0.4       0.43 
 29.1      0.21 
 0         0.73 
 0         0.77 
 0         0.88 
 
Fig. 3. ORs and 95% CI from the subgroup meta-analyses examining the association between gastric 
cancer and CYP2E1 RsaI/PstI 5’-flanking gene polymorphisms (c2 variant allele carriers or c2 homozygotes 
versus c1 homozygotes), according to GSTM1 and GSTT1 gene polymorphisms (see materials and 
methods). The centre of each square represents the OR, the area of the square is the inverse of the 
variance and the horizontal line indicates the 95% CI. The summary OR is represented by the diamond, 
where its centre indicates the OR and its ends correspond to the 95% CI. I2 and p value for χ2 of 
heterogeneity are reported for each subgroup analysis. See results for details of the studies included. 
Subgroups  No. cases/No. controls OR (random) OR (random)
 95% CI  95% CI
I2                     p 
% 
c2 carriers 
GSTM1 wild-type 514/742      1.20 [0.92, 1.56]  0         0.52 
GSTM1 null 168/198      1.07 [0.64, 1.78]  69        0.007 
GSTT1 wild-type
 
197/235      1.08 [0.75, 1.54]
GSTT1 null 155/161      1.07 [0.64, 1.78]
c2 homozygotes
 36.1      0.17 
 53.4      0.06 
GSTM1 wild-type
 
26/17      1.89 [1.00, 3.58]
GSTM1 null
 
34/12      4.93 [0.73, 33.08]
GSTT1 wild-type
 
39/20      2.10 [1.15, 3.84]
GSTT1 null 30/15      1.85 [0.68, 5.02]
 0.01 0.1 1  10  100
 0         0.94 
 68.5      0.04 
0         0.60 
 0         0.88 
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to the association between smoking and alcohol with gastric cancer risk per se. 
However, a high heterogeneity emerged when data were stratified by GSTs genotypes 
(Figure 3), maybe due to the wide variability in the frequency of this polymorphism 
among Caucasians and Asians (32). 
The funnel plot and the Egger test provided evidence that effect estimates were not 
related to study size (p > 0.05 for both c2 carriers and c2 homozygotes, data not 
shown). 
 
 
DISCUSSION 
  
Among the most widely studied metabolic gene polymorphisms as susceptibility factor 
for gastric cancer, is the CYP2E1 RsaI/PstI polymorphism. The less common c2 variant 
allele frequency is highly different among Asians and Caucasians, with a prevalence of 
approximately 25-50% and 5-10%, respectively (32). Since Kato et al. (15) first 
investigated, in 1995, a possible relationship between CYP2E1 c2 allele and gastric 
cancer risk, a further 11 reports mainly conducted in Asian populations have been 
published examining this hypothesis (12-23), with conflicting results. This led us to 
undertake the present meta-analysis, which aims to derive an estimate of the gastric 
cancer risk associated with CYP2E1 RsaI/PstI genotype. The main finding of this meta-
analysis of 13 case-control studies involving 4820 subjects is that individual carriers of 
CYP2E1 c2 allele or c2 homozygous do not have an increased risk of gastric cancer. 
Since the result comes from pooling data from different ethnic groups and studies of 
different quality, we planned a priori to perform subgroup meta-analyses based on 
ethnicity and study-quality. Considering separately, both Caucasian and Asian 
populations, the association between CYP2E1 status and gastric cancer risk did not 
change, however it did reach a statistically significant level when only high-quality 
studies among Asians were considered, with a statistically significant 1.50 and 2.62-
fold increased risk for gastric cancer among c2 carriers and c2 homozygotes, 
respectively. The lack of significance for the association in Caucasian population might 
be explained by substantially lower statistical power to detect an association owing to a 
lower prevalence of CYP2E1 c2 carriers (5-10% against 25-50% for Asians). 
As expected, there was evidence of between study heterogeneity when all 
ethnic groups were pooled, which was higher still when only Asian studies were 
considered. However, Asian reports in the subgroup analysis include a mixture of 
populations from very distant countries and sometimes very different allele frequencies 
for the c2 allele. On the other hand, there was no evidence of heterogeneity when only 
high-quality Asian studies were considered. 
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Since CYP2E1 is presumed to confer susceptibility to gastric cancer via an 
interaction with carcinogens, it is interesting to note that almost all of the studies did 
not explore the interaction between CYP2E1 genotype and smoking habits or alcohol 
consumption. This was probably due to the low statistical power of the individual 
studies to detect interactions however almost all of the studies collected this data, 
which was utilised for this meta-analysis. By combining the collected data on PstI/RsaI 
genotype and smoking habits or alcohol consumption with respect to gastric cancer 
risk, no statistically significant results emerged from the stratified meta-analyses. 
Furthermore, the computation of the attributable proportion due to biological 
interaction was equal to 0 in both cases, thus showing that when the environmental 
and genetic risk factors are both present, the effect on gastric cancer seems to be no 
longer than additive of the separate effects. However we cannot ignore that due to the 
low prevalence of c2 homozygotes in each study, even when data are pooled the 
statistical power to detect an interaction remains low. 
If genetic susceptibility to gastric cancer is, in part, mediated through 
metabolic gene polymorphisms, it is possible that the combinations of certain 
genotypes may be more discriminating as risk factors for gastric cancer than a single 
locus genotype. Among the most investigated metabolic gene polymorphisms, as 
susceptibility factors, are GSTs enzymes, which are mainly involved in the 
detoxification of several different xenobiotics (33). Two recent meta-analyses indicated 
that individuals with both GSTM1 and GSTT1 null genotypes are at higher risk for 
gastric cancer, however no risk emerged when the two unfavourable genotypes were 
considered separately (24,34). Among the 13 studies included in the present meta-
analysis, only one study (19) investigated the interaction between CYP2E1 PstI/RsaI 
and GSTM1 polymorphisms, even though nearly half of the studies collected data on 
GSTM1 and GSTT1 status for cases and controls. By pooling the collected data on 
CYP2E1 PstI/RsaI and GSTM1/GSTT1 genotypes, a statistically significant 5.36-fold 
increased risk for gastric cancer appeared for individuals both CYP2E1 c2 homozygotes 
and GSTM1 null, compared with individuals with both homozygous wild genotypes. 
Based on the definition of biological interaction among two component causes, our 
result suggests that nearly 60% of gastric cancer cases among individuals both CYP2E1 
c2 homozygotes and GSTM1 null are caused through a mechanism in which the two 
risk factors act under biological dependence in the same causal mechanism of disease 
(28). In other words, in the absence of either of the two risk factors, an important 
number of gastric cancer cases would not occur.  
In interpreting the results the main limitation of the study should be 
considered. First, only published studies were included in the meta-analysis, therefore 
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publication bias may have occurred, even though the use of a statistical test did not 
show it. Second, the subgroup meta-analyses considering interactions between CYP2E1 
genotype and smoking habits/alcohol consumption and gene-gene interactions did not 
include all of the studies because a small number of authors, three and one 
respectively, could not share their original data, so selection bias may have occurred 
and our results should be confirmed with the inclusion of the missing data. 
Furthermore, when the analysis was restricted to c2 homozygotes individuals, we had a 
low power to detect an interaction because of the low prevalence of c2 homozygotes in 
each study, so the results need to be confirmed with a larger sample size. Third, our 
meta-analysis is based on unadjusted estimates, while a more precise analysis could 
be performed if individual data were available, which would allow for an adjustment 
estimate (by age and sex). To be made, however this approach requires the authors of 
all of the published studies to share their data. Fourth, the quality score of the 
individual studies included in our meta-analysis was assessed on the basis of efforts to 
minimize the potential for selection bias, misclassification related to exposure, 
collection of data on potential confounders and method of statistical analysis. It is 
known that a validated quality assessment system does not currently exist (35) and it 
is evident that our quality scale has a subjective component. Despite these limitations, 
assessment of the quality of individual studies used in our meta-analysis allowed us to 
see that pooling high-quality scored studies resulted in higher risk estimates than did 
the pooling of low-quality scored studies. If high-quality scored studies are more likely 
to yield valid information than low-quality studies, we can conclude that, based on the 
currently available data, an additional risk of gastric cancer for CYP2E1 c2 carriers and 
c2 homozygotes may exist. We argue that the lack of significance for the association in 
Caucasian population can be most likely explained by the low statistical power to 
detect an association owing to a lower prevalence of CYP2E1 c2 carriers and the few 
number of studies published and included in the present meta-analysis.  
Despite all these remarks, some interesting conclusions have emerged. From 
the results of this quantitative meta-analysis, that combined the data from 4820 
people (2066 cases and 2754 controls), it appears that CYP2E1- PstI/RsaI 
polymorphism may be a risk factor for gastric cancer in Asian populations, and 
particularly for individual homozygotes for the unfavourable gene variant. In addiction, 
a synergistic interaction among GSTM1 and CYP2E1 unfavourable variant genotypes 
may probably account for a proportion of gastric cancer cases. Since more than half of 
the included studies were based on a limited number of cases (< 100) it is critical that 
larger and well-designed multicentric studies based on the same ethnic group confirm 
our results. 
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3.2 
 
Glutathione S-Transferase M1 status and  
gastric cancer risk: a meta-analysis of the literature 
 
 
 
ABSTRACT 
 
Susceptibility to gastric cancer may be in part a attributable to inter-individual 
variability in metabolic activation or detoxification of carcinogens, and in this context 
the polymorphic GSTM1 gene has been extensively studied. Seventeen reports 
detailing a possible association between GSTM1 deletion and gastric cancer have been 
published so far. In order to examine the risk of gastric cancer associated with GSTM1 
null genotype, a meta-analysis of published case-control studies was undertaken using 
a random effect model. Two studies were excluded because some data were missing in 
the results. The principal outcome measure was the odds ratio (OR) for the risk of 
gastric cancer. Pooling all the 15 studies identified, the overall odds ratio of gastric 
cancer risk associated with GSTM1 deficiency was 1.24 (95% CI: 1.00–1.54). By 
pooling 4 studies detailing the possible interaction between GSTM1 status, smoking 
habits and gastric cancer risk, an overall estimate of odds ratio of 1.35 (95% CI: 0.98-
1.86) for ever smokers with GSTM1 deficiency compared with GSTM1 normal genotype 
has emerged. These results suggest that GSTM1 status has probably no effect on the 
risk of gastric cancer per se, but may modulate tobacco-related carcinogenesis of 
gastric cancer. Greater attention should therefore be paid to the design of future 
studies: only well designed population-based control studies considering all the 
possible confounding risk factors and based on a sample size commensurate with the 
detection of small genotypic risk may allow a more definitive conclusion. 
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INTRODUCTION 
 
The incidence and mortality of gastric cancer (GC) is decreasing in the world as well as 
in most European countries, but it still represents the fourth most frequent cancer in 
the world (1). Given to the low rate of five-year survival of GC, identification and 
control of risk factors remains the most effective means of prevention (2). An 
increasing number of epidemiological studies indicate that cigarette smoking (1), 
Helicobacter pylori infection (3) and diet (4) are probably important etiological factors 
increasing the risk of GC. However, it is currently accepted that the development of GC 
results from a complex interaction of both environmental and genetic factors (2).  
According to a multifactorial model, genetic susceptibility due to specific 
variant alleles of different genes (polymorphisms) can modify the effect of 
environmental exposure, probably explaining partly the high variations of GC incidence 
throughout the world (4). In particular, it is possible that some of the susceptibility to 
GC is determined by the interindividual difference in the bioactivation of 
procarcinogens and detoxification of carcinogens due to inherited polymorphisms in 
low- penetrance metabolic genes (5, 6). Among the latter the most widely studied 
polymorphism is the glutathione S-transferase M1 (GSTM1) null allele, which has been 
of considerable interest as a GC susceptibility gene (2).  
GSTM1 gene is polymorphic, and at least four different alleles exist; the 
protein is mainly expressed in the liver, brain and stomach (2). Absence of GSTM1 
expression is due to an inherited deletion of the parental allele of GSTM1 gene and it is 
found in approximately 50% of Caucasian and Asian populations, and 25% of African 
population (7). Since GST- enzyme is involved in detoxification of various 
carcinogens, it may be plausible that an increased or decreased activity of this enzyme 
can be involved in susceptibility to GC (2). Strange et al first reported an association 
between GST1 deficiency and GC (8). Since this publication in 1991, over 16 studies 
have appeared in the literature confirming or refusing an association between GSTM1 
deficiency and GC risk (9-24). In order to clarify the effect of GSTM1 status on the risk 
of developing GC, we carried out a quantitative meta-analysis of the research 
published up to the 31st of March, 2004, that have investigated the association 
between GSTM1 status and GC. 
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METHODS 
 
Identification of relevant studies 
The studies were searched for using the MEDLINE database of the National Library of 
Medicine, and the EMBASE database. The key words used for the research were 
Glutathione S-Transferase M, GSTM1, gastric cancer, epidemiology, without restriction 
on language. The period of research considered included articles published up to 31st of 
March, 2004. For the meta-analysis, the following inclusion criteria were followed: clear 
objective in the relation between GSTM1 status and GC in the introduction/description 
of the research, and description of GSTM1 status in cases and controls.  
 
Statistical analysis 
Two researchers (GLT and SB) extracted the data from each article using a structured 
sheet and entered it into a database. The followings items were considered: year and 
location of the study; ethnicity; characteristics of the control group; number of 
individuals the number of cases and controls with GSTM1 deficiency in the compared 
groups. The heterogeneity was tested by Q statistic. In carrying out the meta-analyses, 
random effect models were used to take into account the possibility of heterogeneity 
between studies (25). The summary Odds Ratios (ORs) of gastric cancer associated 
with GSTM1 null was estimated using the non null genotype for each genotype as 
reference group. To check for publication bias, Begg and Egger tests were used.. 
Statistical analysis was undertaken using the program RevMan, release 4.2 (26). The 
OR of gastric cancer associated with GSTM1 deficiency was estimated for each study.  
We also computed the power of each selected study, in order to assess the 
probability of detecting an association between GSTM1 deficiency and gastric cancer at 
the 0.05 level of significance, assuming a genotypic risk of 2 and 1.5, using the method 
described by Schlesselmann (27). Moreover, separate analyses were conducted taking 
into consideration Asian and Caucasian patients. Lastly, since GSTM1 genotype is 
presumed to affect gastric cancer risk also by influencing detoxification of activated 
tobacco carcinogens, we tried to evaluate this potential modifying effect in patients 
with GSTM1 deficiency. An heterogeneity test was then used to test differences among 
the strata. 
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RESULTS 
 
Identification of relevant studies  
Seventeen studies were identified for the meta-analysis, of which seven were population 
based case-control and ten hospital based case- control studies. In Table the ORs are 
reported with their relative 95% CI, including confounding factors that were analysed in 
each study. Two studies were not included in the meta-analysis as they did not fulfil 
selection criteria. In fact, results are not expressed as number of GSTM1 deficiency in 
cases and controls in Kato S et al. (13), and Conde et al (15) articles. So, the meta-
analysis was conducted using the remaining 15 studies (9-12, 14, 16-24). While Strange 
et al used a phenotypic method for detecting GSTM1 status (8), all the other studies 
were based on genotypic methods (PCR) (9-12, 14, 16-24). The ethnicity of cases and 
controls was detailed in all the 15 studies (Table). In 4 of 15 studies the controls were 
sex and age-matched individuals from the general population (Table). Smoking histories 
had been verified from cases and controls in 5 out of 15 studies, while food consumption 
has been ascertained in only 4 reports (Table 1). In these studies, the relationship 
between GSTM1 status and GC risk were analysed in a stratified manner or by logistic 
regression analysis, taking into account other covariates. In one study, the prevalence of 
GTSM1 deficiency was determined in two control groups (8). 
 
Statistical analysis 
Figure shows the result of the pooling of data, illustrating a plot of odds ratios  and 
95% CI for the risk of developing gastric cancer associated with GSTM1 deficiency in 
15 case-control studies. The meta-analysis provides an OR of 1.24 (95% CI: 1.00–
1.54; p for heterogeneity = 0.002), which testifies the extent to which GSTM1 
deficiency is associated with the risk of gastric cancer. Based on the potential 
overestimation of the true effect of GSTM1 deficiency on gastric cancer risk, 
considering studies using phenotypic method (28), we also conducted a meta-analysis 
considering only studies using the genotyping methods, giving an overall OR of 1.20 
(95% CI: 0.97–1.47; p for heterogeneity = 0.005).  
Analysis provides different results for Asian and Caucasian patients. In fact, 
for the former ones (9 studies) we found a significant OR= 1.22 (95% CI: 1.04–1.43), 
while for the latter (6 studies) the OR was not significant (OR= 1.19; 95% CI = 0.81–
1.75, p for heterogeneity among the two estimates= 0.80). Taking into account only 
studies with controls from the general population, an overall OR of 1.25 (95% CI: 
0.90-1.73; p for heterogeneity = 0.02) was found, whilst an OR of 1.18 (95% CI: 
0.91–1.55; p for heterogeneity = 0.06, p for heterogeneity among the two estimates= 
0.91) resulted by considering studies with hospital controls.  
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Figure. Forest plot of the published studies considered in the meta-analysis 
 
 
As far as concerns the interaction between GSTM1 status and gastric cancer risk in 
relation to cigarette smoking, we found data available for only 4 out of 15 studies 
(11,17,18,22), giving an overall estimate of OR= 1.10 (95% CI: 0.76-1.61) for GSTM1 
null versus non null among never smokers, and an OR of 1.35 (95% CI: 0.98-1.86) for 
ever smokers (p for heterogeneity among the two estimates= 0.50). Lastly, making a 
pooled analysis considering only studies with a power of at least 80% (Table 1), we 
found an overall estimate of OR=1.05 (95%  CI: 0.87-1.28; p for heterogeneity=0.12) 
for a RR=2.0. Results of Begg and Egger tests showed a substantial absence of 
publication bias (p values >0.05). 
 
 
DISCUSSION 
  
In the last two decade advances in DNA technologies have probably determined an 
increase in the knowledge of genetic polymorphisms in cancer risk. While rare 
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alterations of high penetrant susceptibility genes (e.g. tumor suppressor genes) 
dramatically increase cancer risk for the affected subjects, more common differences in 
low penetrant susceptibility genes (e.g. drug metabolism enzymes) could be 
responsible for a relatively small, but rather frequent increase of cancer risk at the 
population level (6). Given that exposure to carcinogens is one of the most important 
risk factors for gastric cancer (2, 3), the hypothesis that the modulation of carcinogen 
metabolism due to inherited polymorphisms in drug metabolism genes, could be a 
plausible way for explaining interindividual susceptibility.  
The most widely studied metabolic gene polymorphism is the GSTM1 null 
allele, whose frequency in Caucasian population is approximately 50%. Since Strange 
et al (8) first drew attention to possible relationship between GSTM1 deficiency and GC 
risk, 16 reports have been published examining this hypothesis (9-24), with conflicting 
results. This prompted us to the present meta-analysis in order to derive an estimate 
of the risk associated with GSTM1 status. In our meta-analysis of 15 published case-
control studies involving 4797 subjects, GSTM1 null genotype confers a 1.24 fold 
statistically significant increased risk of gastric cancer. Our results also suggest that 
this association might be slightly stronger among Asian than Caucasian population, 
even if the difference is not statistically significant (p>0.10). Anyway, these OR values 
obtained support the hypothesis that GSTM1 deficiency does not influence per se the 
inter-ethnic variation in GC incidence throughout the world. 
Since GSTM1 is presumed to confer susceptibility to GC by interaction with 
carcinogens, it is interesting to remark that no data was collected on tobacco or on 
other environmental carcinogens exposure (e.g., passive smoking) from both cases 
and controls in most studies. By pooling 4 studies which investigated the possible 
interactions between GSTM1 status and smoking habits and the risk of GC, a borderline 
statistically significant 35% increased risk appeared for smoker individuals with a 
GSTM1 null genotype versus GSTM1 non null individuals. The same effect estimate was 
far from significant and less pronounced among never smokers, even though the 
heterogeneity test did not show a true effect modification of GSTM1 genotype by 
smoking status. As this stratified analysis is based on limited sample size (around 200 
smokers with a GSTM1 null genotype) it would be worthy to test on a larger sample. 
The principal form of possible bias in this study, i.e. the presence of 
confounding factors which could interfere with the epidemiological meta-analysis, 
shouldn’t have been avoided, given that total estimates reported by each author were 
adjusted by multivariate analysis only in few studies. A potential- selection bias should 
be discussed for each individual study considered. Case-control studies have 
prevalently used population based cancer registries in order to identify the cases. In 
 96 
Meta-analysis of glutathione S-Transferase M1 and gastric cancer 
this latter type of investigation, only seven of fifteen had used population register to 
identify controls. Misclassification bias may be considered as negligible in these studies, 
given that the diagnosis of cancer in the case-control studies has reference to cancer 
registries which routinely foresee a histological confirmation of cancer cases. 
Misclassification related to exposure (GSTM1 status) may be of some interest. By 
pooling studies that used a genotyping method to ascertain the GSTM1 status, the 
overall OR was slightly lower compared with pooling all the studies together, and no 
longer statistically significant. Therefore misclassification of GSTM1 status on the basis 
of phenotype should be taken in great care when pooling data together, even though in 
our study the different results obtained could be also attributable to the small sample 
size of the phenotype-based report (8). Moreover, it is well know that using hospital 
controls could generate some source of bias if not appropriately selected (29), and in 
this pooled analysis we found that the overall risk of developing gastric cancer in 
GSTM1 null patients was underestimated by hospital based case-control studies. In this 
meta-analysis, only published studies were used. Publication bias is, therefore, an 
issue even though the statistical tests used did not detect it. Regarding the statistical 
analysis, this was appropriately guided in most instances, with an adequate indication 
of 95% CI and associated p values. 
 
Despite these limitations, mainly due to a far from perfect in design of some studies, 
some interesting conclusions emerged. From the results of this quantitative meta-
analysis, that pooled together data regarding almost five thousand people (1797 cases 
and 3000 controls), it appears that GSTM1 status has probably no effect on the risk of 
gastric cancer per se, suggesting a potential modulation of tobacco-related 
carcinogenesis. Future research in this field should take great care in the interaction 
between healthy risk factor (life-style conditions, such as smoking habits, alcohol and 
drug consumption) and GSTM1 status.  
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Glutathione S-Transferase T1 status and  
gastric cancer risk: a meta-analysis of the literature 
 
 
 
ABSTRACT 
 
To clarify the risk of gastric cancer associated with glutathione S-transferase (GSTT1) 
status, a meta-analysis of published studies was performed. Eligible studies included all 
reports investigating an association between GSTT1 status and gastric cancer 
published prior to the 31st of October, 2005. A qualitative scoring of papers was applied 
to evaluate the quality of the published data. The principal outcome measure was the 
odds ratio (OR) for the risk of gastric cancer associated with GSTT1 deletion status 
using a random effects model. Eighteen case-control studies detailing a possible 
association between the GSTT1 null genotype and gastric cancer were selected. 
Combining data from these studies, totalling 2508 cases and 4634 controls, a non-
statistically significant OR for gastric cancer risk associated with GSTT1 deficiency of 
emerged (OR= 1.09; 95% CI: 0.97–1.21; I2 = 0%). When only high-quality scored 
studies were considered, a statistically significant increased risk appeared (OR= 1.23; 
95% CI: 1.04-1.45; I2 = 0%), as well as considering only Caucasians (OR= 1.23; 95% 
CI: 1.03-1.56; I2 = 0%). By pooling data from 7 studies (319 cases and 656 controls) 
that considered combinations of GSTT1 and GSTM1 genotypes, a statistically significant 
increased risk for gastric cancer (OR= 1.95, 95% CI: 1.42-2.67; I2 = 0%) was detected 
for individuals with deletion mutations in both genes compared to wild types. In 
conclusion, this meta-analysis suggests that the GSTT1 null genotype may slightly 
increase the risk of gastric cancer and that interaction between unfavourable GST 
genotypes may exist. Greater attention should, therefore, be paid to the design of 
future studies; the investigation of interactions among multiple genotypes and 
environmental exposures are justified to clarify GSTT1 null status influence on gastric 
cancer risk. 
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INTRODUCTION 
 
Sequence variations in genes coding for phase II enzymes, such as the glutathione S-
transferase (GST) family, may potentially alter individual susceptibility to cancer (1). 
Glutathione S-tranferase are a family of genes with a critical function in protecting 
against electrophiles and the products of oxidative stress. The GST enzymes are 
involved in the detoxification of many xenobiotics, including several environmental 
carcinogens and endogenously derived reactive oxygen species (2). Four major GST 
families are widely expressed in mammalian tissue: GSTA (), GSTM (), GSTT () and 
GSTP (). Certain genes within the GSTM and GSTT (GSTM1 and GSTT1) subfamilies 
exhibit homozygous deletion (null genotype) polymorphisms that are considered 
important modifiers of individual risk for environmentally-induced cancers (1). 
Individuals who have the homozyogous deletion in one of these genes have no GSTM1 
and GSTT1 enzyme activity, and thus are more susceptible to carcinogens such as 
benzo[]pyrene-7,8-diol epoxide, the activated form of benzo[]pyrene, and smaller 
reactive hydrocarbons, such as ethylene oxide and diepoxybutane (2,3). The 
prevalence of GSTM1 and GSTT1 null genotypes was found to vary among ethnic 
groups. In human populations, GSTM1 and GSTT1 are absent in 10-60% and 13-55% 
of individuals, respectively (4). 
The common expression of GSTα, GSTT1-1 and GSTP1-1 in many cell types along the 
human gastrointestinal tract suggests an important role in the protection against 
carcinogens and other xenobiotics (5). The deletion mutations in the GSTT1 and 
GSTM1 genes and their association with gastric cancer have been investigated in a 
large number of studies. In our recent meta-analysis, which identified 15 studies 
investigating an association between GSTM1 null genotype and the risk of gastric 
cancer, we reported a slight increase in gastric cancer risk associated with GSTM1 
deficiency [odds ratio (OR) of 1.24; 95% confidence interval (CI): 1.00-1.54] (6). A 
recent review of genetic susceptibility and gastric cancer risk reported that the results 
of case-control studies detailing associations between the GSTT1 gene and gastric 
cancer risk are inconclusive (7). Since Deakin et al. (8) first investigated the 
relationship between GSTT1 deficiency and gastric cancer in 1996, 17 studies have 
appeared in the literature, and most of them have refuted an association between 
GSTT1 deficiency and gastric cancer risk (3, 9-24). One of the major problems with the 
published studies is that most of them were based on small numbers of cases and 
controls. Furthermore, because the GSTT1 genotype is presumed to affect gastric 
cancer risk by influencing detoxification of activated environmental carcinogens and by 
interaction with other unfavourable GST polymorphisms, the potential modifying effect 
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of GSTT1 status on the relationship between tobacco smoking, other GST and gastric 
cancer is of particular interest, even though not often investigated.  
To clarify the effect of GSTT1 status on the risk of developing gastric cancer, we 
carried out a quantitative meta-analysis of research published through the 31st of 
October, 2005. In addition, we combined data available from published papers to 
explore the possible effects of the interactions between the GSTT1 genotype and 
smoking habits and between GSTT1 and GSTM1 genotypes with respect to gastric 
cancer risk. 
 
 
METHODS 
 
Identification of relevant studies 
The digital medical databases used for the search were MEDLINE and EMBASE. The key 
words used for the research were Glutathione S-Transferase T1 or GSTT1, gastric or 
stomach cancer, without restriction on language. The time period includes research 
articles published through the 31st of October, 2005.  
For the meta-analysis, the following inclusion criteria were considered: presence of a 
quantitative assessment of the relationship between GSTT1 status and gastric cancer; 
an appropriate description of GSTT1 status in cases and controls; results expressed as 
relative risk (RR) or OR; studies with a 95% CI for RR or OR, or with the possibility to 
calculate these measures if standard deviation (SD) values were present. 
We compared the results of our literature search to the review articles found using the 
previously mentioned databases. Furthermore, when data from one paper was 
republished by the same author in a larger investigation or written in English, only the 
most recent article was considered. 
 
Quality assessment and data extraction  
Each article was blinded with respect to the authors, institutions and journals. The 
articles were read and scored for quality by two independent researchers using a 
system that incorporates elements of the methods developed by Angelillo et al. (25) 
and Chalmers et al. (26). We also followed suggestions useful to evaluate a molecular 
epidemiological study from Thakkinistian et al. (27) and Bogardus et al. (28). The 
criteria employed are shown in the results section below. A quality score was then 
calculated for each paper as the percentage of applicable criteria that were met in each 
study. Items concerned with efforts to minimize potential bias (nine points, items A-I, 
results section) were given twice the weight of those evaluating data analysis (nine 
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points, items J-R) (25). Lastly, even though reported in the quality score scale, the 
item related to Hardy-Weinberg equilibrium (item R) was not applicable because it 
could not have been checked in the included studies due to the analytical method used 
for GSTT1 genotyping, which doesn’t provide the frequency of heterozygous 
individuals. Therefore high-quality scored studies were considered as the ones with at 
least 70% of the total score (19/26), as suggested by Angelillo et al. (25). 
The same two researchers extracted the data from each article using a structured 
sheet and entered into a database. The following data were considered: year and 
location of study; ethnicity, source, sex ratio and mean age (or range whenever 
possible) of cases and controls; the number of cases and controls with GSTT1 
deficiency; OR values with their 95% CI and covariates investigated in the study.  
 
Statistical analysis 
The OR for gastric cancer associated with GSTT1 deficiency was estimated for each 
study. In carrying out the meta-analysis, the random effect model was used, taking 
into account the possibility of heterogeneity between studies, which was tested with I2 
test and a standard Chi squared test (29). The resulting P value of the Chi squared test 
for heterogeneity is reported in the result section after the result of the I2 test. The 
Mantel-Haenszel method (fixed effect model) was also used to assess the effect of the 
model’s assumptions on our conclusions (30,31). Statistical analysis was undertaken 
using the RevMan program, release 4.2 (32). In order to detect potential publication 
bias, ORs and 95% CI were plotted against standard errors in each study. We also 
computed the power of the selected studies, in order to assess the probability of 
detecting an association between GSTT1 deficiency and gastric cancer at the 0.05 level 
of significance, assuming a genotypic risk of 2.0 and 1.5, using the method described 
by Schlesselmann (33). Based on previous literature findings, we planned to perform 
several subgroup meta-analyses based on the ethnicity, study design, power of the 
study and quality score of the papers. Lastly, we performed two additional sensitivity 
analyses in an attempt to evaluate if the interaction between GSTT1 and cigarette 
smoking, as well as between GSTT1 and GSTM1 null genotypes, can modify the risk of 
gastric cancer. The z statistic was used to formally assess if any statistically significant 
difference among the results of each subgroup meta-analyses exists, as reported by 
Deeks et al. (34). In order to collect the most complete data concerning those 
interactions, when not extensively published in the results section of a paper, the 
corresponding author of the individual studies were contacted by e-mail and fax. We 
thus invited those authors to provide data useful for us in performing the two subgroup 
meta-analyses. 
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RESULTS 
 
Identification of relevant studies  
Eighteen articles were retrieved by our bibliographic search with three papers written 
in non-English language (10,17,20). In order to collect data from the last three papers, 
the corresponding authors were contacted by e-mail and fax and invited to fill in an 
empty table with the results of their studies. All the authors answered and their data 
were included in the analysis. Eighteen case-control studies were therefore considered 
for the present meta-analysis (3,8-24). In Table 1 the ORs are reported with their 
corresponding 95% CI, including all the data that were extracted from each study. In 
each report, GSTT1 status was determined by analysis of the gene via polymerase 
chain reaction. Ten case-control studies were population based (C-C pb), with 6 of 
them enrolling sex and age-matched controls, and 8 were hospital based case-control 
studies (C-C hb), of which only three had sex and age-matched controls (Table 1). 
History of smoking was verified for cases and controls in 12 of 18 studies, with 4 
reporting results of the interaction between GSTT1 status and gastric cancer risk in 
relation to cigarette smoking habits (11,12,15,21). Lastly, though 17 of 18 studies 
collected data on GSTM1 status, only 5 reported data concerning the combination of 
those genotypes with respect to gastric cancer risk in a form suitable for a subgroup 
meta-analysis (3,12,19,21,22). Authors were contacted to obtain data on the 
interactions between GSTT1 status and smoking habits, and GSTT1 status and GSTM1 
status; two authors answered (10,20) and their data were included in the two 
subgroup meta-analyses.  
 
Quality assessment  
Table 2 shows the quality scoring items with the relative%ages of the studies 
complying with those criteria. The quality scoring procedure was performed for all the 
studies included in the meta-analysis with the exception of the articles written in a 
non-English language. The potential for selection bias may be a concern in all of the 
individual studies considered. Cases and controls were chosen in most of the reports in 
the appropriate manner: 5 of 15 studies used cancer registries to identify cases and 7 
identified randomly selected cases. Most of the studies stated that cancer diagnosis 
was validated by histology and all the studies specified disease criteria (Table 2).  
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Table 2. Items used in the quality scoring of observational studies in epidemiology 
Quality scoring items 
% of studies 
complyinga 
Case-control studies  
A1. Cases either randomly selected or selected to include all cases in a 
specific population 
80 
B1. Response rate for identified cases > 75% 40 
C1. Controls drawn from the source population of cases 100 
D1. Population-based controls 67 
E1. Response rate for identified controls > 75% 53 
Cohort studies  
A2. Initial response rate > 75%  NAb 
B2. Comparison of persons who did and did not participate NA 
C2. Follow-up rate > 75% NA 
D2. Comparison of who were and were not lost to follow-up NA 
E2. Exposed/non  exposed  subjects  identified  without knowledge of disease 
status 
NA 
All studies  
F. Disease validated by histology or other gold standard 69 
G. Specific disease/not disease or exposure/not exposure criteria given 100 
H. Exposure/disease  assessment  made  blindly  with  respect  to  the  case-
control/exposure status of subjects (analyst unaware of the clinical 
status/exposure of the sample) c 
13 
I. Reproducibility of laboratory tests mentioned c 13 
J. Age and sex considered as potential confounders  93 
K. Collection of data on other potential confounders/effect modifiers 100 
L. Demographic data listed 47 
M. Place and time of the study reported 93 
N. Power calculations performed 0 
O. Precise p values or confidence interval given 100 
P. Statistic test specified 100 
Q. Appropriate statistical analysis 100 
R. Hardy-Weinberg equilibrium assessed c NA 
 
a If compliance was not specifically indicated in the text, non compliance was assumed 
b NA: not applicable in the present meta-analysis, see methods and results section 
c Specific for molecular-epidemiological studies 
 
 
Furthermore, in all of the studies the controls were drawn from the same population as 
the cases; 10 reports selected population controls. However, the response rate for 
cases and controls were frequently less than 75%, which may have led to a selection 
bias. Misclassification bias should be considered as a concern: only 2 of 15 studies 
clearly stated that the analyst was unaware of the clinical status of the subjects when 
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genotyping their samples, so exposure misclassification may exist (Table 2). One other 
issue is that almost all the studies did not report the reproducibility of the laboratory 
method used. Age, sex and other potential confounders/effect modifiers were 
considered in almost of the studies, while demographic data were reported in only 7 
reports. Statistical analysis was judged appropriate in all of the studies, and p values 
and/or 95% CI were always listed, while no study provided power calculations. Quality 
scores for the individual studies ranged from 0.46 to 0.81, and five of fifteen resulted 
as high-quality scored studies (11, 12, 14, 22, 23). 
 
Statistical analysis 
Figure 1 shows the results of the combined data, depicting a plot of ORs (95% CI) for 
the risk of developing gastric cancer associated with GSTT1 deficiency in the 18 case-
control studies, involving a total of 7142 subjects (2508 cases and 4634 controls). The 
meta-analysis resulted in a statistically non-significant association between GSTT1 
deficiency and gastric cancer risk (OR= 1.09; 95% CI: 0.97-1.21; I2 = 0%, p for 
heterogeneity = 0.48). This analysis is based on combining data from studies based on 
a number of different ethnic groups. Separate meta-analyses were therefore conducted 
stratified by ethnicity. For Asians (10 studies) we found an OR= 1.02 (95% CI: 0.89-
1.18; I2 = 12.1%, p for heterogeneity = 0.33), while for Caucasians (8 studies) the OR 
value was 1.27 (95% CI: 1.03-1.56; I2 = 0%, p for heterogeneity = 0.87; p value of z 
statistic among the two groups = 0.08). By considering separately C-C hb and C-C pb 
studies, similar OR values were found [C-C hb: OR of 1.08 (95% CI: 0.92-1.27; I2 = 
0%, p for heterogeneity = 0.56); C-C pb: OR of 1.09 (95% CI: 0.92-1.29; I2 = 16.7%, 
p for heterogeneity = 0.29]. When combining data from the studies with a power of at 
least 80% for a RR = 2.0 (Table 1), we found an OR of 1.08 (95% CI: 0.95–1.24; I2 = 
17.9%, p for heterogeneity = 0.27). In addition, when only high quality papers were 
considered, a statistically significant increase in risk for gastric cancer appeared (OR= 
1.23, 95% CI: 1.04-1.45; I2 = 0%, p for heterogeneity = 0.41), while an OR of 0.99 
(95% CI: 0.85-1.15; I2 = 0%, p for heterogeneity = 0.75; p value of z statistic among 
the two groups = 0.07) resulted by pooling data from low quality papers. 
The funnel plot (Figure 2) shows no evidence of publication bias, with the exception of 
one outlier (16). As far as the interaction between GSTT1 status and smoking habits is 
concerned, in relation to gastric cancer risk, we obtained data from 6 of the 12 studies 
in a form suitable for a subgroup meta-analysis. After stratification by smoking status, 
an overall OR of 1.54 (95% CI: 0.95–2.48; I2 = 59.2%, p for heterogeneity = 0.03) for 
the risk of gastric cancer appears in ever-smokers with GSTT1 deficiency compared to 
ever-smokers with a normal GSTT1 genotype. On the other hand, an overall estimate  
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Fig. 1. Forest plot of developing gastric cancer associated with GSTT1 null status and subgroup analyses.  
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of OR= 0.86 (95% CI: 0.59-1.27; I2 = 26.3%, p for heterogeneity = 0.24) appears 
when comparing the effect of GSTT1 status (null vs. normal genotype) in never-
smokers with respect to gastric cancer risk. Furthermore, pooling data concerning the 
combination of GSTT1 and GSTM1 genotypes from 7 studies, demonstrated that 
individuals with combined deletion mutations in those genes have an OR of 1.95 for 
gastric cancer (95% CI: 1.42-2.67; I2 = 0%, p for heterogeneity = 0.58) in comparison 
with individuals with wild type genotypes.  
 
 
DISCUSSION 
  
Most of the cancer susceptibility genes identified to date are rare and highly penetrant. 
While the individuals with rare alterations of these genes (e.g. tumor suppressor 
genes) have a dramatically higher risk of cancer, more common differences in low 
penetrant susceptibility genes (e.g. drug metabolism enzymes) could be responsible for 
a relatively small, but observable increase of gastric cancer risk at the population level 
(35). Although gastric cancer is one of the most common malignancies worldwide, its 
pathogenesis and the molecular genetic events that contribute to its development are 
poorly understood (7). One of the most widely studied metabolic polymorphisms 
examined as a susceptibility factor for gastric cancer is the GSTT1 null allele; it’s 
frequency in the Caucasian population is approximately 20-30% (4). Since Deakin et 
al. (8) first investigated a possible relationship between GSTT1 deficiency and gastric 
cancer risk, a further 17 reports have been published examining this hypothesis (3,9-
24), with conflicting results. 
This led us to undertake the present meta-analysis, which aims to derive an estimate 
of the gastric cancer risk associated with GSTT1 status. The main finding of this meta-
analysis of 18 case-control studies involving 7142 subjects is that the GSTT1 null 
status seems to be unrelated to gastric cancer risk. Absence of heterogeneity between 
studies emerged from the statistical analysis, however as Blettner et al. pointed out, 
the tests formally used to assess heterogeneity have low statistical power to detect it 
(36). Therefore, we decided a priori to perform several subgroup meta-analyses 
according to ethnicity, study design, quality and power of the studies. Considering 
separately Caucasian and Asian studies, the association between GSTT1 null status and 
gastric cancer risk reaches a slight statistically significant level among Caucasians. In 
human populations, the frequency of GSTT1 deficiency is 13-26% and 36-52% in 
Caucasian and Asian individuals, respectively (4). However, the Caucasian reports in 
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the subgroup analysis include a mixture of populations from very distant countries, so 
the result must be interpreted with caution. Unexpectedly, when only high-quality 
scored studies were considered, a statistically significant increased risk of gastric 
cancer for GSTT1 null individuals was detected. 
Since GSTT1 is presumed to confer susceptibility to gastric cancer via an interaction 
with carcinogens, it is interesting to note that no data was collected from the cases or 
the controls on tobacco usage, alcohol intake, food consumption, or Helicobacter pylori 
in many of the studies. By combining the data available from 6 studies, which 
investigated the possible interaction between GSTT1 status and cigarette smoking with 
respect to gastric cancer risk, a slightly increased risk appears for ever-smokers with a 
GSTT1 null genotype compared to individuals with a GSTT1 normal genotype. Even 
though the result is not statistically significant, from the z test a statistically significant 
difference among the two estimates appears, so it would be interesting to pool all the 
missing data to confirm this result. If genetic susceptibility to gastric cancer is, in part, 
mediated through polymorphic variation, it is probable that the risk associated with any 
one locus will be small because an interaction is likely to operate in these 
circumstances. Hence, combinations of certain genotypes may be more discriminating 
as risk factors than a single locus genotype. Unfortunately, only a few reports 
investigated this aspect, even though 17 of 18 selected studies collected data on 
GSTM1 status. By pooling the data from 7 available studies investigating a possible 
interaction between GSTT1 and GSTM1 status and gastric cancer risk, a 95% 
statistically significant increased risk of gastric cancer appeared for individuals with 
combined deletion mutations in GSTT1 and GSTM1 genes in comparison with 
individuals with both homozygous wild genotypes.  
The main limitations of the study have to be considered in interpreting the results. 
First, only published studies were included in the meta-analysis, therefore a publication 
bias may have occurred. It is known that positive results usually have a greater 
probability of being published, and even though unpublished studies are generally of 
lesser quality than published ones (37), if they are not included an overestimation of 
the GSTT1 null effect may appear.  
Second, the two subgroup meta-analyses considering interactions between GSTT1 null 
genotype and cigarette smoking, as well as between GSTT1 null and GSTM1 null 
genotypes, were performed based on a fraction of all of the possible data to be pooled, 
so selection bias may have occurred and our results may be over inflated. In this 
context, it is well known that an important issue in performing a meta-analysis is that 
literature-based meta-analysis rather than individual data-based meta-analysis could 
be a potential source of bias. Meta-analyses are in general insufficient to calculate a 
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pooled estimate since published estimates are based on heterogeneous populations, 
different study designs and different statistical models. More reliable results can be 
expected if individual data are available for a pooled analysis, so that confounding 
factors can be considered, although this approach requires the authors of all of the 
published studies to share their data. 
Third, the quality score of the individual studies included in our meta-analysis was 
assessed on the basis of efforts to minimize the potential for selection bias, 
misclassification related to exposure, collection of data on potential confounders and 
method of statistical analysis. It is known that any quality assessment system has not 
yet been validated (38) and it is evident that our quality scale has a subjective 
component. Despite these limitations, assessment of the quality of individual studies 
used in our meta-analysis allowed us to draw two conclusions: the possibility of a 
selection bias and even more misclassification related to exposure cannot be ruled out; 
most importantly, pooling high-quality scored studies resulted in higher risk estimates 
than did pooling low-quality scored studies. If high-quality scored studies are more 
likely to yield valid information than low-quality studies, we can conclude that, based 
on the currently available data, an additional slight risk of gastric cancer for GSTT1 null 
individuals may exist.  
Despite these remarks, some interesting conclusions have emerged. From the results 
of this quantitative meta-analysis that combined the data from 7142 people (2508 
cases and 4634 controls), it appears that GSTT1 null status has a very small effect on 
the risk of gastric cancer per se, but it may modulate the tobacco-related 
carcinogenesis of gastric cancer, and that the combination of unfavourable genotypes 
may result in an additional risk of gastric cancer. A clearer picture of the interaction 
between different polymorphisms and environmental factors on gastric cancer risk will 
be adequately addressed only by large and well-designed epidemiological studies. 
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Meta- and pooled analyses of the  
Methylenetetrahydrofolate reductase C677T  
and A1298C polymorphisms and gastric  
cancer risk: a HuGE-GSEC review  
 
 
ABSTRACT 
 
Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the metabolism of 
folate, whose role in gastric carcinogenesis is controversial. A meta-analysis and 
individual data pooled analysis of case-control studies that examined the association 
between C677T and A1298C polymorphisms (the former being associated with low folate 
serum levels) and gastric cancer (meta-analyses: 16 studies, 2727 cases and 4640 
controls for C677T, 7 studies, 1223 cases and 2015 controls for A1298C; pooled 
analyses: 9 studies, 1540 cases and 2577 controls for C677T, 5 studies, 1146 cases and 
1549 controls for A1298C) was performed. An increased risk appeared for MTHFR 677 TT 
in the meta-analysis (OR= 1.52; 95% CI: 1.31, 1.77) and pooled analysis (OR= 1.49; 
95% CI: 1.14, 1.95). No association resulted for MTHFR 1298 CC (meta-OR= 0.94; 95% 
CI: 0.65, 1.35; pooled-OR= 0.90 (95% CI: 0.69, 1.34). When results from the pooled 
analysis of four studies on C677T were stratified according to folate levels, results 
showed an increased risk among individuals with low levels (OR= 2.05; 95% CI: 1.13, 
3.72) respect to those with high folate levels (OR= 0.95; 95% CI: 0.54, 1.67). Overall, 
these findings support the hypothesis that folate play a role in gastric carcinogenesis.  
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GENE AND FUNCTION 
 
The 5,10-methylenetetrahydrofolate reductase (MTHFR) gene maps to chromosome 
1p36.3 (1). The complementary DNA sequence is 2.2kb long and contains 11 exons 
(1). The gene product is a 77-kD protein, although a smaller isoform of approximately 
70-kD has been observed in some tissues such as liver (2). MTHFR plays a central role 
in folate metabolism, together with other enzymes, by irreversibly catalyzing the 
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the primary 
circulating form of folate and a cosubstrate for homocysteine methylation to 
methionine (Figure). In humans, folate plays the fundamental role of providing methyl 
groups for de novo deoxynucleotide synthesis and for intracellular methylation 
reactions (2,3). 
 
 
Figure. Folate pathway 
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MTHFR enzyme function may influence cancer risk in two ways. The substrate of 
MTHFR enzyme, 5,10-methylenetetrahydrofolate, is involved in the conversion of 
deoxyuridylate monophosphate (dUMP) to deoxythymidylate monophosphate (dTMP), 
and low levels of 5,10-methylenetetrahydrofolate would lead to an increased 
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dUMP/dTMP ratio. In this situation an increased incorporation of uracil into DNA in 
place of thymine may follow, resulting in an increased chance of point mutations and 
DNA/chromosome breakage (3). A less active form of MTHFR would lead, all other 
factors being equal, to an accumulation of 5,10-methylenetetrahydrofolate, thus a 
lower dUMP/dTMP ratio, and a presumably lower cancer risk (3). 
The second way in which an impaired MTHFR activity might influence cancer risk is 
determined by the level of s-adenosylmethionine (SAM), the common donor of methyl 
that is necessary for the maintenance of the methylation patterns in DNA. Changes in 
methylation modify DNA conformation and gene expression. A less active form of 
MTHFR leads to lower SAM and consequently to hypomethylation; this phenomenon 
would be expected to increase the risk of some cancers (4) (figure 1). Similarly, low 
folate intake may modify cancer risk by inducing uracil misincorporation during DNA 
synthesis, leading to chromosomal damage, DNA strand breaks and impaired DNA 
repair, and DNA hypomethylation (5). 
 
GENE VARIANTS  
 
Twenty-nine rare mutations of MTHFR have been described in homocystinuric patients 
resulting in very low enzymatic activity (6), while two common polymorphisms are 
present in healthy individuals with lower enzyme activity: C→T in exon 4 at nucleotide 
677, leading to Ala222Val (7); and A→C in exon 7 at nucleotide 1298, leading to 
Glu429Ala (8,9). These polymorphisms are located 2.1 kb apart, and have been 
investigated in association with the risk of gastric and other cancers (10). Three 
additional polymorphisms have been described, T1059C, T1317C, and G1793A (9, 11, 
12). While T1317C polymorphism is a silent change with no effect on plasma 
homocysteine and folate concantrations (9), the T1059C has been reported to be 
associated with increased neural tube defects in an Iowa population (11). The G1793A 
allele is least frequent among Ashkenazi Jewish individuals (1.3%) compared to 
Caucasians (6.9%) (12); it has been reported that individuals with the heterozygous 
genotype for the variant allele show borderline or deficient values in folate 
concentration compared to individuals with the wild genotype (13). 
Individuals who are homozygous for the MTHFR 677 less frequent variant (TT) have 
30% of the expected enzyme activity in vitro, compared with those who are 
homozygous for the common variant (CC), while heterozygous carriers have 65% 
activity (2). Van der Put et al. (8) evaluated the MTHFR activity according to the 
combination of A1298C and C677T genotypes, showing that individuals carrying the 
677CC allele and contemporarily the 1298 variant allele (CC) have 60% activity 
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compared to subjects carrying the 1298AA variant, while in the same population 80% 
activity was detected for the 1298 heterozygotes (AC). Enzyme activity for individuals 
who are heterozygous for both C677T and A1298C appears to be around 50-60% of 
the activity of those without either variant (9). It has been reported that subjects who 
are TT homozygous for the MTHFR 677 exhibit reduced folate status and higher serum 
homocysteine levels compared to those who carry at least one 677C allele (14-16). The 
evidence on the association of the 1298 variant allele with increased folate levels is 
less consistent (14,15,17,18). 
Three recent studies reported that the MTHFR TT genotype is related to DNA 
hypomethylation (19,20), particularly in individuals with reduced plasma folate 
concentrations (21). Inconsistent results derive from studies on A1298C polymorphism, 
plasma folate and homocysteine levels (15,18,22,23). 
 
POPULATION FREQUENCIES 
 
The T allele frequency of MTHFR 677 polymorphism is reported to be of 0.36-0.44 in 
Europeans, 0.35-0.53 in Asians, 0.33-0.35 in US, and 0.10-0.24 in African Americans 
(24). The frequency of homozygosity ranges from 1% [95% Confidence Interval (CI): 
0.2, 2.0] in US African American populations to more than 20% (95% CI: 14.6, 26.8) 
in US Latinos; 5% (95% CI: 1.2, 9.6) to 30% (95% CI: 21.4, 38.9) in White 
populations in Europe and North America; 32.2% (95% CI: 28.3, 36.4) in Mexico; 5.8 
(3.5, 9.6) in White Canadians in Alberta to 14.3 (10.9, 17.6) in Canada, Quebec; 0.8 
(0.2, 2.1) in West Africa to 0.0 (0.0, 1.2) in Sub-Saharan Africa; 10.7% in Oceania 
(5.5, 19.7); 11.5% (95% CI: 10.2, 12.7) in Japanese and 16% (95% CI: 8.0, 31.0) in 
Chinese (24-27). For A1298C, the variant allele frequency is reported to be 0.14-0.35 
in Europeans and 0.11-0.17 in Asians. The frequency of homozygosity ranges from 
10% (95% CI: 9.0, 11.0) in White populations in Europe and North America to 3.5% 
(95% CI: 0.2, 7.2) in Asians (28). 
 
DISEASE 
 
Gastric cancer is the second most common cause of cancer mortality, with 647,000 
deaths reported worldwide in 2002 (29). In many populations, particularly in high-
income countries, in the last decades its incidence has gradually decreased, however it 
still represents the fifth most common type of cancer in Europe and the fourth 
internationally (30). Infection with Helicobacter pylori is the single most common cause 
of adenocarcinoma of the distal stomach (31), however it is not a necessary neither a 
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sufficient cause. The development of gastric cancer appears in fact to be the result of a 
complex interaction between Helicbacter pylori infection, lifestyle and genetic factors. 
Among the lifestyle risk factors tobacco smoking, a high intake of salt and lack of food 
refrigeration seem to play a major role (32). Lastly, gastric cancer risk shows a familial 
clustering (33). 
With regards to genetic factors, several SNPs might potentially alter the individual 
susceptibility to gastric cancer (34). Among them are polymorphisms in genes involved 
in the protection of gastric mucosa against damaging agents and inflammatory 
response, genes that influence the ability to detoxify carcinogens (metabolic genes) 
and involved in oxidative damage response and DNA repair, as well as oncogenes (35). 
Genes involved in folate metabolism have also been considered to play a role in gastric 
cancer risk (28). 
 
GENE-ENVIRONMENT AND GENE-GENE INTERACTIONS 
 
Some nutrients involved in the folate metabolic pathway (eg, vitamin B6 and B12, and 
methionine), alcohol (a folate antagonist) and smoking (which impairs folate level) 
may interact with plasma folate levels and the MTHFR polymorphisms in determining 
cancer risk (36,37). It has been reported that alcohol perturbs folate metabolism by 
reducing folate absorption, increasing folate excretion, or by inhibiting methionine 
synthase (38,39). The inverse association between folate intake and plasma 
homocysteine levels can be modified by alcohol intake and by the MTHFR 677, but not 
the 1298 polymorphism (40). The inverse effect of smoking on folate status might be 
confounded by alcohol intake or dietary habits (41,42), even though the association 
persists after adjusting for dietary folate intake and alcohol (42,43). Additional studies 
reported that elevated folate turnover in response to rapid tissue proliferation or DNA 
repair in aerodigestive tissues among people exposed to tobacco smoke might partially 
explain this phenomenon (44,45). 
According to recent reports, alcohol drinkers carrying the MTHFR 677 TT genotype had 
around 5-fold increased risk of gastric cancer compared to drinkers carrying the wild 
homozygous variant, namely an OR of 5.36 (95% CI: 1.94, 14.83) from Graziano et al 
(19) and 5.32 (95% CI: 1.66-17.02) from Stolzenberg-Solomon et al. (46) while 
others did not show such interaction (47, 48). Additionally, Gao et al. reported that 
smokers carrying the T allele in MTHFR 677 had a 7.7-fold increased risk (OR= 7.72; 
95% CI: 2.23-26.79) of gastric cancer compared to non-smokers with the CC genotype 
(49). To our knowledge, no study ever explored if the effect of MTHFR 677 TT genotype 
on gastric cancer is modified by the individual folate intake or by the plasma folate 
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levels. Finally, the interaction between alcohol, smoking or folate status and MTHFR 
A1298C polymorphism has never been tested in gastric cancer. 
The effect of the combination of the two common MTHFR polymorphisms on gastric 
cancer was investigated by Miao et al. and Boccia et al. (50,51), both reporting no 
interaction between them. 
 
OBJECTIVE 
 
A meta-analysis of prospective studies showed an inverse association between fruit 
and vegetables intake, the main dietary source of folate, and gastric cancer risk, 
particularly after 10 years or more of follow-up (52). Discrepant results, however, 
recently emerged from a large European cohort study, showing no association between 
fresh fruit intake and gastric cancer, and a slight protective effect of the total vegetable 
intake only for the intestinal histotype (53). Results from a meta-analysis of 
prospective and retrospective studies specifically focusing on dietary folate intake and 
risk of gastric cancer also reported no clear effect of dietary folate intake, with no 
differences between cohort or case-control studies (54). 
On the other hand, two recent meta-analyses show that MTHFR 677 TT genotype is 
associated with an increased risk of gastric cancer, suggesting an important role of 
folate levels and subsequent impaired chromosomal DNA synthesis and aberrant DNA 
methylation in gastric carcinogenesis (28,54). Neither meta-analyses, however: 
included all the published reports available at the time they were published, and 
specifically included either eight (28) or nine studies (54), compared to 16 studies of 
the present meta-analysis. In addition, they provided unadjusted overall estimates, 
and were unable to stratify the results according to potential factors affecting folate 
status and MTHFR polymorphisms, because of the nature of already published data. We 
accomplished both the last two points by carrying out also a pooled analysis of 
individual-level data. 
With the present meta- and pooled analyses we aim to assess the overall effect of 
MTHFR C677T and A1298C polymorphisms on gastric cancer by including all the 
available published papers, and to contribute in clarifying the interrelations between 
these polymorphisms with folate, alcohol and smoking in gastric cancer risk.  
 
 
 
 
 126 
Meta- and pooled analyses of the Methylenetetrahydrofolate and gastric cancer 
METHODS 
 
We assessed the association between MTHFR C677T and A1298C polymorphisms and 
gastric cancer through meta-analyses of all published papers, and pooled analyses of 
individual-level data when available. 
 
Meta-analysis 
Selection criteria 
Identification of the papers was carried out through a search of Medline and Embase up 
to January 2007 using the following terms: (“methylenetetrahydrofolate reductase” or 
MTHFR) and (gastric or stomach) and (cancer or carcinoma), without any restriction on 
language. The research produced 35 articles. A cited reference search of the retrieved 
articles was carried out, and publications were also identified by reviewing the 
bibliographies of the retrieved articles. Eligible studies were community-based that 
reported the frequency of the MTHFR C677T and/or A1298C polymorphisms as number 
of gastric cancer individuals and controls according to the three variant genotypes of 
both polymorphisms. Studies whose allele frequencies in the control population 
deviated from the Hardy-Weinberg Equilibrium (HWE) at a p value equal or less than 
0.05 were excluded from the meta-analysis. If more than one article was published 
from the same case series, we included the paper where the most individuals were 
reported in the analysis. 
Of the 35 articles retrieved, 22 studies resulted eligible for the analysis (19,46-51,55-
69). Five reports (55-59) were excluded either because they concerned subjects 
included in an expanded series (50,60) or because they partially overlapped with 
another study (49) that was eventually selected because it gave the absolute number 
of individuals according to the three variant genotypes of MTHFR 677 (57-59). Finally, 
one study was excluded from the meta-analysis for the association between MTHFR 
C677T and gastric cancer (60), and one excluded from the analysis of A1298C (46), 
due to deviations from HWE.  
The final number of articles considered for the meta-analysis of the association 
between MTHFR C677T and gastric cancer risk was 16 case-control studies (19,46-51, 
61-69), of which three written in Chinese language (49,61,62), comprising a total of 
7367 subjects (2727 cases and 4640 controls). A description of the studies is given in 
table 1. Ten out of 16 were population based; one was a case-control nested in a 
cohort (46). Among them seven were also included in the meta-analysis of the 
association between MTHFR A1298C and gastric cancer risk (48,50,51,60,61,63,64) for 
a total of 3238 subjects (1223 cases and 2015 controls). 
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Statistical analysis 
Two researchers (S.B. and F.G.) extracted the data from each article using a structured 
sheet and entered it into a database. The followings items were considered: year and 
location of the study; ethnicity; characteristics of the control group; tumour site 
(cardia/non-cardia gastric cancer); number of individuals heterozygous and 
homozygous for the MTHFR 677 and 1298 variant alleles in the compared groups. The 
heterogeneity was tested by Q statistic (70). In carrying out the meta-analyses, 
random effect models were used (71) to take into account the possibility of 
heterogeneity between studies. The summary Odds Ratios (ORs) of gastric cancer 
associated with MTHFR 677 TT and CT genotypes and MTHFR 1298 CC and CA 
genotypes were estimated using the homozygous wild-type for each genotype as 
reference group. To determine the deviation from HWE we used the Fisher’s exact 
permutation test with a Monte Carlo technique (72). A visual inspection of Begg’s 
funnel plot and Begg and Egger asymmetry tests (70) was used to investigate for 
publication bias when appropriate (73). 
Since two potential causes of heterogeneity among studies were ethnicity and tumour 
site, we calculated separate ORs in subgroups of studies performed in different ethnic 
groups (Asian/Europeans) and in subgroups of studies including cardia and non-cardia 
gastric cancer cases, when genotype data were tabulated according to the tumour site 
in the published papers. A heterogeneity test was then performed to test for 
statistically significant differences among the strata estimates. 
 
Pooled analysis 
Data collection  
The pooled analysis was performed using the Genetic Susceptibility to Environmental 
Carcinogens (GSEC) database. The International Collaborative Study on GSEC 
(http://www.upci.upm.edu/research/ccps/ccontrol/g_intro.html) is a collaborative 
project that gathers information from both published and unpublished population-
based studies on metabolic gene polymorphisms and cancer risk. The design of GSEC 
study was reported elsewhere (74). Investigators were appositely contacted and asked 
to provide their data for the pooled analyses. A questionnaire was provided by email to 
each investigator, collecting information on study design, selection and source of cases 
and controls, laboratory method used for genotyping, source of DNA used for the 
genotype analysis, and response rate for cases and controls. We contacted all the 
authors of the identified published papers including those whose controls subjects were 
not in HWE for the studied polymorphisms (46,60). Of the 17 eligible data-sets, we 
were able to obtain data from 10, with one of them (60) later excluded for the pooled 
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analysis on MTHFR 677 and one more (46) on MTHFR 1298 since the allele frequency 
of control population did not respect the HWE. We finally included nine studies for 
MTHFR 677, of which four conducted on Asians, four on Europeans and one on Latinos, 
totalling for 4117 subjects (1540 cases and 2577 controls) (table 1 for details). As for 
MTHFR 1298, five studies were included, totalling for 2695 subjects (1146 cases and 
1549 controls; table 1 for details). 
Statistical analysis 
To assess the association of MTHFR 677 TT and 1298 CC genotypes with gastric 
cancer, the logistic regression model was used to estimate study specific ORs and 95% 
CI in each single study. Adjusted ORs were obtained by including age, gender, and 
smoking status (ever/never) as covariates. In some studies, ORs estimated for 
individual studies and number of cases and controls did not precisely match those 
reported in the publications. A pooled OR was estimated by inverse-variance weighting 
with the random effects model (71), taking into account the possibility of heterogeneity 
between studies, which was tested with Q statistics (70).  
We could perform stratified analyses only for MTHFR 677 TT, since MTHFR A1298C was 
available only in six studies. 
Results were stratified according to ethnicity (Asians/European descendants), alcohol 
drinking, tobacco smoking and folate status. Since the information of pack-years of 
smoking was available from only four studies (47,48,50,51), subjects were divided in 
ever (current and former) and never smokers. For alcohol drinking, individuals were 
categorized as ever (current and/or former) and never (<1 glass of each alcoholic 
beverage/month) drinkers. Folate serum levels were obtained from Gotze et al. (66) 
and gastric mucosa folate levels from Weng et al. (63). Nutrient density of folate 
(dietary folate intake/total caloric intake: µg/kcal*1,000) was obtained by Zhang et al. 
(48), while portions intake of fruit and vegetables by Boccia et al (51). For the analysis 
subjects were categorized in two classes based on the lower quartile of each variable 
estimated in the control population.  
For each stratified analysis a pooled OR was estimated by inverse-variance weighting 
with the random effects model (71), taking into account the possibility of heterogeneity 
between studies, which was tested with Q statistics. A heterogeneity test was 
performed to assess for statistically significant differences among the pooled strata 
estimates.  
Statistical analyses were carried out using the STATA software package v.8.2 (Stata 
Corporation, College Station, Texas). 
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RESULTS 
 
Meta-analysis of MTHFR C677T 
The OR of eleven out of sixteen studies were above the unit, among them four 
(19,50,65,62) reported a significant positive association between gastric cancer and 
the MTHFR 677 TT genotype (Table 1). The meta-analysis gave an overall OR of 1.52 
(95% CI: 1.31, 1.77) and 1.17 (95% CI: 0.99, 1.39) for gastric cancer and MTHFR TT 
(Figure 2) and CT genotypes, respectively. The heterogeneity tests were 0.37 and 0.01 
for TT and CT, respectively. The funnel plot (not shown) and the Begg’s test provided 
no evidence of publication bias (p = 0.72) for MTHFR 677 TT genotype, while the Egger 
test provided a p value of 0.007. 
When stratifying the data by ethnicity, we observed an OR of 1.34 (95% CI: 0.90, 
1.99) and 1.64 (95% CI: 1.36, 1.97) for MTHFR 677 TT versus CC genotype, from six 
studies among Europeans and nine studies among Asians, respectively (p value for 
heterogeneity = 0.38). The analysis by anatomic tumour site showed that both gastric 
cardia cancer (eleven studies) and non-cardia cancer (six studies) were significantly 
associated with MTHFR 677 TT, with an OR of 1.51 (95% CI: 1.11, 2.05) and 1.57 
(95% CI:1.09, 2.24), respectively (p value for heterogeneity = 0.87). There was no 
evidence of heterogeneity in all the subgroup meta-analyses performed. 
 
Meta-analysis of MTHFR A1298C 
All seven included studies reported ORs spread around the null effect (Table 1). From 
the meta-analysis the association between gastric cancer and MTHFR 1298 CC was 
0.94 (95% CI: 0.65, 1.35) (Figure 3), while an OR of 1.01 (95% CI: 0.86, 1.18) was 
found for the association with 1298 AC. There was no evidence of heterogeneity in the 
overall meta-analysis and in subgroup meta-analyses. 
By restricting the analysis of MTHFR A1298C to the five studies conducted on Asians 
(50, 60, 61, 63, 64), an overall OR of 0.81 (95% CI: 0.43, 1.51) emerged. When the 
analysis was stratified by tumour site, an OR of 0.99 (95% CI: 0.43, 2.28) resulted for 
cardia cancer, while an OR of 0.81 (95% CI: 0.38, 1.74) was found for non-cardia 
cancer (p value of heterogeneity = 0.76). 
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Fig. 2. Forest plot of the Odds Ratios and 95% confidence intervals of studies on the association between 
gastric cancer and MTHFR C677T polymorphism (TT versus CC). On the left, the first author of the study is 
followed by the publication year in parentheses. The size of the black box corresponding to each study is 
proportional to the sample size; the horizontal line shows the corresponding 95% confidence interval of the 
odds ratio. The combined estimate is based on a random-effects model shown by the diamond. The solid 
vertical line represents the null result. 
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 1.81 (0.93,3.52) Boccia et al. (2007)   4.9
 1.63 (1.15,2.33) Wang Y et al. (2007)  15.1
 0.67 (0.28,1.58) Gotze et al. (2007)   3.0
 1.16 (0.69,1.95) Zhang et al. (2007)   7.7
 0.67 (0.18,2.54) Weng et al. (2006)   1.3
 1.42 (0.45,4.53) Zeybek et al. (2006)   1.7
 1.48 (0.95,2.31) Lacasana-Navarro et al. (2006)  10.3
 2.79 (1.48,5.23) Graziano et al. (2006)   5.4
 0.96 (0.57,1.63) Sarbia et al. (2005)   7.6
 1.50 (0.61,3.70) Si et al. (2005)   2.7
 1.46 (0.83,2.57) Kim et al. (2005)   6.6
 1.78 (1.02,3.11) Wang LD et al. (2005)   6.8
 1.79 (1.06,3.02) Mu et al. (2004)   7.6
 1.14 (0.60,2.18) Stolzenberg-Solomon et al. (2003)   5.1
 2.02 (1.28,3.19) Miao et al. (2002)   9.8
 1.81 (0.89,3.66) Gao et al. (2002)   4.4
 1.52 (1.31,1.77) Overall (95% CI)
 
 
Fig. 3. Forest plot of the Odds Ratios and 95% confidence intervals of studies of the association between 
gastric cancer and MTHFR A1298C polymorphism (CC versus AA). On the left, the first author of the study 
is followed by the publication year in parentheses. The size of the black box corresponding to each study is 
proportional to the sample size; the horizontal line shows the corresponding 95% confidence interval of the 
odds ratio. The combined estimate is based on a random-effects model shown by the diamond. The solid 
vertical line represents the null result. 
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 1.02 (0.44,2.37) Boccia et al. (2007)  18.4
 1.01 (0.60,1.69) Zhang et al. (2007)  48.8
 0.28 (0.01,7.30) Weng et al. (2006)   1.2
 0.38 (0.05,3.11) Kim et al. (2005)   3.0
 0.84 (0.33,2.17) Shen et al. (2005)  14.5
 0.79 (0.22,2.88) Si et al. (2005)   7.9
 1.30 (0.31,5.49) Miao et al. (2002)   6.2
 0.94 (0.65,1.35) Overall (95% CI)
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Pooled analyses 
The study specific adjusted ORs for MTHFR 677 TT are reported in Table 1. Out of the 
nine studies included in the pooled analysis, ORs were above the unit in six, among 
them three (19,50,51) reported a significant positive association between gastric 
cancer and MTHFR 677 TT genotype (Table 1). Results from the pooled analysis are 
shown in Table 2. The overall OR adjusted for age, gender and smoking status was 
1.49 (95% CI: 1.14, 1.95; p value for heterogeneity= 0.06) for MTHFR 677 TT, while 
an OR of 1.21 (95% CI: 0.90, 1.62; p value for heterogeneity= 0.03) was detected for 
MTHFR 677 CT. Publication bias was not tested because of the low statistical power of 
the tests when the number of studies is ≤10 (73,75,76). 
The pooled OR for MTHFR 677 TT among Asians was 1.54 (95% CI: 1.09, 2.15; p value 
for heterogeneity= 0.34), among Europeans was 1.52 (95% CI: 0.84, 2.76; p value for 
heterogeneity= 0.03). The p value for heterogeneity test among Asians and Caucasians 
was 0.86 (Table 2). 
When stratifying for smoking habits, an OR of 2.04 (95% CI: 1.27, 3.26) for MTHFR 
677 TT appeared among ever-smokers, while an OR of 1.36 (95% CI: 1.03, 1.80) 
appeared among never-smokers, with a p value for heterogeneity test among them of 
0.14 (Table 2). The stratified analysis according to alcohol intake included 6 studies; 
similar risk estimates were found for ever-drinkers versus never-drinkers (p value for 
heterogeneity test = 0.49; Table 2). The stratified analysis according to estimated 
folate status showed an OR for gastric cancer of 2.05 (95% CI: 1.13, 2.72) for MTHFR 
677 TT individuals with low folates, while an OR of 0.95 (95% CI: 0.54, 1.67) in those 
with high folates (p value for the heterogeneity among the two estimates of 0.06) 
(Table 2). 
The study specific adjusted odds ratios for MTHFR 1298 CC are reported in Table 1. It 
was not possible to compute the adjusted OR for the homozygous variant genotype in 
one study because of the small amount of subjects (60). The overall OR adjusted for 
age, gender and smoking status was 0.90 (95% CI: 0.69, 1.34; p value for 
heterogeneity= 0.50, 4 studies) for MTHFR 1298 CC, while an OR of 1.01 (95% CI: 
0.83, 1.22; p value for heterogeneity= 0.50, 5 studies) was found for MTHFR 1298 AC. 
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DISCUSSION 
 
The results from the meta-analysis performed on sixteen studies highlighted a higher 
risk of developing gastric cancer for subjects carrying the MTHFR 677 TT genotype. The 
results were confirmed by the pooled analysis including nine studies. No association 
was detected from either the meta-analysis or the pooled analysis between the MTHFR 
1298 CC genotype and gastric cancer. Our results were consistent with two previously 
published meta-analyses by Zintzaras E. and Larsson et al. (28,54), showing an 
increased risk of gastric cancer only for MTHFR 677 TT genotype, and an absence of 
risk for the MTHFR 1298 CC. The two previously published meta-analyses, however, 
included a smaller number of studies and results were based on unadjusted estimates. 
From our pooled analysis on MTHFR 677, an increased risk of gastric cancer was 
observed among subjects with low folate status compared with those with a high folate 
status. These results support with our a priori hypothesis of a higher risk of gastric 
cancer for subjects carrying the variant MTHFR 677 homozygous variant who have low 
folate levels as compared to subjects carrying the same variant but with high folate. 
A limitation common to both the meta- and the pooled analysis might be the presence 
of publication bias. In the meta-analysis of MTHFR 677 TT, we did not observe 
evidence of publication bias from the visual inspection of the Begg’s funnel plots and 
the results of the rank correlation statistical test. Results from the Egger’s regression 
method highlighted some publication bias, however this method is usually more 
sensitive than the Begg’s test, reporting to provide evidences for bias (false positive 
results) when in fact is not present, especially when the number of studies is low (75, 
76). We cannot rule out, however, that the effect of MTHFR 677 TT on gastric cancer is 
overestimated from our meta-analysis because negative results from small studies 
remained unpublished. 
In the pooled analysis we explored a possible effect modification of MTHFR 677 TT 
genotype on gastric cancer by stratifying for tobacco smoking and alcohol drinking, two 
factors that may affect folate levels. We were unable to observe any effect 
modification, however we should keep in mind that in both instances the information 
did not take into account the amount or the duration of alcohol intake and tobacco 
smoking. 
When the results from the pooled analysis were stratified according to folate status 
(available from 4 studies), a strong association between MTHFR 677 TT genotype and 
gastric cancer was noted among subjects with low folate status compared to subjects 
with a high folate status. The heterogeneity test showed that results were borderline 
significantly different, therefore our result needs to be confirmed with a larger 
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population. This result support our hypothesis, suggesting that concomitant inadequate 
folate intake and impaired MTHFR activity might be important susceptibility factors for 
gastric cancer. A limitation is the heterogeneity in which on folate information was 
collected: gastric mucosa level (63), serum level (66), nutrient density of folate (48), 
or dietary fruit an vegetables intake (51). 
To our knowledge, this is the first pooled analysis assessing the role of two common 
MTHFR polymorphisms on the risk of gastric cancer. In fact, the two previously 
published meta-analyses did not include individual level data (28,54), therefore the 
authors were unable to calcualate adjusted estimates and to stratify the results of the 
meta-analyses according to folate status, alcohol or smoking habits. Because the data 
sets included information on age, gender and cigarette smoking for all studies, it was 
possible to adjust for the potential confounding effect of these variables, and to assess 
consistently the presence of gene-lifestyle interactions for MTHFR 677, a factor that 
makes the pooled-analysis preferable to the meta-analysis (7). The absence of 
publication bias and statistical heterogeneity among studies strengthens our results. 
 
LABORATORY TESTS 
Both MTHFR C677T and A1298C can be detected by means of polymerase chain 
reaction (PCR followed by restriction fragment-length polymorphism (RFLP) analysis 
with HinfI and MboII for C677T and A1298C, respectively (7,8). Other methods include 
direct DNA sequencing or TaqMan assays (48). Most studied did not report the success 
rate in extracting DNA from samples, the proportion of eligible subjects from whom 
genotyping failed, while 43.0% (7/16) of them reported the degree of genotyping 
reproducibility (19,46,48,50,51,61,68). HWE was tested by 87.5% (14/16) of the 
studies. All the previously mentioned variables are important indicators of the 
analytical validity of the genotyping methods, also influencing the potential non-
differential misclassification of the exposure. In addition, only 31.2% of studies (5/16) 
clearly reported that the analysts were unaware of the clinical status of the subjects 
when genotyping the samples, therefore differential exposure misclassification may not 
be ruled out. 
 
POTENTIAL PUBLIC HEALTH IMPACT 
 
At the moment the potential public health impact of is limited, given the small 
association between gastric cancer and homozygosis TT for MTHFR 677. Additional 
studies, however, on the possible additional risk of gastric cancer among subjects who 
are homozygous 677 TT and have low folate levels are urgently needed. If this 
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preliminary result is confirmed, a proper evaluation of the clinical utility of MTHFR 
C677T testing for identifying gastric cancer susceptibility among populations with folate 
deficiency, as well as the introduction of specific folate supplementation (versus no 
folate supplementation) would be warranted. Currently, however, population testing for 
MTHFR C677T polymorphism for gastric cancer prevention is not indicated. 
 
CONCLUSION AND RESEARCH PRIORITIES 
 
MTHFR plays a central role in balancing DNA synthesis (which involves 5,10-
methylentetrahydrofolate), and DNA methylation (which involves 5,10-
methyltetrahydrofolate). Specifically, the 677T allele contributes to DNA 
hypomethylation, which in turn may lead to altered gene expression; at the same time 
this polymorphism might exert a protective effect as observed for colorectal cancer 
(24), by increasing the levels of the MTHFR substrate, essential for DNA synthesis. 
Therefore, the exact interpretation of MTHFR-cancer association is not straightforward; 
although the observed increased risk for gastric cancer associated with the MTHFR 677 
homozygous variant suggests that dietary folate might be protective in gastric 
carcinogenesis mainly by limiting aberrant DNA methylation in situation of impaired 
folate status. In general, the study of the association between sequence variants of 
folate related genes and cancer has the advantage of being less prone to the 
confounding effect exerted by dietary or lifestyle factors (78). The observed increased 
risk of gastric cancer among MTHFR 677 TT individuals strengthens the hypothesis of a 
protective effect of folate in gastric carcinogenesis. If this holds true, it would be 
interesting to explore if the introduction of folate fortification in some common food 
items (79) in North America since 1998 had actually contributed to the decreasing 
rates of gastric cancer (80). However, in view of the lag-time for an effect of folic acid 
and the lengthy induction time for gastric cancer, this issue could probably be 
addressed only in the next decade. 
 The observation of a potential role of folate in gastric carcinogenesis is also 
strengthened by our results of an increased risk of gastric cancer in MTHFR 677 
homozygous subjects with low folate levels, suggesting that concomitant inadequate 
folate intake and impaired MTHFR activity might be important susceptibility factors for 
gastric cancer. 
 Despite the limitations of this analysis in terms of comparable folate data, 
which requires confirmation from large prospective studies based on blood folate 
measurement, the results are in keeping with the model proposed by Friso et al. (21). 
In circumstances of folate deficiency, a decrease in downstream MTHFR-products 
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results in a lower global DNA methylation status. Recently, aberrant methylation of 
proto-oncogenes has been explored as both a mechanism and a marker of carcinoma 
progression (81), with some studies reporting an altered methylation pattern 
particularly for diffuse gastric cancer (82). Additionally, it has been recently reported 
that a significant global DNA hypomethylation occurs in MTHFR 677 TT subjects when 
compared with those with the wild type genotype (19,20), especially when plasma 
folate level is reduced (21). Taken together, these results suggest that the increased 
risk for gastric cancer associated with the homozygous MTHFR 677 variant might be 
referable to the subsequent impaired folate levels affecting DNA methylation status. 
Therefore, the negative association between the homozygous variant MTHFR genotype 
and gastric cancer might be counterbalanced to some extent by an adequate folate 
intake. 
 Other genes involved in folate metabolism should be considered for a more 
comprehensive understanding of the exact role of the folate pathway in gastric cancer 
susceptibility. Given the controversial evidence from nutritional studies on the effect of 
fruit and vegetables on gastric cancer, there is a need for large prospective cohort 
studies based on repeated serological dosage of folate levels and/or detailed and 
repeated nutritional data which would further clarify the role of folate in gastric 
carcinogenesis. This would lay the foundation for evaluating the possible benefits of 
preventive nutritional interventions in individuals at risk for gastric cancer. 
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General Discussion 
BACKGROUND AND KEY OBJECTIVE 
 
Background. Gastric cancer still ranks as the fourth most common cancer and the 
second most frequent cause of cancer deaths, accounting for 10.4% of cancer 
worldwide (1). High incidence regions include various countries in Asia and Europe 
including Japan, China and Russia, where the prevalence of Helicobater pylori is 
relatively high compared to Europe and USA (60-90% versus 30-40% of the 
population). In contrast, there has been a progressive fall in the incidence of gastric 
cancer in many Western Countries, particularly for cancers located distal to the cardia 
and for the intestinal type. The effect has been attributed to food refrigeration, a lower 
intake of preserved foods and salt, and higher intake of fruit and vegetables.  
 
Gastric carcinogenesis is a multistep and multifactorial process resulting from a 
complex interaction between environmental and genetic factors. It is currently 
recognized that multiple genetic abnormalities accumulating during the long process of 
carcinogenesis are responsible for the onset and progression of cancer, however in 
gastric carcinoma the molecular mechanism remain poorly understood. Recently, 
genome-wide array-based comparative genomic hybridization (CGH) has been shown 
to have a high resolution and high sensitivity in detecting gene-copy aberrations. A 
study published in 2008 on 38 primary gastric tumor tissues from a population in 
Helsinki, identified amplification of ERBB2 gene and gains at 20q13.12-q13.33 (2). 
Expression analysis showed an overexpression of MUC1, GRB7, PPP1R1B and PPARBP, 
in addition to ERBB2 among the intestinal type.  
 
Conventional epidemiological research in the last two decades identified H.pylori 
infection, tobacco smoking, low fruit and vegetable intake, salt or salty foods intake, 
and the lack of food refrigeration as playing a major role in gastric cancer aetiology 
(3). Individuals infected by H. pylori have at least a twofold increase of gastric cancer 
compared to uninfected subjects. In areas where gastric cancer is highly prevalent the 
great majority of cases are H.pylori related, as 95% of the strains circulating in East 
Asia are particularly virulent (cagA positive) compared to Western clinical isolates 
(60% are cagA +, also showing less virulent properties). (4) 
 
The vast majority of H. pylori infected pepole, however, do not develop gastric cancer, 
suggesting for the potential role of the genetic background and other causative factors. 
Accumulating evidences report that the individual genetic susceptibility to gastric 
cancer involves several genes with small effects (5). Genes involved in the protection 
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of gastric mucosa against damaging agents, in inflammatory response, in detoxification 
of carcinogens (also known as metabolic genes), in synthesis and repair of DNA, in 
regulation of gene expression, and in cell adhesion and in cell cycle, have been studied 
(6). A well known study published in 2000 by El-Omar et al (7) demonstrated that the 
risk of non-cardia gastric cancer is associated with the gene cluster polymorphisms of 
IL-1 encoding for IL-1β promoter (-511 T/T variant) and the receptor antagonist IL-1 
RN (IL-1RN*2), especially in combination with H. pylori CagA positive and/or VacA 
positive strains (8). These evidences have been confirmed by additional studies, as two 
recent meta-analyses showed that individuals carrying the T variant allele of IL-1B-511 
have a significant 25% increased risk of developing intestinal gastric cancer compared 
with the homozygous wild types, so as subjects carrying the *2 polymorphic allele of 
the receptor antagonist of IL-1β (OR= 1.20, 95% CI: 1.01-1.41), especially in 
combination with H. pylori infection (OR= 4.81, 95% CI: 1.4-17.28) (9, 10). These 
results, however, were not confirmed among Asians, so as the suspected associations 
between IL-1B-31 *C variant, and +3954 *T, with gastric cancer (10). One possible 
biological explanation for the ethnic differences in gastric cancer risk associated with 
the IL-1β polymorphisms could be the varying H. pylori infection rates between Asian 
and Caucasians, as the positive associations were more likely detected in low incidence 
compared to high incidence regions (11).  
 
According to the pie model of disease aetiology (12), we could think of gastric cancer 
aetiology as determined through several different complete causal mechanisms. Every  
mechanism is a ‘sufficient cause’, and it is defined as a set of mininal conditions that 
inevitably produce disease, involving the action of several component causes. The 
weight of each component cause inside each causative pie mechanism cannot be 
distinguished by the weight of the others, as all of them need to be present for the 
mechanism being complete, however the weight of a single component cause can be 
larger if it present in many causative pies. According to this concept, even though H. 
pylori infection and its interaction with certain cytokine polymorphisms can be thought 
as two component causes for gastric cancer that might explain a large proportion of 
the 70% gastric cancer cases with past or present H. pylori infection, other component 
causes still have to be discovered, as gastric cancer occurs also in H. pylori free 
individuals through different causal mechanisms. The latter component causes might 
include tobacco smoking, alcohol, low fruit and vegetable intake, high meat and salt 
intake, and the lack of food refrigeration, together with inherited gene variants 
affecting their metabolism. These component causes might be involved, however, also  
 150 
General Discussion 
in the disease aetiology of H. pylori positive individuals with or without certain cytokine 
polymorphisms. 
 
The discovery of the genes affecting gastric cancer risk as influencing the individual 
susceptibility to tobacco and alcohol damages, the effect of a low fruit and vegetable 
intake, and a high consumption of meat and salt intake may allow for better risk 
prediction, and the most powerful approach to identify these low risk variants is 
through association studies. These studies test the frequency of genetic variants in 
(gastric cancer) cases and controls and are convenient because they do not require 
high-risk families, as does linkage analysis. The power to detect alleles with moderate 
effect is much larger for association than linkage studies (13). So far, the vast majority 
of studies focused on candidate genes, chosen by the investigator because of their 
potential role in carcinogenesis (3). 
 
In this thesis I followed the classical association approach in which I targeted candidate 
genes, which, given their function, have a high probability to be involved in gastric 
cancer. Selected different polymorphic genes involved in the detoxification of 
carcinogens, in the DNA synthesis, and in the cell-cycle regulation were selected. 
Additionally, I report the results of three meta-analyses and one pooled analysis on the 
effect of polymorphisms in selected phase I and II enzymes, and in a gene involved in 
one-carbon metabolism, and the risk of gastric cancer. 
 
Key objective. The objective of the work described in this thesis was dual: 
- to investigate the association of candidate genes and gastric cancer risk by 
selecting genes that, given their function, should have a high probability to be 
involved in gastric cancer; 
- to assess the cumulative evidence on the most extensively studied gene 
polymorphisms in association with gastric cancer risk through meta-analyses 
and pooled analysis.  
 
Study population used in this work. The study subjects were selected according to 
a case-control study design. Cases were consecutive primary gastric adenocarcinoma 
patients, with histological confirmation, who underwent a curative gastrectomy in the 
"A. Gemelli" teaching hospital starting from 2002. Controls were selected from cancer-
free patients, with a broad range of diagnoses, admitted to the same hospital during 
the same time period. All subjects were Caucasians born in Italy. A venous blood 
sample was drawn from each participant from which DNA was isolated from peripheral 
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blood lymphocytes. All subject participants filled in a questionnaire for collecting 
demographic data, lifestyle habits and environmental exposures. The study was 
approved by the local review board and written informed consent was obtained from 
each subject. The procedures followed were in accordance with the Helsinki 
Declaration. 
 
 
REVIEW AND INTEPRPETATION OF MAIN FINDINGS 
 
The objective of the work described in this thesis was to gain more insight into genetic 
risk factors underlying gastric cancer aetiology. The research question was addressed 
by using three approaches. First, within the context of an Italian hospital-based case-
control study, we assessed the impact of variation in genes involved in the 
detoxification of carcinogens, DNA synthesis, and cell cycle regulation, on the risk of 
gastric cancer. Polymorphisms in Cytochrome P450 1A1 and 2E1, Glutathione S-
Transferase T1 and M1, Sulfotransferase 1A1, microsomal Epoxide Hydrolase, N-
acetyltransferase 2 (all known as metabolic genes), Methylenetetrahydrofolate 
reductase, and p53 and p73 genes were selected. 
 Then, we performed three meta-analyses and one pooled-analysis on the 
effect of gene polymorphisms coding for a phase I enzyme (Cytochrome P450 2E1), 
phase II enzymes (Glutathione S-Transferase M1 and T1), and 
Methylenetetrahydrofolate reductase gene on the risk of gastric cancer, respectively 
(one meta-and pooled analysis was on the same gene).  
 
1. Genetic polymorphisms and risk of gastric cancer in an Italian hospital-
based case-control study 
 
Metabolic gene polymorphisms.  
A major part of carcinogenic substances require metabolic activation by enzymes to be 
genotoxic, and inherited variations in carcinogens metabolizing genes may alter 
enzyme activity and subsequently carcinogens activation or deactivation. Based on the 
knowledge that metabolic genes are presumed to modulate an individual’s 
susceptibility to cancer by interacting with carcinogens, and since the inheritance of 
several unfavourable genotypes is supposed to additionally increase the risk of gastric 
cancer (14-16), I investigated the effect on gastric cancer of selected SNPs of genes 
coding for phase I enzymes [Cytochrome P450 1A1 (CYP1A1) and 2E1 (CYP2E1)], 
phase II enzymes [Glutathione S-Transferase T1 (GSTT1) and M1 (GSTT1), 
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Sulfotransferase 1A1 (SULT1A1), microsomal Epoxide Hydrolase (mEH), N-
acetyltransferase 2 (NAT 2)], and their differential effect according to tobacco smoking 
and alcohol habits. 
The results reported in chapter 2.1 demonstrated an increased risk of gastric 
cancer among subjects carrying the GSTT1 null variant genotype, and among those 
homozygotes for the SULT1A1 variant allele, especially if smokers. While the first result 
basically confirms those of the recent literature (14), the second is a new finding as no 
papers have been published so far at this regard. Individuals carrying the SULT1A1 
variant allele have limited detoxification capability of polycyclic aromatic hydrocarbons 
and arylamine through sulfonate conjugation, which is confirmed by the additional 
increased risk among smokers. Additionally, an increased risk of gastric cancer resulted 
for the carriers of CYP2E1*5A or *6 (DraI) variant alleles among drinkers. CYP2E1 s a 
naturally ethanol-inducible enzyme that is mainly involved in the metabolic activation 
of N-nitrosamines, and it plays a role in alcohol metabolism through the oxidation of 
ethanol to acetaldehyde and 1-hydroxyacetyl radicals (17). Two previous studies (18, 
19) reported no association between CYP2E1*5A or *6 allele and gastric cancer, 
however no one of them stratified data according to alcohol habits. Since the *5A or *6 
alleles of CYP2E1 are characterized by an increased gene expression (20), I 
hypothesise that individuals carrying the unfavourable variant are at higher risk of 
gastric cancer because of: i) hyper activation of N-nitrosamines in more reactive 
species, especially among drinkers since enzyme activity is induced by alcohol; ii) 
hyper production of reactive oxygen species and subsequent cell toxicity generated by 
ethanol metabolism among drinkers.  
From the gene-gene interaction analyses, we showed that individuals with 
combined GSTT1 null and NAT2 slow acetylator variants had an additional increased 
risk of gastric cancer, with an attributable proportion due to their interaction of 52%. 
N-acetylation is considered a major detoxification step for carcinogenic aromatic 
arylamines, while GSTT1 is involved in the detoxification of polycyclic aromatic 
hydrocarbons, so individuals with one or both depleted phase II enzyme activities 
might be particularly susceptible to gastric damage from carcinogens, which is 
supported by the finding of an additional risk for ever-smokers carrying the 
unfavourable combination. 
 
Methylenetetrahydrofolate reductase gene. 
Methylenetetrahydrofolate reductase (MTHFR) enzyme irreversibly converts 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, the primary circulating form of 
folate, providing methyl donor for DNA methylation and deoxynucleoside synthesis. 
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Two prominent mechanisms whereby folate deficiency may influence cancer risk have 
been described (21) low folate levels might induce misincorporation of uracil into DNA, 
which could lead to chromosomal breaks and mutations; and/or by causing DNA 
hypomethylation, resulting in altered gene expression (22). Two functional 
polymorphisms of the MTHFR, C677T and A1298C, have been identified (19), 
associated with decreased enzyme activity and folate levels (23,24). We explored 
whether MTHFR C677T and A1298C polymorphisms are related with gastric caner risk 
and progression, and their differential effect according to histological type and 
concomitant exposures affecting serum folate levels (smoking status, alcohol, and fruit 
and vegetables intake). Results showed an increased risk of gastric cancer for MTHFR 
677T carriers, particularly among ever smokers and, among 677 TT individuals, those 
with a low intake of fruit and vegetables. The strongest effect, however, was noted for 
the MTHFR 677 TT genotype among the diffuse gastric cancer histotype. Lastly, the 
survival analysis showed that during first year of follow up after the surgical 
intervention, MTHFR 677 CC subjects have an improved survival compared to those 
carrying the T variant allele. No association was detected for the effect of MTHFR 
A1298C polymorphism. As MTHFR 677 TT genotype is associated with aberrant 
genomic DNA methylation (25), overall the results suggest that aberrant DNA 
methylation pattern, trough impaired folate metabolism, might play a key role in 
gastric carcinogenesis. 
 
Genes involved in the cell cycle regulation.  
p53 and p73 tumor suppressor genes encode for proteins involved in cell cycle 
regulation and differentiation, DNA repair, and apoptosis (26). Both p53 and p73 genes 
are highly polymorphic, with at least 13 SNPs described for p53 and 19 for p73 (27). 
We investigated the effect of four selected p53 polymorphisms (exon4 Arg72Pro, and 
intron 3 and 6), and the p73 exon 2 G4C14-to-A4T14 dinucleotide polymorphisms, 
their combination and interaction with environmental exposures, on gastric cancer risk 
and progression. A recent meta-analysis reported a significantly increased risk og 
gastric cancer among Asians carrying the homozygous variant of p53 exon4 Arg72Pro, 
but not Caucasians (28). Oppositely, a recent study among Asians (29) reported no 
association between p73 G4C14-to-A4T14 dinucleotide polymorphism and gastric 
cardia. No one study ever explored the effect of p53 intron 3 and 6 polymorphisms and 
gastric cancer so far. 
Results showed that p73 G4C14-to-A4T14 homozygous variant genotype 
increases the risk of gastric cancer 4.77-times compared with individuals with the wild 
type genotype, and that the risk is particularly strong for the intestinal histotype. The 
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gene-environment interaction analysis showed an effect modification by gender on the 
association of p73 G4C14-to-A4T14 polymorphism and gastric cancer, with an 
increased risk among females, known have a lower capacity for DNA repair with 
respect to men (30). From the gene-gene interaction analysis, a protective effect 
resulted for individuals carrying the mutant alleles of p53 exon 4 and intron 6, with 
50% reduced risk compared with those both wild-types, which is in line with results 
from breast and lung cancer (31,32). Lastly, we showed that carriers of the p53 intron 
6 variant allele have a poorer prognosis for intestinal gastric adenocarcinoma after 
surgical intervention, which is in line with a recent report on chronic lymphocitic 
leukaemia when considering the time of treatment-free survival as the main outcome 
(33).    
 
2. Meta-analyses of genetic polymorphisms and risk of gastric cancer 
 
In the second approach, the results of three meta-analyses on the effect of gene 
polymorphisms coding for a phase I enzyme (Cytochrome P450 2E1, CYP2E1), phase II 
enzyme (Glutathione S-Transferase T1, GSTT1), and Methylenetetrahydrofolate 
reductase gene (MTHFR) on the risk of gastric cancer are reported. Additionally, we 
performed a pooled analysis using individual level data through the Genetic 
Susceptibility to Environmental Carcinogens (GSEC) collaborative group on MTHFR 
polymorphisms and gastric cancer and compared the results with those from the meta-
analysis on the same gene. 
 
Meta-analysis of CYP2E1PstI/RsaI polymorphism and gastric cancer. 
CYP2E1 is a naturally ethanol-inducible phase I enzyme that is mainly involved in the 
metabolic activation of N-nitrosamines, and it plays a role in alcohol metabolism 
through the oxidation of ethanol to acetaldehyde and 1-hydroxyacetyl radicals (17). 
Two point mutations, existing in close linkage disequilibrium in the 5’-flanking region 
(PstI, RsaI), are known to alter the transcriptional activity of the (34). These mutations 
generate the CYP2E1*1 (c1) allele and the less common CYP2E1*2 (c2) allele and have 
been reported to be associated with an increased risk for oral, pharyngeal (35), liver 
(36) and lung cancers (37,38). By pooling together the results of thirteen case-control 
studies identified through Medline and Embase, that include 2066 cases and 2754 
controls, we showed the absence of association between CYP2E1 c2 variant allele and 
gastric cancer. By pooling the studies of high-quality among Asians, where the c2 
variant is more common, an increased risk appeared for those carrying c2 variant 
allele. Additionally, by collecting individual level data from the authors of the papers 
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included in the meta-analysis, a significant 5.36-fold increased risk for gastric cancer 
was shown for individuals both CYP2E1 c2 homozygotes and GSTM1 null (an 
homozygous deletion causing the absence of enzyme activity), compared with 
individuals with both homozygous wild genotypes (attributable proportion due to 
interaction of 60%). Absence of significant associations resulted from CYP2E1-alcohol/-
smoking interaction analyses. Overall, these results suggest that the c2 variant allele 
of the phase I enzyme CYP2E1*2 might affect the risk of gastric cancer, especially by 
interacting with a key phase II enzyme as GTSM1, which is completely deleted among 
those carrying the null variant. 
 
Meta-analysis of GSTM1 and T1 status and gastric cancer. 
The GST enzymes are involved in the detoxification of many xenobiotics, including 
several environmental carcinogens and endogenously derived reactive oxygen species 
(35). Individuals who have the homozyogous deletion (null genotype) in GSTM1 and 
GSTT1 enzyme activity are more susceptible to carcinogens such as benzo[]pyrene-
7,8-diol epoxide, the activated form of benzo[]pyrene, and smaller reactive 
hydrocarbons, such as ethylene oxide and diepoxybutane (39). By pooling together the 
results of fifteen case-control studies identified through Medline and Embase, including 
1797 cases and 3000 controls, I showed a slight increased risk for gastric cancer 
among those carrying the GSTM1 null genotype. By pooling data from 4 studies (478 
cases and 870 controls) that considered combinations of GSTM1 and smoking status, a 
statistically significant increased risk for gastric cancer was detected for GSTM1 null 
individuals if smokers compared to non-smokers GSTM1 wild types. By pooling 
together the results of eighteen case-control studies identified through Medline and 
Embase, including 2508 cases and 4634 controls, we showed the absence of 
association between GSTT1 null genotype and gastric cancer. There was a substantial 
absence of heterogeneity among studies. When I considered, however, only high-
quality studies, a significant increased risk of gastric cancer appeared, as well as 
considering only Caucasians. Additionally, by pooling data from 7 studies (319 cases 
and 656 controls) that considered combinations of GSTT1 and GSTM1 genotypes, a 
statistically significant increased risk for gastric cancer was detected for individuals 
with deletion mutations in both genes compared to wild types. 
 
Meta- and pooled analyses of the MTHFR C677T and A1298C polymorphisms 
and gastric cancer.  
Results from a meta-analysis of prospective and retrospective studies specifically 
focusing on dietary folate intake and risk of gastric cancer also reported no clear effect 
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of dietary folate intake, with no differences between cohort or case-control studies 
(21). Conflicting results come from studies exploring the association between fruit and 
vegetables intake, the main dietary source of folate, and gastric cancer. As MTHFR is a 
key enzyme in folate metabolism, we wished to verify if the variant 677T and 1298C 
alleles related with reduced enzyme activity and folate serum concentration (especially 
C677T), are associated with an increased risk of gastric cancer by performing a meta-
and pooled analyses of individual level data of the published reports. If folic acid has a 
role in gastric carcinogenesis, I would expect that MTHFR C677T genotype is related to 
gastric cancer risk to the extent predicted by individuals having a low folate serum 
concentration. This approach is called ‘Mendelian randomization’. From the meta-
analysis of 16 studies (2727 cases and 4640 controls), subjects homozygous for the 
MTHFR 677 variant genotype have an increased risk of gastric cancer, as well as from 
the pooled analysis (9 studies, 1540 cases and 2577 controls). No association was 
found between MTHFR 1298 CC and gastric cancer (7 studies in the meta-analysis, 
1223 cases and 2015 controls; 3 studies in the pooled-analysis, 766 cases and 1011 
controls). There was no statistical heterogeneity among studies or substantial 
publication bias in the two meta-analyses. When results from the pooled analysis of 
four studies on C677T were stratified according to estimated folate levels, results 
showed an additional increased risk among individuals with low levels respect to those 
with high folate levels. Overall, these findings support the hypothesis that folate plays 
a role in gastric carcinogenesis.  
 
 
METHODOLOGICAL CONSIDERATIONS 
 
In this work I aimed to explore the impact of some genetic factors on the risk of gastric 
cancer through a population based case-control study and meta-and pooled-analyses 
of the literature. Beside the study design considered, the ability of identifying a factor 
involved in gastric cancer aetiology depends on the absence of random error (precision 
of measurement) and systematic error (comparison, information and selection bias), 
both affecting the validity of a study. In the previous chapter I have discussed the 
methodological considerations of each study separately. In this section I will give an 
overall review of the methodological strengths and limitations specifically concerning 
the studies described in this thesis. For an overview of general methodological 
considerations in epidemiological research I refer to a standard text (40).  
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Strengths of the approach used in this thesis.  
Case-control study.  
The study adopted in this thesis was designed in order to minimize selection bias. 
Namely, cases were selected as all the incident cases of gastric cancer undergoing a 
surgical resection at the Department of Surgery, and controls randomly recruited 
among individuals stemming from the source population for the cases and hospitalized 
during the same time period for all the diagnosis but gastric cancer. Since the 
participation rate was similar for cases and controls and above 90%, selection bias 
should be minimized in this study. As for comparison bias, known also as confounding, 
I can exclude the potential for confounding by ethnicity, as the present study was 
performed in an ethnically homogenous sample, namely Italians. This should protect 
from confounding by ethnicity, also called ‘population stratification’, which usually 
results from the mixing of different ethnic groups with different allele frequencies: in 
this situation confounding arises since the ethnicity itself might be related to a specific 
disease as well as the allele frequencies (41). Additionally, controls were matched by 
age and gender in order to control for both confounding factors. Non differential 
misclassification of the genotype exposure is unlikely in this study, as quality control 
for each genotyping was performed in each experiment, and 10% of the total samples 
were randomly selected and reanalyzed with 100% concordance. Lastly, differential 
misclassification of the disease status is also unlikely as the analyst was blinded to the 
case or control status of the samples.  
Meta-analyses and pooled-analysis.  
A primary concern in meta- and pooled-analyses is publication bias. This phenomenon 
stems from the selective reporting of ‘positive’ findings, and current statistical tests are 
not sensitive enough to demonstrate it when the number of studies included is lower 
than 10 (42). In all the meta-analyses presented in this thesis, however, there was no 
evidence of publication bias neither from the statistical tests or the visual inspection of 
the funnel plot. An important strength of the meta-analyses of GSTT1 and CYP2E1 was 
the possibility to explore potential source of heterogeneity by stratifying the meta-
analyses according to some covariates, which was possible because individual level 
data were collected by contacting the authors of the included papers. Lastly, the pooled 
anlaysis was possible to adjust for the potential confounding effect of several variables 
individually collected from the collaborating authors, and to assess consistently the 
presence of gene-lifestyle interactions for MTHFR 677, a factor that makes the pooled-
analysis preferable to the meta-analysis. 
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Limitations of the approach used in this thesis.  
Case-control study.  
In general, a large sample size is the primary way to increase precision in any 
epidemiological study. Therefore, precision was a concern as gastric cancer cases 
recruited never exceeded 115 subjects. However, when appropriately conducted, large 
and small studies should give, theoretically, the same results, with just a more precise 
effect measure estimate from the larger ones (43). The low power of this study also 
affected the gene-environment interaction analyses, whose results should be confirmed 
by replication in a different population. As in any case-control study, differential 
misclassification of the environmental exposures might exist, thus affecting the results 
of the gene-environment interaction analyses.  
Another limitation of this case-control study was the inability to gain information on 
Helicobacter pylori infection, as all the cases were surgical, thus serological tests for 
the germ detection were not routinely performed. Also, serum from controls was not 
routinely collected from the beginning of the study. In order to overcome this issue, we 
are currently recovering all the gastric biopsies paraffin embedded at the Pathology 
Department, so to search for H. pylori infection at least among the cases by 
polymerase-chain reaction of the DNA of the extracted tissues. This limitation, 
however, is not affecting the validity of this study, as all the genes investigated in this 
thesis are not in linkage with the IL-1 gene cluster polymorphisms known to influence 
the host response to H. pylori attack and the subsequent gastric mucosa damages. In 
fact, the candidate genes selected in this thesis are relevant for gastric carcinogenesis 
as they affect the host capacity in the response to the damages caused by the use of 
tobacco smoke, alcohol, and a low fruit and vegetables intake, that can act as effect 
modififers of the genes-gastric cancer relationship. Even though most of the papers 
published in relation with gastric cancer actually report data on H. pylori serology 
among cases and controls, actually even the larger studies (44) that investigated the 
effect of the candidate genes considered in this thesis did not test for any effect 
modification by H. pylori infection, as not biologically plausible in view of the current 
knowledge.  
A crucial question in the design of our study is whether we should adjust for H. pylori 
status, which means whether I should think of H. pylori as a potential confounder of 
the relationship between the investigated genes and gastric cancer. I personally do not 
think that any comparison bias affected our data analysis because, even if future 
studies highlight that the asset of the selected genes influence the susceptibility to H. 
pylori infection, this would imply that the susceptibility to H. pylori infection is an effect 
of the genotype ‘exposure’, acting as an intermediate step in the causal pathway 
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towards gastric cancer. And a key property of a confounding factor is that must not be 
an effect of the exposure (12), so in any case it would have been inappropriate to 
adjust for H. pylori status as it is beyond a doubt the H. pylori is in the causal patway 
of around 70% of gastric cancer cases. 
 
Meta-analyses and pooled analysis. 
Our stratified meta-analyses of GSTT1 and MTHFR according to some covariates did 
not include all of the studies because a small number of authors could not share their 
original data, so selection bias may have occurred. Stratified meta-analyses were also 
based on a few number of subjects, so precision of the estimates is an additional 
concern. Pooled-analysis was able to show an effect modification of the folate status on 
the risk of gastric cancer by MTHFR C677T genotype. Information on folate status, 
however, was collected in an heterogeneous way across the studies included (different 
source of folates, and questionnaires used to collect the information on dietary intake). 
This situation, however, could lead to non differential misclassification of the folate 
exposure and bias the effect measures towards the null. Thus, if such bias is present in 
the stratified pooled analysis by folate status, it would indicate that the underlying true 
effect modification should be stronger than what observed.  
 
 
SUGGESTIONS FOR FUTURE RESEARCH 
 
The work in this thesis has provided more insight into the role of several genetic 
factors in gastric cancer aetiology, and has raised the hypothesis of a potential role of 
folic acid in gastric cancer prevention. Briefly, results show that gastric cancer risk is 
increased in an Italian population by the inheritance of the variant alleles of the 
metabolic genes SULT1A1 and CYP2E1 *6, especially among smokers and drinkers, 
respectively. An additional increased risk is conferred by the inheritance of GSTT1 null 
variant, especially if combined with the NAT2 slow acetylator status. Additionally, I 
showed that the variant allele of MTHFR C677T, associated with inherited low serum 
folate levels, increases the risk of gastric cancer, especially among those with a low 
intake of fruit and vegetables. Lastly, I reported that a combination of p53 exon 4 and 
intron 6 variant alleles protects from gastric cancer, thus confirming recent evidences 
from other tumour sites. Meta-analyses showed that the c2 variant allele of the phase I 
enzyme CYP2E1*2 might affect the risk of gastric cancer, especially by interacting with 
a key phase II enzyme as GTSM1, and that the phase II enzyme GSTT1 confer an 
increased risk of gastric cancer if combined with GSTM1 null. Pooled analysis confirmed 
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the role of folate in gastric carcinogenesis, as individuals with the homozyogous MTHFR 
C677T variant genotype are at increased risk of gastric cancer especially if carrying a 
low folate status. Our meta-analysis reporting that MTHFR C677T is a true risk factor 
for gastric cancer has been confirmed from a recently published paper that evaluated 
the false-positive report probability (FPRP) of genetic associations stemming from 
meta-analyses in the field of cancer research (45). Authors showed that, by assuming 
a very low prior probability of 0.000001 (as those appropriate for a randomly selected 
SNP in a genome-wide association study), and a statistical power to detect an OR of 
1.5, the FPRP of our reported association [OR= 1.52 (95% CI: 1.31-1.77) between 
MTHFR 677 TT and gastric cancer] was 4.9 x 10-8, thus indicating a noteworthy 
association.  
 
Beside the eradication of H. pylori infection, currently the management of individuals at 
moderate/high risk for gastric cancer is based on endoscopic screening programme 
(46). From a public health perspective, however, the results of this thesis raise several 
questions related to the possibility of preventive nutritional interventions at population 
level towards individuals at moderate/high risk for gastric cancer. Since 1998 North 
America introduced the folate fortification of some common food items (47) for the 
prevention of neural tube defects. Even though it is early to test for a possible 
decrease in gastric cancer incidence related to the folate fortification, in view of the lag 
time for the effect of folate, and the lengthy induction time for gastric cancer, it would 
be worthy to address this issue in the next decade. Given the controversial evidence 
from nutritional studies on the effect of folate and fruit and vegetables on gastric 
cancer, however, there is a need for large prospective cohort studies based on 
repeated serological dosage of folate levels and/or detailed and repeated nutritional 
data which would further clarify the role of folate in gastric carcinogenesis. Future 
studies should also consider other genes involved in folate metabolism for a more 
comprehensive understanding of the exact role of the folate pathway in gastric cancer 
susceptibility.  
 
This thesis showed for the first time a borderline significant 2-fold reduced risk of 
gastric cancer for individuals carrying a combination of variant alleles of both p53 exon 
4 and intron 6. Since the identical result was gained from two studies on lung and 
breast cancer, it is urgently needed a replication from a large study on gastric cancer, 
together with functional studies on the effect of such linked SNPs combination on p53 
folding and activity.  
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Despite all these evidences, currrently there is no genetic testing indicated or validated 
for the prevention of gastric cancer or for its clinical management. As we showed that 
the odds ratio associated with the most common inherited genetic variants affect the 
risk of gastric cancer for no more than 50% as in the case of MTHFR, it is premature to 
think about the application of any genetic testing for identify more susceptible 
individuals, in view of their potential limited predictive value. However, because of the 
risk for gastric cancer in several hereditary cancer syndromes, genetic testing is 
currently recommended only in family at high risk (6). 
 
Athough the candidate gene approach that select genes based on their biological 
plausibility of a role in gastric carcinogenesis currently seems to be the most robust 
strategy for identifying genetic loci for gastric cancer, it has a potential disadvantage. 
It only studies the genetic variation in specific candidate gene(s) in relation to the 
disease of interest. Genetic loci associated with the disease risk but not outside and not 
in linkage disequilibrium with the gene studied remain therefore undetected. As such, 
the recent GWA approach is revolutionary as it permits interrogation of the entire 
human genome at levels of resolution previously unattainable, uncostrained by prior 
hypotheses regarding genetic associations with disease (48). The Study Group 
Millenium Project for Cancer in 2008 performed a two-stage GWA and identified the 
intronic SNP (rs2976392) of PSCA gene as a potential gene associated with diffuse 
gastric cancer (49). Additional GWA studies should confirm this evidence, and new 
studies are required for understanding the genetic bases of the most common gastric 
cancer intestinal histotype.  
 
In conclusion, merging the conventional epidemiological research with genome-wide 
association studies and expression profiling might allow in the next future to identify 
disease loci that are likely to be involved in the suceptibilty and progression of gastric 
carcinogenesis not assessed so far in candidate gene studies. To further validate the 
clinical and biological significance of the loci that will be identified, investigation of the 
protein level alterations and functional properties should also be warranted.  
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Gastric cancer is the fourth most common cancer and the second most frequent cause 
of cancer deaths, accounting for 10.4% of cancer worldwide. High incidence regions 
include various countries in Asia and Europe including Japan, China and Russia. In the 
last decade the incidence of gastric cancer in many Western Countries has declined, 
mostly due to food refrigeration, a lower intake of preserved foods and salt, and higher 
consumption of fruit and vegetables. 
 
Gastric carcinogenesis is a multistep and multifactorial process resulting from a 
complex interaction between environmental and genetic factors. Among the former, 
Helicobacter pylori infection, tobacco smoking, low fruit and vegetable intake, high 
meat and salt intake, and the lack of food refrigeration play a major role, while for the 
latter accumulating evidences report that the individual genetic susceptibility to gastric 
cancer involves several genes with small effects. Polymorphisms in genes involved in 
the protection of gastric mucosa against damaging agents, in inflammatory response, 
in detoxification of carcinogens, in synthesis and repair of DNA, in regulation of gene 
expression, and in cell adhesion and in cell cycle, have been studied in association with 
gastric cancer. The majority of the population-based studies conducted so far, 
however, are underpowered to detect a robust association, or to explore gene-gene 
and gene-environment interactions. 
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The objective of the work described in this thesis was dual: 
- to investigate the association of candidate genes and gastric cancer risk by 
selecting genes that, given their function, should have a high probability to be 
involved in gastric cancer; 
- to assess the cumulative evidence on the most extensively studied gene 
polymorphisms in association with gastric cancer risk through meta-analyses 
and pooled analysis.  
After introducing the scientific background and the key objective underlying this work 
in Chapter 1, I summarize in Chapter 2 studies exploring the association between 
polymorphic genes involved in the detoxification of carcinogens, in the DNA synthesis, 
and in the cell-cycle regulation, with gastric cancer risk. The candidate genes were 
selected, as, given their function, should have a high probability to be involved in 
gastric cancer.  
 In the study relating Cytochrome P450 1A1 (CYP1A1) and 2E1 (CYP2E1), 
Glutathione S-Transferase T1 (GSTT1) and M1 (GSTM1), Sulfotransferase 1A1 
(SULT1A1), microsomal Epoxide Hydrolase (mEH), N-acetyltransferase 2 (NAT2) 
polymorphisms, I reported an increased risk of gastric cancer among subjects carrying 
the GSTT1 null variant genotype, and among those homozygotes for the SULT1A1 
variant allele, especially if smokers. An increased risk of gastric cancer resulted for the 
carriers of CYP2E1*5A or *6 (DraI) variant alleles among drinkers. I also showed that 
individuals with combined GSTT1 null and NAT2 slow acetylator variants had an 
additional increased risk of gastric cancer, especially if smokers. 
 In the study relating Methylenetetrahydrofolate reductase (MTHFR) gene 
polymorphisms and gastric cancer, I showed an increased risk for MTHFR 677T 
carriers, particularly among ever smokers and, among 677 TT individuals, those with a 
low intake of fruit and vegetables. An additional increased risk was noted for the 
MTHFR 677 TT genotype among the diffuse gastric cancer histotype. Survival analysis 
showed that during first year of follow up after the surgical intervention, MTHFR 677 
CC subjects have an improved survival compared to those carrying the T variant allele.  
 In analyses relating three known p53 polymorphisms (exon4 Arg72Pro, and 
intron 3 and 6), and the p73 exon 2 G4C14-to-A4T14 dinucleotide polymorphisms, with 
gastric cancer, I reported that p73 G4C14-to-A4T14 homozygous variant genotype is 
associated with an increased risk for intestinal histotype of gastric cancer. I reported a 
protective effect against gastric cancer for individuals carrying the combination of 
mutant alleles of p53 exon 4 and intron 6. I also showed that carriers of the p53 intron 
6 variant allele have a poorer prognosis for intestinal gastric adenocarcinoma after 
surgical intervention. 
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 In Chapter 3, I reported the results of three meta-analyses and one meta- 
and pooled analysis on the effect of polymorphisms in selected phase I and II 
enzymes, and in a gene involved in one-carbon metabolism, respectively, and the risk 
of gastric cancer. 
In the meta-analysis of thirteen case-control studies, including 2066 gastric 
cancer cases and 2754 controls, I showed that the c2 variant allele of the phase I 
enzyme CYP2E1 might affect the risk of gastric cancer especially by interacting with a 
key phase II enzyme as GTSM1. 
In the meta-analysis of fifteen case-control studies, including 1797 cases and 
3000 controls, I reported that the phase II enzyme GSTM1 confers a borderline 
increased risk of gastric cancer, especially among smokers. 
In the meta- and pooled analysis of eighteen case-control studies, including 
2508 gastric cases and 4634 controls, I reported that the phase II enzyme GSTT1 
confer an increased risk of gastric cancer if deleted, especially in combination with the 
null variant of GSTM1. 
In the meta-analysis of 16 studies (2727 cases and 4640 controls), subjects 
homozygous for the MTHFR 677 variant genotype have an increased risk of gastric 
cancer, as well as from the pooled analysis (9 studies, 1540 cases and 2577 controls). 
When results from the pooled analysis of four studies on C677T were stratified 
according to estimated folate levels, results showed an additional increased risk among 
individuals with low levels respect to those with high folate levels. 
In Chapter 4, I reflect on these findings in the context of current knowledge 
and potential methodological limitations, and give suggestions for future research. 
 
In summary, several genetic polymorphisms of genes involved in the cellular 
metabolism, DNA synthesis and cell cycle regulation were associated with the risk of 
gastric cancer. MTHFR 677 TT genotype doubled the risk of gastric cancer among 
subjects carrying a low folate status. The merge of modern genome science with 
prospective population-based, epidemiological research may provide powerful tools for 
evaluating possible benefits of public health, preventive nutritional interventions in 
individuals at risk for gastric cancer. 
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Maagkanker is de op drie na meest voorkomende kanker en de op een na meest 
voorkomende oorzaak voor het overlijden aan kanker, en is verantwoordelijk voor 
10.4% van alle kankers wereldwijd. Hoge incidentie regio’s zijn voornamelijk 
verschillende landen in Azië en Europa, onder andere Japan, China en Rusland. In de 
laatste 10 jaar is de incidentie van maagkanker in veel Westerse landen gedaald, 
voornamelijk door het koud bewaren van voedsel, een lagere opname van 
gepreserveerd voedsel en zout, en een hogere consumptie van fruit en groenten. 
 
Het ontwikkelen van maagkanker is een proces met meerdere stappen waarbij 
verschillende factoren een rol spelen, resulterend in een complexe interactie tussen 
genetische en omgevingsfactoren. Omgevingsfactoren die een rol spelen in dit proces 
zijn Helicobacter pylori infectie, roken, lage fruit en groente consumptie, hoge vlees en 
zoutconsumptie en het niet koud bewaren van voedsel. Voor genetische factoren is er 
een groeiend bewijs dat voor het individuele genetische risico voor maagkanker 
meerdere genen met kleine effecten een rol spelen. Polymorfismes in genen betrokken 
bij de bescherming van de maagwand tegen schadelijke stoffen, in het 
immuunsysteem, in de detoxificatie van carcinogene stoffen, in DNA synthese en 
reparatie, in de regulatie van genexpressie, en in cel adhesie en celcyclus, zijn 
bestudeerd voor associatie met maagkanker. De meeste van de populatie studies tot 
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nu toe waren echter niet groot genoeg om een robuuste associatie te vinden, of om 
naar gen-gen en gen-omgeving interacties te kijken. 
 
Het doel van het werk beschreven in deze thesis was tweezijdig: 
- om de associatie tussen kandidaatgenen en maagkanker te bestuderen door 
genen te selecteren die, gegeven hun functie, een hoge waarschijnlijkheid 
hebben betrokken te zijn bij maagkanker. 
- om het cumulatieve bewijs te bestuderen voor de meest bestudeerde gen 
polymorfismes in associatie met maagkanker risico door meta-analyses en 
gepoolde analysis. 
Na het introduceren van de wetenschappelijke achtergrond van het belangrijkste doel 
in dit werk in Hoofdstuk 1, vat ik in Hoofdstuk 2 studies samen die de associatie 
tussen polymorfismes in genen betrokken in de detoxificatie van carcinogenen, in DNA 
synthese, en in cel cyclus regulatie, met maagkanker. De kandidaat-genen waren 
geselecteerd aan de hand van hun functie en moesten een grote kans hebben 
betrokken te zijn bij maagkanker. 
 In de studie waar Cytochrome P450 1A1 (CYP1A1) en 2E1 (CYP2E1), 
Glutathione S-Transferase T1 (GSTT1) en M1 (GSTM1), Sulfotransferase 1A1 
(SULT1A1), microsomal Epoxide Hydrolase (mEH), N-acetyltransferase 2 (NAT2) 
polymorfismes, vermeld ik een verhoogd risico op maagkanker onder mensen die de 
GSTT1 null variant dragen, en voor mensen die homozygoot zijn voor de SULT1A1 
variant, met name in rokers. Drinkers die dragen waren van de CYP2E1*5A of *6 
(Dra1) variante allelen hadden een verhoogd risico op maagkanker. Ik heb ook 
aangetoond dat mensen met een combinatie van GSTT1 null en NAT2 langzame 
acetylator variant een extra verhoogd risico voor maagkanker hebben, voornamelijk als 
ze ook nog eens rookten. 
 In de studie over Methylenetetrahydrofolate reductase (MTHFR) gen 
polymorfirsmes en maagkanker, toon ik een verhoogd risico voor MTHFR 677T dragers, 
met name onder mensen die ooit gerookt hebben, en voor MTHFR 677 TT dragers die 
een lage consumptie van fruit en groenten hadden. Een extra verhoogd risico is 
gevonden voor dragers van de MTHFR 677 TT onder het diffuse maagkanker histotype. 
Survival analyse toont dat tijdens het eerste jaar na een chirurgische interventie de 
MTHFR 677 CC mensen een betere overleving hebben vergeleken met mensen met het 
T variant allel. 
 In analyses van 3 bekende p53 polymorfismes (exon4 Arg72Pro, intron 3 en 
intron 6), en de p73 exon2 G4C14-naar-A4T14 polymorfisme associatie met 
maagkanker, vermeld ik dat homozygoten voor de p73 G4C14-naar-A4T14 een 
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verhoogd risico hebben op intestinaal histotype van maagkanker. Ik vermeld een 
beschermend effect voor maagkanker voor individuen die dragers zijn van een 
combinatie van mutante allelen op p53 exon 4 en intron 6. Ik toon ook dat dragers van 
de p53 intron 6 variant allel een slechtere prognose voor intestinale maag 
adenocarcinoom na chirurgische ingreep hebben. 
 In Hoofdstuk 3, toon ik de resultaten van 3 meta-analyses en 1 gepoolde 
analyse op het effect van polymorfismes in geselecteerde fase 1 en 2 enzymen, en in 
een gen betrokken bij 1-koolstof metabolisme, respectievelijk, en het risico voor 
maagkanker. 
 In de meta-analyse van 13 case-control studies, met in totaal 2066 patiënten 
en 2754 controles, toon ik dat de c2 variant allel van de fase 1 enzym CYP2E1 
misschien een effect heeft op de risico voor maagkanker, zeker door interactie met een 
belangrijk fase 2 enzym zoals GTSM1. 
 In de meta-analyse van 18 case-control studies, met in totaal 2508 patiënten 
en 4634 controles, toon ik dat de fase 2 enzym GSTT1 een verhoogd risico geeft voor 
maagkanker als het gedelete is, zeker in combinatie met de null variant van GSTM1. 
 In de meta-analyse van 16 studies (2727 patiënten en 4640 controles), 
hadden mensen die homozygoot voor de MTHFR 677 variant genotype waren een 
verhoogd risico voor maagkanker, dit ook in de gepoolde analyse (9 studies, 1540 
patiënten en 2577 controles). Wanneer de resultaten van de gepoolde analyse van 4 
studies over C677T gestratificeerd werden volgens hun folaat levels toonden de 
resultaten een extra verhoogd risico voor mensen met lage levels in vergelijking tot 
mensen met hoge levels. 
 In Hoofdstuk 4, reflecteer ik op deze vondsten in de context van huidige 
kennis en potentiële methodologische limitaties, en geef ik wat suggesties voor 
toekomstig onderzoek. 
 
In het kort, verschillende genetische polymorfismes van genen betrokken bij cellulair 
metabolisme, DNA synthese en cel cyclus regulatie zijn geassocieerd met de risico voor 
maagkanker. MTHFR 677 TT genotype verdubbelde de risico voor maagkanker onder 
mensen met een laag folaat status. De menging van moderne genomische wetenschap 
met prospectieve populatie-gebaseerde epidemiologisch onderzoek kan krachtige 
methoden leveren voor het evalueren van mogelijke voordelen voor volksgezondheid, 
preventieve nutritionele interventies in mensen met een verhoogd risico op 
maagkanker. 
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Il cancro gastrico è la quarta più comune forma di tumore e la seconda più frequente 
causa di morte per cancro, responsabile del 10.4% dei tumori al mondo. Esistono 
regionali ad alta prevalenza in alcuni paesi in Asia ed Europa, tra cui Giappone, Cina e 
Russia. Nell’ultimo decennio l’incidenza del cancro gastrico è diminuita in molti paesi 
industrializzati, soprattutto per la refrigerazione dei cibi, un minor consumo di cibi 
inscatolati e di sale, ed un aumento nel consumo di frutta e verdura.  
 
Il processo di cancerogenesi gastrica è multifasica e multifattoriale, risultante da una 
complessa interazione tra fattori ambientali e genetici. Tra i fattori ambientali più 
importanti vi è l’Helicobacter pylori, il fumo di sigaretta, un basso consumo di frutta e 
verdura, mentre tra i fattori genetici diversi studi mostrano come la suscettibilità 
genetica individuale al cancro gastrico coinvolga diversi geni, ciascuno con un effetto 
piccolo. Diverse classi di geni sono state studiate in associazione con il carcinoma 
gastrico, tra cui geni coinvolti nella protezione della mucosa gastrica, nella risposta 
infiammatoria, nella detossificazione di cancerogeni, nella sintesi e riparo del DNA, 
nella regolazione dell’espressione genica, nella adesione e nel ciclo cellulare. La 
maggior parte degli studi di associazione condotti sinora, però, sono sottodimensionati 
per stimare un’associazione robusta, o per esplorare l’interazione gene-gene o gene-
ambiente. 
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L’obiettivo del lavoro descritto in questa tesi è duplice: 
- Valutare l’associazione tra geni candidati e rischio di cancro gastrico 
slezionando geni, che per la loro plausibilità biologica, hanno una elevata 
probabilità di essere coinvolti nell’eziologia del cancro gastrico; 
- riassumere i risultati della letteratura scientifica sui polimorfismi genici più 
studiati in associazione con il cancro gastrico mediante tre meta-analisi e 
un’analisi cumulativa della letteratura scientifica. 
Dopo aver introdotto il background sulla epidemiologia del cancro gastrico e l’obiettivo 
precipuo di questo lavoro nel Capitolo 1, nel Capitolo 2 mostro i risultati dello studio 
caso-controllo relativo all’associazione tra alcune varianti geniche coinvolte nella 
detossificazione di cancerogeni, nella sintesi del DNA, e nella regolazione del ciclo 
cellulare, e rischio di cancro gastrico. I geni candidati sono stati selezionati in base alla 
loro plausibilità biologica in quanto potenzialmente coinvolti nella genesi del cancro 
gastrico. 
 I risultati dello studio di associazione tra le varianti dei geni Citocromo P450 
1A1 (CYP1A1) e 2E1 (CYP2E1), Glutatione S-Transferasi T1 (GSTT1) e M1 (GSTM1), 
Sulfotransferasi 1A1 (SULT1A1), Epossido Idrolasi microsomiale (mEH), N-
acetiltransferasi 2 (NAT2), mostrano come il rischio di cancro gastrico aumenta negli 
individui portatori della variante GSTT1 nullo, e tra coloro che sono omozigoti per 
l’allele variante di SULT1A1, specialmente se fumatori. Un aumento del rischio di 
cancro gastrico è emerso anche per gli individui portatori della variante genica di 
CYP2E1*5A o *6 (DraI) se bevitori. Ho altresì mostrato che gli individui portatori della 
combinazione delle varianti GSTT1 nullo and NAT2 acetilatore lento hanno un rischio 
aggiuntivo di cancro gastrico specialmente se fumatori. 
 Lo studio che ha investigato l’effetto delle varianti geniche di 
Metilentetraidrofolatoreduttasi (MTHFR) sul rischio di cancro gastrico mostra che gli 
individui portatori della variante MTHFR 677T hanno un rischio aumentato di cancro 
gastrico, specialmente se fumatori, e tra gli individui omozigoti MTHFR 677 TT, coloro 
che consumano poca frutta e verdura. Inoltre la variante omozigote MTHFR 677 risulta 
associata ad un rischio maggiore di cancro dello stomaco di istotipo diffuso. L’analisi di 
sopravvivenza mostra che durante il primo anno di follow-up dopo l’intervento 
chirurgico, i soggetti con genotipo MTHFR 677 CC hanno una sopravvivenza migliore se 
confrontata con coloro che sono portatori della variante T.  
 
L’analisi che correla le tre varianti più comuni di p53 (Arg72Pro esone 4, e introne 3 e 
6), e la variante dinucleotidica G4C14-a-A4T14 di p73 esone 2 con il cancro gastrico, 
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riporta che la variante omozigote di p73 G4C14-a-A4T14 è associato ad aumento del 
rischio di cancro gastrico istotipo intestinale. I risultati mostrano anche un effetto 
protettivo verso il cancro gastrico per gli individui portatori delle varianti di p53 esone 
4 e introne 6. Il lavoro mostra anche che i portatori della variante allelica di p53 
introne 6 hanno una prognosi peggiore per ciò che riguarda l’istotipo intestinale dopo 
intervento chirurgico. 
 Nel Capitolo 3 riporto i risultati di 3 meta-analisi e un’analisi cumulativa 
relative rispettivamente agli effetti di polimorfismi in alcuni enzimi di fase I e II, e in un 
gene coinvolto nel metabolismo delle molecole ad un atomo di carbonio, e rischio di 
cancro gastrico.  
 La meta-analisi di tredici studi caso-controllo che include 2066 casi di tumore 
e 2754 controlli, mostra che la variante c2 dell’enzima di fase I CYP2E1 aumenta il 
rischio di cancro gastrico specialmente interagendo con l’enzima chiave di fase II 
GSTM1. 
 La meta-analisi di diciotto studi caso-controllo che include 2508 casi e 4634 
controlli, mostra che l’enzima di fase II GSTT1 aumenta il rischio di cancro gastrico se 
deleto, specialmente in combinazione con la variante nulla di GSTM1.  
 La meta-analisi di tredici studi (2727 casi e 4640 controlli) mostra che i 
soggetti omozigoti per la variante allelica di MTHFR 677 hanno un rischio aumentato di 
cancro gastrico, così come la analisi cumulativa di 9 studi (1540 casi e 2577 controlli). 
Quando i risultati dell’analisi cumulativa di 4 studi relativi a C677T vengono stratificati 
in base ai valori stimati dei livelli di folati, i risultati mostrano un incremento 
addizionale del rischio tra individui con bassi livelli di folati rispetto ad alti livelli. 
Nel Capitolo 4 vengono portate avanti alcune considerazioni in merito ai risultati 
ottenuti alla luce delle conoscenze attuali e di potenziali limitazioni metodologiche, e si 
propongono alcuni suggerimenti per le ricerche future. 
 
In conclusione, i risultati di questa tesi mostrano che alcuni polimorfismi di geni 
coinvolti nel metabolismo cellulare, nella sintesi del DNA e nella regolazione del ciclo 
cellulare sono associati al rischio di cancro gastrico. Inoltre il genotipo MTHFR 677 TT 
sembra raddoppiare il rischio di cancro gastrico tra coloro che hanno livelli di folati 
bassi. La convergenza delle attuali tecnologie basate sulla conoscenza del genoma con 
ampi studi di popolazione di tipo prospettico, ci permetteranno di valutare 
nell’immediato futuro i possibili benefici derivanti da interventi nutrizionali a livello di 
popolazione in individui ad alto rischio di cancro gastrico. 
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by Mia Hashibe at the International Agency for Research on Cancer, Lyon, France. 
Currently she is the Coordinator of the Italian Network for Public Health Genomics and 
Associate Editor of the Italian Journal of Public Health. In addition of the two 
aforementioned hospital-based case-control studies on gastric and head and neck 
cancer, she coordinates two national research projects evaluating the appropriateness 
of execution of genetic tests for the 1) susceptibility to deep venous thrombosis 
(funded by the Minister of University, 2008/9), and 2) hereditary breast and colon 
cancer in some Italian regions (funded by the Abruzzo Regional Health Service, 2009). 
 PhD Portfolio Summary 
Summary of PhD training and teaching activities 
 
Name PhD student: Stefania Boccia 
Erasmus MC Department: Epidemiology  
Research School: NIHES 
 
PhD period: 2005-2009 
Promotors: Prof.dr. C.M. van Duijn 
                   Prof.dr. W. Ricciardi 
Supervisor: - 
1. PhD training 
 Year Workload 
(Hours/ECTS) 
General academic skills  
- Biomedical English Writing and Communication 
 
2006 
 
4 ECTS 
Research skills 
- Master of Science in Epidemiology 
- Doctor of Science in Genetic Epidemiology 
 
2005 
2006 
 
80 days 
60 days 
In-depth courses (e.g. Research school, Medical Training) 
- Genetic Epidemiology Research Methods 
- Conceptual Foundation of Epidemiologic Study Design 
- Bayesian Analysis 
- Spatial Epidemiology 
- Principles of Epidemiologic Data Analysis 
- Advances in Population-based Studies of Complex 
Genetic Disorders 
- Genetic Linkage Analysis: Model Based Analysis 
 
2005 
2006 
2006 
2006 
2006 
2006 
 
2006 
 
12 days 
5 days 
2.5 days 
2.5 days 
5 days 
5 days 
 
5 days 
Presentations 
- Meta and pooled-analysis of MTHFR C677T and gastric 
 
2007 
 
6 hours 
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 cancer, IARC, Lyon, France 
- Meta-analysis of population-based genetic association 
studies: potential and limitations from a public health point 
of view. Meeting on Consequences from Epigenetics for 
Nutrition, Environmental and Public Health, Vienna, 
Austria 
- The Italian Task Force of Public Health Genomics, 
PHGEN Meeting, Rome, Italy 
 
2007 
 
 
 
 
2007 
 
6 hours 
 
 
 
 
3 hours 
International conferences-oral presentations 
- 13rd EUPHA Annual Conference, Rome, Italy. Genetic 
polymorphism of Sulfotransferase 1A1 as susceptibility 
factor for cancer: a case-control analysis. 
- 14th EUPHA Annual Conference, Oslo, Norway. Head and 
neck cancer risk in an Italian population is associated with 
tobacco, alcohol and fruit and vegetables consumption but 
not with genetic polymorphisms of metabolic genes. 
- 15th EUPHA Annual Conference, Lisbon, Portugal. ALDH2 
and head and neck cancer: a meta-analysis implementing 
a Mendelian Randomization approach. 
- 10th ICEM Conference, Florence, Italy. Public health and 
genomic epidemiology. 
 
2005 
 
 
2006 
 
 
 
2007 
 
 
2009 
 
35 hours 
 
 
35 hours 
 
 
 
35 hours 
 
 
20 hours 
Seminars and workshops 
- Monthly seminars of the post-graduate School of Public 
Health 
 
2008-on 
 
25 hours 
Other 
- Visiting scientist at the IARC, Lyon, France 
 
2007 
 
30 days 
2. Teaching activities 
 Year Workload 
(Hours/ECTS) 
Lecturing 
- At the Degree in Medical Laboratory techniques, 
Università Cattolica del Sacro Cuore, Rome, Italy, she 
teaches Epidemiology 
- At the Master of Science in Biotechnology, Università 
Cattolica del Sacro Cuore, Rome, Italy, she teaches 
 
2005-on 
 
 
2006-on 
 
 
30 hours 
 
 
30 hours 
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 Molecular Biology and Biotechnology 
- At the Master of Science in Food and Beverage Quality 
Control, Università ‘La Sapienza’, Rome, Italy, she 
teaches Biomolecular Techniques for pathogen detection 
and  bacteria genotyping  
- At the Degree in Prevention Techniques in the 
Environment and at the Workplace, Università Cattolica 
del Sacro Cuore, Bolzen, Italy, she teaches Cellular 
Biology 
- At the Master of Science in Epidemiology, and at the Post-
graduate Schools in Biochemistry, Oncology , Psychiatry,  
Public Health, and Radiology, of the Università Cattolica 
del Sacro Cuore, Rome, Italy, she teaches the following 
modules: Measuring the Associations; Study Design (with 
emphasis on Case-Control Studies); Confounding and 
Stratification in Data Analysis; Bias (Selection and 
Information); Public Health Genomics 
- At the Degree in Nursery, Università Cattolica del Sacro 
Cuore, Turin, Italy, she teaches Advances in Biomolecular 
Techniques for the diagnosis and prevention of 
Oncological diseases 
 
2006-on 
 
 
 
2006-on 
 
 
2007-on 
 
 
 
 
 
 
 
2008-on 
 
 
20 hours 
 
 
 
15 hours 
 
 
100 hours 
 
 
 
 
 
 
 
15 hours 
 
Supervising practicals and excursions 
- Supervising practicals on epidemiology 
 
2007/2009 
 
5 hours 
Supervising Master’s theses 
- Supervised Alessandra Frustaci: Meta-analysis of the 
Brain-Derived Neurotrophic Factor gene (BDNF) Val66Met 
Polymorphism in Anxiety Disorders and Anxiety-related 
Personality Traits 
- Supervised Rachel Kamangar: p73 G4C14-to-A4T14 
gene polymorphism and interaction with p53 exon 4 
Arg72Pro on  cancer susceptibility: a meta-analysis of the 
literature 
 
2007 
 
 
 
2008 
 
20 hours 
 
 
 
20 hours 
Other 
- Partner of the European Network of Public Health 
Genomics (PHGEN I and II) funded by EC  
 
2006-on 
 
 
20 hours 
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- Principal Investigator of a Unit inside a national project 
funded by Italian Minister of University on the study of the 
epidemiology of Legionellosis in Italy 
- Partner of the International Head and Neck Cancer 
Epidemiology (INHANCE), IARC, Lyon 
- Partner of the National Multicenter project on HTA of 
genetic tests for venous thromboembolism (Coordinator: 
Prof. G. Ricciardi) funded by the Minister of University 
- Scientific Coordinator of the project funded by Abruzzo 
region on Predictive genomic tests for hereditary breast 
and colon cancer: evaluation of the appropriateness of 
screening individuals at high-risk in selected Italian 
regions. 
2006-2007 
 
 
2007-on 
 
2008-on 
 
 
2009 
100 hours 
 
 
40 hours 
 
50 hours 
 
 
20 hours 
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